publicli
fund
repositori
covid
databas
right
unrestrict
research
reus
analys
form
mean
acknowledg
origin
sourc
permiss
grant
free
elsevi
long
resourc
centr
remain
activ
abstract
accept
public
pathogenesi
use
isola
system
faecal
genit
sampl
ea
ap
van
boxtel
utrecht
nl
introduct
studi
follow
studi
urin
sampl
valu
previ
isola
system
routin
diagnost
laboratori
analyz
eccmid
abnr
previ
isola
system
autom
inocul
streak
abl
process
materi
patient
liquid
format
urin
sampl
observ
less
sub
cultur
earlier
identif
result
save
labor
time
cost
aim
studi
explor
use
previ
isola
difficult
sampl
fece
genit
swab
method
fece
genit
swab
differ
patient
process
manual
previ
isola
fecal
sampl
cultur
campylobact
campylobact
agar
salmonella
shigella
xldagar
yersinia
yersinia
agar
genit
swab
cultur
aerob
bacteria
blood
agar
anaerob
bacteria
anaerob
blood
agar
neisseria
gonorrhoea
go
agar
gardnerella
vaginali
gardnerella
agar
yeast
sabouraud
agar
previ
isola
fece
ml
genit
swab
suspend
ml
nacl
result
fecal
sampl
sampl
could
evalu
salmonella
shigella
found
sampl
campylobact
found
previ
isola
individu
suspect
coloni
better
distinguish
seen
earlier
day
high
count
yersinia
found
sampl
previ
isola
method
result
genit
swab
gener
count
differ
bacteria
somewhat
higher
previ
isola
method
manual
inocul
previ
isola
individu
coloni
differ
bacteria
much
better
distinguish
differ
isol
gonococci
sampl
seen
method
gardnerella
day
earlier
seen
much
easier
distinguish
bacteria
previ
isola
method
conclus
urin
sampl
previ
isola
lead
better
readabl
result
difficult
cultur
fece
genit
swab
individu
suspect
coloni
better
distinguish
count
higher
cultur
also
often
day
earlier
posit
suspect
coloni
therefor
previ
isola
use
time
consum
cultur
especi
genit
swab
also
fecal
cultur
identif
done
earlier
n
vei
ahmadi
izadi
aa
imani
sa
mousavi
zanjan
tehran
ir
object
osteomyel
refer
infect
bone
marrow
may
spread
bone
cortex
periosteum
via
haversian
chanal
osteomyel
inflamm
bone
caus
payogen
organ
osteomyel
categor
acut
sub
acut
chronic
present
type
base
time
diseas
onset
occurr
infect
injuri
investig
preval
factor
produc
infect
also
estim
comparison
disk
diffus
agar
method
etest
method
order
determin
antibiot
sensibl
isol
bacteria
osteomyel
infect
main
purpos
studi
method
osteomyel
infect
diseas
select
studi
sampl
collect
bone
tissu
wound
secret
bodi
fluid
order
microbiolog
studi
sampl
cultur
accord
standard
procedur
disk
especi
antibiot
chosen
bacterium
studi
antibiot
sensibl
via
disk
diffus
agar
kirbi
bauer
minimum
inhibitori
concentr
via
etest
method
use
especi
antibiot
final
compar
two
antibiogram
method
togeth
result
isol
bacterium
aureu
pseudomona
aeruginosa
least
isol
eikenella
morganella
showenella
conclus
number
possibl
pathogen
staphylococcu
aureu
far
common
studi
show
result
comparison
antibiogram
result
treatment
evalu
osteomyel
infect
accord
etest
method
success
kirbi
bauer
method
found
eikenella
corroden
caus
chronic
osteomyl
n
lamdjadani
z
guechi
algier
dz
object
aim
studi
evalu
seropreval
risk
factor
helicobact
pylori
hp
infect
schoolchildren
algier
investig
children
age
year
mean
age
year
sex
ratio
differ
public
school
locat
differ
district
algier
chosen
draw
lot
igg
anti
hp
antibodi
detect
elisa
platelia
hp
igg
biorad
risk
factor
collect
questionnair
includ
mother
father
educ
level
sourc
water
presenc
domest
anim
localis
school
statist
analysi
use
epi
info
result
children
hp
seroposit
static
signific
differ
accord
sex
p
seropreval
accord
age
among
children
year
age
among
year
among
year
among
year
static
signific
differ
accord
water
sourc
presenc
anim
seropreval
decreas
mother
father
educ
level
increas
respect
p
p
seropreval
rate
hp
infect
differ
district
anoth
one
p
also
find
static
signific
differ
accord
promiscu
rate
p
seropreval
rate
school
high
almost
half
children
infect
age
school
rate
increas
age
infect
fond
link
poor
socioeconom
condit
educ
attain
parent
clinic
studi
therapeut
effect
mycocidin
treatment
ringworm
cattl
j
sarab
ir
ringworm
dermatophytosi
infecti
zoonot
diseas
caus
differ
speci
ringworm
fungi
mani
speci
anim
includ
human
suscept
ringworm
infect
cattl
hors
cat
dog
domest
livestock
commonli
affect
anim
lesion
ringworm
usual
found
head
muzzl
eccmid
abstract
accept
public
ear
neck
trunck
particulari
around
eye
infect
anim
lesion
gener
circular
oval
shape
gray
dri
red
crusti
hairless
patch
typic
ringworm
studi
conduct
determin
therapeut
effect
mycocidin
plant
extract
antifung
drug
treatment
ringworm
cattl
infect
cattl
skin
lesion
ringworm
treat
mycocidin
skin
scale
collect
scrape
lesion
usig
strile
scalpel
apetri
dish
sampl
use
direct
microscop
examin
cultur
sabaroud
dextros
agar
isol
ringworm
fungi
anim
studi
divid
two
age
group
old
year
old
infect
anim
subject
treatment
two
time
daili
applic
local
topic
mycocidin
resul
show
rapid
effect
cure
affect
anim
occur
week
use
drug
morev
signific
differ
therapeut
rate
two
differ
age
group
overal
mycocidin
effect
age
group
year
age
age
cure
complet
week
applic
mycocidin
conclus
present
studi
reveal
mycocidin
effect
treatment
ringworm
applic
recommend
mycobacterium
tuberculosissuscept
ist
mice
object
find
whether
tbsuscept
ist
mice
suscept
pulmonari
pathogen
investig
manifest
experiment
infect
caus
microorgan
taxonom
distant
mycobacteria
chlamydia
pneumonia
intracellular
pathogen
burkholderia
cepacia
intracellular
bacteria
challeng
use
mutant
burkholderia
cepacia
dramat
increas
capac
biofilm
format
method
real
time
pcr
flow
cytometri
sandwich
elisa
assay
histochem
stain
intranas
inocul
use
ist
tbresist
asn
inbr
mice
g
bodi
weight
result
comparison
tbsuscept
ist
tbresist
asn
mice
demonstr
former
suscept
chlamydia
burkholderia
infect
display
significantli
shorten
surviv
time
follow
chlamydia
challeng
chlamydia
infect
sever
lung
patholog
rapidli
develop
ist
asn
mice
agreement
higher
macrophag
content
lung
significantli
macrophagederiv
cytokin
tnfa
detect
ist
lung
tissu
burkholderia
infect
increas
virul
mutant
super
abil
biofilm
format
demonstr
ist
asn
mice
ist
asn
mice
suscept
mutant
burkholderia
infect
display
significantli
shorten
surviv
time
follow
challeng
shown
mutant
strain
increas
abil
biofilm
format
virul
ist
asn
mice
parent
burkholderia
strain
equal
mortal
ist
asn
mice
correl
equal
bacteri
load
lung
spleen
mice
strain
conclus
gain
result
probabl
indic
common
mechan
control
differ
intercellular
pathogen
ist
mice
biofilm
biofilm
format
escherichia
coli
foodcontact
stainless
steel
highdens
polyethylen
surfac
object
biofilm
defin
sessil
bacteri
commun
cell
live
attach
surfac
attach
biofilm
format
foodborn
pathogen
spoilag
microorgan
food
contact
surfac
process
plant
public
health
crosscontamin
concern
biofilm
format
escherichia
coli
commonli
use
surfac
viz
stainless
steel
high
densiti
polyethylen
studi
method
studi
stainless
steel
chip
hdpe
chip
use
e
coli
strain
ad
beaker
tsb
sampl
result
escherichia
coli
form
biofilm
mean
cell
densiti
log
cfucm
stainless
steel
hdpe
respect
signific
differ
p
bacteri
count
two
type
surfac
conclus
base
result
conclud
escherichia
coli
surviv
milk
contact
surfac
eg
stainless
steel
hdpe
surfac
form
biofilm
first
report
far
awar
biofilm
format
escherichia
coli
food
contact
stainless
steel
hdpe
surfac
unabl
find
report
search
literatur
evalu
differ
mechan
biofilm
format
clinic
commens
isol
staphylococcu
epidermidi
object
current
two
bestunderstood
mechan
epidermidi
biofilm
format
ica
intercellular
adhesin
depend
icaindepend
proteinac
biofilm
format
icadepend
biofilm
format
character
icaencod
polysaccharid
synthesi
second
mechan
character
surfac
protein
accumulationassoci
protein
aap
biofilmassoci
protein
bap
baphomolog
protein
bhp
glucos
induc
mechan
wherea
nacl
abolish
icaindepend
biofilm
format
complet
studi
examin
characterist
biofilm
format
epidermidi
isol
method
speci
identif
done
vitek
studi
isol
includ
previous
describ
epidermidi
strain
isol
blood
cultur
hospit
patient
isol
skin
healthcar
personnel
presenc
ica
operon
aap
agr
accessori
gene
regul
operon
gene
investig
pcr
isol
use
semiquantit
microtit
plate
method
biofilm
format
isol
bhi
bhi
supplement
nacl
glucos
quantifi
isol
neg
control
nonbiofilmform
strain
posit
control
biofilmform
strain
strong
biofilmform
strain
classifi
non
moder
strong
biofilmform
isol
respect
result
four
isol
nonbiofilmform
signific
differ
biofilm
format
clinic
commens
biofilmform
isol
test
isol
agrposit
preval
ica
operon
twice
high
clinic
isol
commens
isol
mechan
biofilm
format
differ
isol
studi
base
effect
nacl
glucos
icadepend
isol
icaindepend
isol
includ
icaposit
six
icaneg
isol
could
produc
biofilm
bhi
wherea
nacl
glucos
reduc
biofilm
format
result
show
presenc
ica
operon
nt
alway
ensur
abil
isol
form
biofilm
via
icadepend
mechan
presenc
biofilmform
isol
icaneg
aapposit
icaneg
aapneg
biofilm
format
ca
nt
affect
nacl
glucos
suggest
novel
mechan
biofilm
format
f
v
r
brno
cz
yeast
genu
candida
belong
among
import
ethiolog
agent
nosocomi
bloodstream
infect
indwel
medic
devic
consid
one
main
predisposit
yeast
infect
therefor
adhes
biofilm
format
import
virul
factor
microorgan
biofilm
assess
biofilm
format
candida
albican
candida
parapsilosi
blood
stream
isol
two
commonli
use
method
polystyren
microtit
plate
method
mtp
cultiv
pvc
plastic
disc
biofilm
layer
structur
examin
scan
electron
microscopi
sem
process
sampl
freezedri
techniqu
simultan
hydrocarbon
xylen
adhes
assay
use
hydrophob
assess
select
strain
isoelectr
point
pi
two
yeast
speci
evalu
capillari
isoelectr
focus
cief
biofilm
format
surfac
plastic
disc
detect
test
strain
hand
detect
biofilm
format
number
strain
microtit
plate
method
c
albican
strain
c
parapsilosi
strain
found
biofilmposit
microtit
plate
assay
probabl
due
differ
cultur
surfac
differ
manipul
sampl
sem
observ
show
strain
consid
biofilmneg
mtp
form
thin
rudiment
biofilm
layer
pvc
disc
found
biofilmneg
c
parapsilosi
strain
c
albican
strain
less
hydrophob
comparison
biofilmposit
c
parapsilosi
strain
isoelectr
point
determin
c
albican
strain
clearli
biofilmneg
c
parapsilosi
strain
focu
near
pi
valu
pi
valu
clearli
biofilmposit
strain
near
result
cief
correspond
well
cell
surfac
hydrophob
p
object
pathogenesi
staphylococcu
epidermidi
epidermidi
enhanc
abil
attach
surfac
biomateri
form
multilay
structur
increas
resist
antimicrobi
host
immun
respons
lipoteicho
acid
lta
enabl
ionic
bind
artifici
surfac
cell
cell
adhes
part
mediat
polysaccharid
intercellular
adhesin
pia
studi
investig
effect
subinhibitori
concentr
tigecyclin
vancomycin
upon
express
gene
involv
synthesi
pia
icaa
lta
lta
epidermidi
biofilm
plankton
cell
addit
express
icaa
lta
plankton
biofilm
cell
compar
method
plankton
epidermidi
cell
grown
hour
subinhibitori
concentr
tigecyclin
x
plankton
mic
vancomycin
mgml
x
plankton
mic
broth
control
rna
extract
use
trizol
convert
cdna
use
cdna
synthesi
kit
stratagen
quantit
realtim
pcr
carri
use
gyrb
intern
control
subinhibitori
concentr
tigecyclin
vancomycin
effect
upon
express
icaa
fold
lta
fold
plankton
cell
subinhibitori
concentr
tigecyclin
vancomycin
weak
effect
upon
express
icaa
fold
lta
fold
biofilm
cell
compar
plankton
cell
grown
broth
alon
biofilm
cell
demonstr
fold
increas
express
icaa
signific
chang
express
lta
fold
conclus
subinhibitori
concentr
tigecyclin
vancomycin
minim
effect
upon
express
icaa
lta
plankton
biofilm
cell
provid
reassur
applic
antimicrobi
biofilm
relat
therapi
observ
increas
icaa
express
biofilm
cell
compar
plankton
cell
provid
evid
genotyp
phase
variat
two
cell
state
contrast
compar
plankton
cell
biofilm
cell
demonstr
increas
lta
indic
conserv
express
regardless
cell
state
object
staphylococcu
epidermidi
epidermidi
opportunist
pathogen
lead
caus
indwel
devic
prosthet
infect
tigecyclin
novel
glycylcyclin
antibiot
broad
rang
antibacteri
activ
steadili
increas
antibiot
resist
within
clinic
environ
tigecyclin
may
consid
altern
treatment
option
prophylaxi
treatment
biofilm
relat
infect
studi
investig
effect
subinhibitori
concentr
tigecyclin
vancomycin
upon
biofilm
format
method
plankton
cultur
epidermidi
cfuml
expos
subinhibitori
concentr
tigecyclin
x
plankton
mic
vancomycin
mgml
x
plankton
mic
muellerhinton
broth
control
cell
grown
aerob
hour
microtitr
plate
biofilm
cell
wash
three
time
follow
manual
scrape
minut
mild
sonic
cell
dispers
viabl
cell
count
determin
serial
dilut
coloni
count
mueller
hinton
agar
result
compar
broth
control
subinhibitori
concentr
tigecyclin
reduc
epidermidi
biofilm
format
p
subinhibitori
concentr
vancomycin
minim
effect
upon
epidermidi
biofilm
format
reduct
conclus
tigecyclin
may
secondari
effect
upon
epidermidi
biofilm
growth
distinct
protein
synthesi
inhibit
work
must
employ
determin
genet
mechan
low
concentr
tigecyclin
illicit
effect
upon
biofilm
growth
tigecyclin
effect
reduc
bacteri
biofilm
format
even
subinhibitori
concentr
pronounc
tissu
retent
make
potenti
candid
use
prophylact
therapi
effect
subinhibitori
concentr
tigecyclin
upon
epidermidi
biofilm
growth
aim
studi
determin
slime
product
differ
c
albican
nonalbican
candida
speci
isol
variou
clinic
sampl
compar
intens
biofilm
layer
produc
yeast
strain
studi
total
candida
speci
recov
differ
clinic
specimen
test
slime
product
microorgan
evalu
modifi
tube
adher
test
briefli
organ
growth
sabouraud
broth
supplement
glucos
final
concentr
remov
liquid
medium
tube
gentli
wash
distil
water
stain
safranin
tube
examin
visual
presenc
viscid
slime
layer
intern
wall
slime
product
score
neg
weak
posit
moder
posit
strong
posit
accord
intens
biofilm
layer
slime
product
demonstr
candida
isol
test
thirtyeight
c
albican
strain
nonalbican
candida
strain
slime
posit
object
cyclodextrin
deriv
use
solvent
vehicl
poorli
watersolubl
drug
voriconazol
itraconazol
mainli
clear
kidney
consequ
accumul
patient
renal
insuffici
therefor
use
intraven
administr
form
voriconazol
itraconazol
recommend
patient
popul
addit
limit
pharmacokinet
pk
data
regard
cyclodextrin
accumul
patient
receiv
form
hemodialysi
method
investig
critic
ill
patient
women
age
year
anur
acut
renal
failur
treat
empir
mg
per
kg
bodi
weight
intraven
voriconazol
twice
day
invas
fungal
infect
extend
daili
dialysi
edd
period
h
perform
daili
use
geniu
batch
dialysi
system
freseniu
medic
care
germani
polysulphon
highflux
dialyz
surfac
area
freseniu
medic
care
dialys
flow
mlmin
blood
flow
mlmin
day
blood
sampl
collect
differ
time
point
h
medic
sulphobutyletherbcyclodextrin
sbecd
voriconazol
plasma
concentr
determin
valid
hplc
method
object
carbapenem
potent
activ
often
use
last
resort
treatment
infect
due
multiresist
acinetobact
baumannii
mdrab
julyoctob
baumannii
isol
involv
outbreak
clinic
hospit
center
zagreb
thirtyfour
isol
carbapenem
resist
aim
studi
character
mechan
carbapenem
resist
molecular
epidemiolog
isol
method
antibiot
suscept
determin
broth
microdilut
oxacillinas
gene
detect
multiplex
pcr
genotyp
strain
perform
pulsedfield
gel
electrophoresi
pfge
reppcr
determin
sequenc
group
multiplex
pcr
result
thirtythre
carbapenem
resist
isol
posit
one
unrel
isol
posit
nine
carbapenem
sensit
isol
possess
natur
ocur
blactamas
associ
isabai
insert
sequenc
five
isol
mbl
found
blactamas
inhibit
sodium
chlorid
chromosom
ampc
blactamas
affect
suscept
carbapenem
isabaiii
found
upstream
gene
like
produc
isol
uniformli
resist
ceftazidim
cefotaxim
ceftriaxon
piperacillintazobactam
strain
produc
blactamas
suscept
intermedi
carbapenem
resist
ciprofloxacin
isol
show
variabl
degre
susceptibilityresist
ceftazidim
gentamicin
posit
isol
shown
clonal
relat
reppcr
pfge
part
eu
clonal
lineag
ii
singl
isol
isol
possess
type
blactamas
display
distinct
rapd
pfge
fingerprint
mainli
eu
clonal
lineag
conclus
basi
suscept
test
blactamas
character
genotyp
isol
conclud
clonal
spread
endem
isol
respons
high
frequenc
posit
mdrab
set
isol
origin
icu
indic
local
dissemin
within
hospit
point
potenti
sourc
isol
infect
control
measur
introduc
restrict
meropenem
use
recommend
reduc
spread
posit
baumannii
isol
within
hospit
pneumonia
isol
turkey
chang
suscept
test
method
detect
subtl
mechan
object
although
resist
rate
pneumonia
variou
antibiot
increas
recent
year
turkey
izmir
fluoroquinolon
fq
resist
rate
seem
low
despit
wide
usag
therefor
studi
aim
investig
whether
test
levofloxacin
suscept
sole
effici
determin
suscept
pneumonia
fq
mechan
action
resist
method
total
pneumonia
isol
recov
bacteriolog
laboratori
dokuz
eylul
univers
analys
levofloxacin
lvx
disk
modifi
disk
diffus
test
report
varon
et
al
suscept
norfloxacin
pefloxacin
pef
ciprofloxacin
cip
sparfloxacin
spx
also
determin
implic
modifi
method
also
show
molecular
mechan
resist
phenotyp
test
result
also
confirm
sequenc
analysi
parc
e
gyra
b
gene
resist
isol
presenc
efflux
pump
also
determin
verapamil
inhibit
assay
result
although
rate
lvx
resist
among
isol
analys
suscept
addit
fluoroquinolon
fluoroquinolon
nonsuscept
rate
increas
efflux
type
singl
topoisomeras
iv
mutat
type
topoisomeras
iv
gyras
dual
mutat
type
sequenc
analysi
also
confirm
result
mutat
detect
qrdr
region
suscept
isol
isol
efflux
whilst
parc
gene
isol
topoisomeras
iv
type
resist
contain
mutat
addit
mutat
gyra
gene
found
case
topoisomeras
iv
gyras
dual
mutat
type
isol
efflux
type
resist
verapamil
reduc
cip
mic
fold
although
clinic
signific
known
fq
nonsuscept
rate
pneumonia
isol
higher
thought
versu
lvx
detect
first
step
mutant
efflux
type
resist
pneumonia
low
level
resist
usual
facilit
acquisit
higher
resist
potenti
risk
high
preval
fq
resist
shown
studi
determin
fluoroquinolon
suscept
pneumonia
disk
mg
also
use
addit
lvx
le
bouter
r
leclercq
v
caen
fr
object
temtyp
blactamas
repres
preval
esbl
ongo
evolut
recent
esbl
well
character
laboratori
enzym
show
follow
amino
acid
substitut
unusu
valin
residu
posit
never
found
natur
mutagen
tem
variant
goal
studi
creat
new
mutant
residu
histidin
posit
order
assess
contribut
substitut
phenotyp
resist
pattern
e
coli
mutat
blactamas
gener
sitedirect
mutagenesi
use
overlap
extens
method
mutat
primer
use
combin
extern
primer
temfor
temrev
gener
two
partial
overlap
dna
fragment
subsequ
use
overlap
extens
reaction
coupl
amplif
entir
code
sequenc
extern
primer
direct
sequenc
amplicon
perform
strand
deriv
three
independ
pcr
accord
dideoxi
chain
termin
method
use
abi
prism
automat
sequenc
confirm
authent
sequenc
result
amplicon
clone
pbcsk
vector
recombin
plasmid
insert
transform
e
coli
determin
mic
perform
convent
microdilut
broth
procedur
use
bacteri
inoculum
x
cfuml
recommend
clsi
mutant
enzym
valin
posit
replac
histidin
residu
clone
pbcsk
vector
introduc
e
coli
compet
cell
vitro
suscept
e
coli
test
versu
larg
panel
blactam
compar
valu
obtain
e
coli
wild
type
notic
decreas
mic
valu
aztreonam
mgl
mgl
ceftazidim
mgl
mgl
mic
valu
mgl
observ
meropenem
conclus
e
coli
product
surprisingli
abl
confer
resist
meropenem
recombin
strain
suscept
cefotaxim
aztreonam
extendedspectrum
blactamas
produc
among
nontyphoid
salmonella
isol
clinic
case
malaysia
n
f
shamsudin
kuala
lumpur
object
determin
presenc
esbl
among
nontyphoid
salmonella
sp
malaysia
method
total
nontyphoid
salmonella
isol
receiv
hospit
malaysia
year
isol
show
ceftriaxon
zone
size
mm
subject
esbl
screen
use
clsi
recommend
method
pcr
amplif
blashv
blatem
blactxm
perform
use
primer
describ
previous
eccmid
abstract
accept
public
result
isol
phenotyp
describ
esbl
posit
ampc
posit
pcr
result
show
posit
least
one
blactamas
gene
except
esbl
posit
isol
isol
posit
blatem
posit
blactxm
posit
blashv
except
one
isol
ampc
posit
also
posit
gene
seven
isol
neg
esbl
ampc
phenotyp
posit
either
tem
ctxm
gene
conclus
esbl
produc
becom
increasingli
common
among
local
isol
salmonella
sp
resist
caus
blatem
resist
mechan
also
uncommon
studi
also
show
strain
phenotyp
neg
esbl
could
also
harbor
resist
gene
case
treatment
blactam
antibiot
may
effect
object
class
blactamas
ambler
posit
especi
conserv
residu
howev
shown
amino
acid
substitut
posit
associ
hydrolysi
gener
cephalosporin
biochem
character
klebsiella
pneumonia
enzym
carri
amino
acid
substitut
knowledg
appear
natur
shv
blactamas
first
time
method
k
pneumonia
strain
isol
urin
male
intens
care
unit
centr
hospitalouniversitair
mustapha
pacha
algeria
gene
detect
identifi
pcr
sequenc
pcr
product
ligat
smai
site
plasmid
pbkcmv
recombin
plasmid
electropor
escherichia
coli
purif
perform
ion
exchang
gel
filtrat
chromatographi
kinet
constant
obtain
computer
microacidimetr
method
result
clinic
strain
resist
penicillin
cephalosporin
monobactam
although
transform
exhibit
blactam
resist
phenotyp
similar
clinic
strain
respect
penicillin
suscept
cephalosporin
monobactam
kinet
paramet
show
lower
catalyt
effici
kcat
compar
kcat
neither
one
show
abil
hydrolys
oxyiminoblactam
aztreonam
mutat
seem
respons
higher
km
valu
oxyiminoblactam
found
blactamas
km
fact
present
catalyt
activ
kcat
catalyt
effici
kcatkm
mm
aztreonam
whose
valu
undetermin
conclus
residu
hydrogen
bond
may
therefor
stabil
catalyt
conserv
sdn
loop
increas
oxyiminoblactam
affin
due
substitut
aspart
glycin
seem
first
step
recognit
side
chain
subtract
allow
better
accommod
antibiot
activ
site
class
blactamas
studi
show
substitut
alon
unabl
gener
esbl
profil
howev
might
involv
discrimin
recognit
antibiot
letowska
lublin
warsaw
pl
introduct
isol
brevibacterium
strain
clinic
materi
regard
contamin
microorgan
constitut
normal
flora
skin
hand
case
report
describ
bacteriemia
periton
ostemyel
call
attent
bacteria
studi
drug
suscept
occur
drugresist
mechan
isol
clinic
materi
brevibacterium
strain
specif
import
object
characterist
drugresist
drugresist
mechan
phenotyp
method
strain
brevibacterium
spp
isol
clinic
materi
method
twenti
strain
brevibacterium
spp
isol
pure
cultur
number
indic
etiolog
agent
infect
isol
differ
clinic
materi
blood
urin
wound
sputum
includ
studi
identif
perform
apicoryn
apizym
supplementari
biochem
test
drug
suscept
strain
determin
basi
mic
valu
etest
accept
corynebacterium
spp
staphylococcu
spp
mlsb
resist
phenotyp
detect
disc
diffus
method
use
employ
staphylococcu
spp
streptococcu
spp
blactamas
product
detect
cephinas
test
result
among
isol
strain
follow
speci
identifi
commonli
b
casei
b
epidermidi
highest
level
resist
found
cotrimoxazol
chloramphenicol
fusid
acid
blactamas
product
also
detect
twelv
strain
induc
mlsb
resist
mechan
observ
isol
strain
suscept
vancomycin
teicoplanin
conclus
basi
perform
studi
found
antibiot
specif
recommend
vancomycin
teicoplanin
highest
effect
treatment
diseas
caus
brevibacterium
speci
macrolid
lincosamid
streptogramin
group
antibiot
use
caution
possibl
induc
mlsb
resist
mechan
occurr
well
cotrimoxazol
fusid
acid
chloramphenicol
blactam
studi
strain
detect
resist
drug
agrdefici
express
chang
regulatori
cellwal
gene
respons
hvisa
visa
phenotyp
v
result
toler
treatment
intraven
voriconazol
good
seriou
dialysi
relat
advers
event
observ
sbecd
plasma
concentrationtim
curv
day
shown
figur
clear
accumul
cyclodextrin
day
see
higher
peak
trough
level
vs
mg
x
hl
termin
elimin
halflif
vs
h
increas
singl
multipl
dose
pk
paramet
voriconazol
howev
compar
healthi
control
group
given
literatur
data
indic
accumul
sbecd
renal
insuffici
critic
ill
patient
treat
intraven
voriconazol
edd
fortun
toxic
effect
observ
although
accumul
dose
lower
compar
use
previou
toxic
studi
anim
hand
edd
affect
pharmacokinet
voriconazol
staphylococcu
saprophyticu
clinic
isol
recov
urin
sampl
institut
resist
macrolid
andor
relat
compound
ie
lincosamid
streptogramin
mechan
macrolid
resist
poorli
investig
speci
aim
studi
identifi
macrolid
resist
gene
well
genet
support
among
isol
collect
method
strain
mic
erythromycin
eri
spiramycin
lincomycin
lin
clindamycin
cli
dalfopristin
dal
quinupristin
qui
dalfopristinquinupristin
determin
agar
dilut
method
muellerhinton
agar
accord
recommend
antibiogram
committe
french
societi
microbiolog
induct
lincomycin
resist
erythromycin
check
dzone
test
clindamycin
inactiv
test
got
test
resist
gene
erm
erm
b
erm
c
msr
lin
amplifi
use
pcr
specif
primer
plasmid
analysi
carri
use
modifi
kieser
techniqu
tabl
erm
erm
b
erm
c
msr
lin
gene
detect
among
isol
respect
erm
c
posit
isol
exhibit
posit
induct
test
wherea
lin
posit
isol
posit
got
test
preliminari
result
plasmid
analysi
suggest
msr
gene
born
smallsiz
plasmid
kb
wherea
larger
plasmid
kb
harbour
erm
c
lin
gene
conclus
studi
show
highlevel
preval
resist
strain
especi
harbour
msr
gene
speci
might
constitut
reservoir
macrolid
efflux
gene
among
coagulaseneg
staphylococci
g
g
feierl
e
leitner
l
masoud
k
krziwanek
e
marth
aj
grisold
graz
linz
object
aim
studi
determin
trend
resist
micdistribut
clinic
isol
hospit
acquir
ha
communityacquir
induc
macrolidelincosamidestreptogramin
b
mlsb
constitut
mlsb
resist
found
associ
hamrsa
clindamycin
erythromycin
resist
rang
camrsa
mlsb
resist
found
resist
fusid
acid
found
hamrsa
camrsa
respect
focus
analyz
valu
test
antibiot
statist
signific
varianc
could
observ
observ
period
conclus
resist
nonblactam
antibiot
vari
hamrsa
camrsa
resist
found
vancomycin
teicoplanin
quinopristindalfopristin
newer
antibiot
tigecyclin
linezolid
resist
also
rare
rifampicin
resist
ciprofloxacin
erythromycin
clindamycin
common
hamrsa
contrast
resist
fusid
acid
tetracyclin
found
often
camrsa
concern
valu
test
antibiot
mic
creep
could
observ
observ
period
staphylococcu
aureu
among
intens
care
unitadmit
patient
preliminari
result
object
colon
methicillin
resist
staphylococcu
aureu
mrsa
risk
factor
associ
sever
morbid
mortal
excess
length
stay
well
extra
cost
care
especi
patient
admit
critic
area
intens
care
unit
icu
nasal
screen
mrsa
current
guidelin
recommend
calfe
dp
et
al
infect
control
hosp
epidemiol
power
strategi
prevent
limit
spread
infect
combin
major
control
measur
isol
decolonis
carriag
site
hand
hygien
program
aim
studi
evalu
mrsa
colon
rate
among
patient
admit
icu
use
new
rapid
molecular
method
method
april
octob
total
patient
screen
mrsa
carriag
admitt
icu
nasal
swab
analyz
molecular
method
genexpert
mrsa
cepheid
abl
amplifi
realtim
pcr
target
sequenc
mrsa
sccmecorfx
junction
sampl
test
also
cultur
analysi
plate
swab
onto
columbia
agar
sheep
blood
mannitol
salt
agar
kyma
identif
oxacillin
test
perform
suspici
coloni
use
result
data
genexpert
mrsa
show
high
sensit
specif
new
molecular
method
among
patient
examin
mrsa
posit
screen
result
molecular
culturebas
method
identifi
mssa
neg
result
molecular
test
sampl
neg
molecular
method
neg
also
cultur
conclus
genexpert
mrsa
show
high
effici
efficaci
compar
cultur
method
fact
requir
seventi
minut
complet
analysi
allow
shorter
turnaround
time
tat
improv
patient
manag
better
clinic
therapeut
outcom
studi
allow
us
benchmark
colon
level
among
icu
patient
admiss
start
point
infect
control
strategi
prevent
mrsa
spread
develop
focus
therapeut
measur
colon
patient
object
clinic
effect
antimicrobi
therapi
constantli
undermin
develop
antimicrobi
resist
appropri
antibiot
prescrib
critic
good
patient
outcom
signific
factor
battl
emerg
resist
resist
constantli
evolv
problem
activ
real
time
surveil
suscept
rate
necessari
optimis
empir
treatment
prophylact
regimen
aim
develop
local
surveil
system
monitor
suscept
rate
present
tool
initi
find
method
microbiolog
sampl
result
retriev
laboratori
comput
system
telepath
isoft
laboratori
system
use
list
gener
function
either
hospit
commun
gener
practic
locat
microsoft
access
databas
use
process
result
allow
simpl
search
antibiot
suscept
rate
trend
time
dedupl
result
achiev
identifi
sampl
hospit
number
antibiogram
leav
singl
episod
within
select
time
frame
either
monthli
quarterli
twentythre
antibiot
two
antifung
agent
import
hospit
databas
cumul
result
report
across
whole
trust
locat
ward
special
level
eighteen
antibiot
import
commun
databas
cumul
result
report
across
whole
citi
primari
care
trust
databas
report
via
separ
access
interfac
allow
user
select
locat
organ
gener
bespok
report
result
graphic
result
obtain
display
number
isol
test
within
time
frame
absolut
suscept
rate
trend
time
period
exampl
output
shown
figur
display
suscept
rate
staphylococcu
aureu
wound
swab
flucloxacillin
report
trend
antibiot
suscept
use
microsoft
access
shown
feasibl
use
simpl
sourc
suscept
rate
prove
use
develop
empir
prescrib
guidelin
allow
proactiv
chang
local
prescrib
guidelin
treatment
prophylaxi
respons
observ
trend
activ
common
uti
agent
enter
urinari
isol
europ
impact
patient
popul
activ
profil
n
draghi
c
pillar
sahm
chantilli
us
object
concern
empir
treatment
urinari
tract
infect
uti
resist
r
among
enterobaceriacea
spp
en
r
vari
patient
popul
furthermor
organ
harbor
extendedspectrum
blactamas
esbl
exhibit
multidrug
resist
mdr
pose
addit
threat
global
surveil
initi
monitor
suscept
en
agent
commonli
util
treat
uti
studi
evalu
current
suscept
enter
uti
eu
select
agent
impact
patient
age
locat
activ
profil
eckp
esbl
common
among
eld
ip
respect
mdr
rang
across
subpopul
conclus
r
uti
agent
among
en
vari
lower
r
lvxcipamc
rel
sxt
r
among
en
increas
patient
age
esbl
rate
higher
among
kp
compar
ec
common
among
eld
ip
popul
mdr
rate
rel
low
across
evalu
popul
activ
profil
uti
agent
impact
patient
age
patient
locat
import
consid
factor
treat
uti
empir
j
zgurbertok
lorenc
robnik
goll
pir
mueller
premru
v
krizan
hergouth
k
seme
ljubljana
maribor
si
object
twenti
year
ago
carbapenemas
describ
speciesspecif
chromosom
encod
blactamas
howev
identif
plasmid
encod
carbapenemas
chang
percept
pattern
resist
gene
dissemin
predominantli
interspeci
dispers
rather
clonal
spread
aim
studi
therefor
evalu
preval
carbapenemas
resist
determin
among
ertapenem
resist
intermedi
gramneg
isol
method
total
klebsiella
pneumonia
three
escherichia
coli
one
pseudoman
aeruginosa
ertapenem
resist
intermedi
isol
test
presenc
carbapenemas
phenotyp
hodg
test
genotyp
method
pcr
specif
primer
use
standard
pcr
condit
detect
class
carbpenemas
nmc
sme
imi
kpc
ge
class
b
metalloblactamas
class
oxa
blactamas
pcr
product
purifi
sequenc
result
among
isol
test
hodg
method
gave
neg
result
one
posit
k
pneumonia
one
could
clearli
interpret
p
aeruginosa
analys
nucleotid
sequenc
reveal
presenc
gene
p
aeruginosa
isol
presenc
screen
carbapenemas
gene
could
confirm
e
coli
k
pneumonia
isol
although
one
k
pneumonia
isol
gave
posit
hodg
test
howev
first
detect
metalloblactamas
gene
p
aeruginosa
isol
indic
need
perform
screen
control
emerg
carbapenemas
resist
determin
becom
major
public
health
issu
greek
tertiari
hospit
miyaki
c
moschopoulo
gatsiou
alexiad
charalampid
c
v
koulourida
sion
thessaloniki
gr
object
examin
differ
antibiot
suscept
gram
posit
bacteria
antibiot
consumpt
tertiari
hospit
within
year
oper
method
clinic
sampl
inpati
identif
suscept
test
use
wider
semiautom
system
clsi
breakpoint
antibiot
consumpt
express
defin
daili
dose
ddd
per
patientday
result
isol
identifi
respect
methicillin
resist
aureu
mrsa
rate
significantli
higher
isol
p
proport
communityacquir
strain
among
mrsa
also
increas
vs
one
mrsa
reduc
suscept
vancomycin
linezolid
mic
strain
found
aureu
resist
increas
penicillin
isol
vs
p
consumpt
widespectrum
antibiot
increas
hospitalday
hospitalday
vs
consumpt
antimrsa
antibiot
also
increas
vs
conclus
within
year
mark
increas
nonsuscept
rate
gramposit
bacteria
includ
mrsa
parallel
increas
consumpt
widespectrum
antibiot
antibiot
activ
multiresist
gramposit
bacteria
survey
molecular
epidemiolog
resist
resist
gene
strain
serotyp
isol
blactxm
group
extendedspectrum
blactamas
among
clinic
isol
enterobacteriacea
hospit
thailand
p
wongsuk
p
chongtrakool
srisangkeaw
bangkok
th
object
ctxmtype
encod
extendedspectrum
blactamas
esbl
produc
gram
neg
bacteria
particularli
among
member
enterobacteriacea
famili
becom
recogn
distribut
gene
vari
differ
countri
howev
rare
uncommon
ctxmtype
esbl
report
scatter
variou
part
world
therefor
came
attent
investig
exist
rare
gene
thailand
method
four
hundr
seventi
esblphenotyp
posit
clinic
isol
enterobacteriacea
member
detect
presenc
blactxm
group
includ
upstream
region
use
pcr
method
addit
ericpcr
analysi
perform
result
among
test
organ
sixteen
isol
detect
carri
uncommon
ctxm
group
includ
k
pneumonia
isol
morganii
isol
e
coli
isol
p
mirabili
isol
interestingli
sequenc
blactxm
ctxm
group
posit
morganii
e
coli
p
mirabili
show
strict
ident
similar
contrast
isol
k
pneumonia
found
contain
seven
isol
reveal
reveal
strict
ident
similar
pcr
sequenc
upstream
region
show
presenc
transposas
gene
tnpa
element
conclus
knowledg
first
report
clinic
isol
produc
esbl
thailand
order
gain
clearer
view
distribut
gene
larger
scale
investig
throughout
countri
may
requir
detect
oxa
carbapenemas
multidrugresist
clinic
isol
acinetobact
baumannii
krakow
poland
p
nowak
p
paluchowska
tokarczyk
w
mudyna
maciuszek
cracow
pl
object
acinetobact
baumannii
increasingli
import
nosocomi
pathogen
often
caus
outbreak
intens
care
unit
mani
clinic
isol
resist
almost
antibiot
includ
carbapenem
common
mechan
respons
carbapenemresist
carbapenemhydrolys
blactamas
belong
molecular
class
oxa
enzym
drug
resist
baumannii
strain
may
also
associ
presenc
insert
sequenc
aim
studi
detect
oxa
encod
gene
presenc
method
studi
includ
total
thirti
isol
multidrug
resist
baumannii
strain
carbapenemresist
isol
obtain
patient
hospit
icu
special
hospit
krakow
baumannii
identif
sensit
test
poland
perform
standard
criteria
clsi
strain
test
mbl
metaloblactamas
product
diskdiffus
synergi
test
multiplex
pcr
describ
woodford
al
appli
detect
oxa
carbapenemas
encod
gene
strain
test
presenc
fragment
contain
portion
resist
rate
piperacillin
piperacillintazobactam
ceftazidim
cefepim
imipenem
meropenem
gentamicin
tobramycin
amikacin
ciprofloxacin
respect
phenotyp
test
mbl
product
neg
strain
multiplexpcr
analysi
show
presenc
gene
encod
blactamas
belong
group
isol
nine
isol
carri
gene
respect
two
isol
carri
acquir
oxa
gene
isol
contain
insert
sequenc
conclus
result
support
these
detect
use
effici
method
identif
baumannii
strain
carbapenem
resist
test
isol
might
associ
express
acquir
oxacillinas
belong
group
extend
express
intrins
oxacillinas
belong
group
support
presenc
insert
sequenc
b
n
aydin
aydin
tr
object
macrolid
resist
pneumonia
becom
clinic
problem
turkey
countri
aim
studi
analyz
distribut
capsular
serotyp
clone
phenotyp
macrolid
resist
gene
among
macrolideresist
pneumonia
clinic
isol
hospit
method
total
pneumonia
clinic
isol
isol
clinic
sampl
minimum
inhibitori
concentr
erythromycin
clindamycin
penicillin
determin
agar
dilut
method
accord
clsi
guidelin
suscept
azithromycin
telithromycin
tetracyclin
linezolid
vancomycin
levofloxacin
determin
disc
diffus
method
clsi
criteria
use
interpret
suscept
test
result
serotyp
perform
use
capsular
swell
procedur
quellung
reaction
doubledisk
method
erythromycin
clindamycin
disc
use
determin
macrolid
resist
phenotyp
macrolid
resist
gene
mefa
erma
ermb
ermc
ermtr
detect
pcr
reaction
erythromycin
resist
strain
genotyp
pulsedfield
gel
electrophoresi
pfge
digest
smai
result
thirti
five
isol
resist
erythromycin
penicillin
clindamycin
azithromycin
tetracyclin
levofloxacin
resist
ratio
respect
isol
suscept
linezolid
vancomycin
telithromycin
serotyp
distribut
among
erythromycinresist
isol
strain
serotyp
strain
serotyp
strain
serotyp
strain
serotyp
strain
serotyp
strain
serotyp
strain
serotyp
strain
nonvaccin
serotyp
typi
macrolid
resist
phenotyp
erythromycin
resist
gene
mic
valu
among
erythromycinresist
pneumonia
isol
present
tabl
twenti
nine
genotyp
detect
among
erythromycinresist
pneumonia
isol
pfge
clonal
spread
resist
strain
could
demostr
studi
show
common
mechan
erythromycin
resist
pneumonia
isol
cmlsb
constut
phenotyp
encod
ermb
gene
serotyp
predomin
erythromycin
resist
pneumonia
isol
howev
clonal
dissemin
resist
strain
found
first
report
carbapenem
resist
klebsiella
pneumonia
due
porin
loss
croatia
k
b
beden
sestan
crnek
sardel
j
skrlin
kalen
l
martinez
martinez
zagreb
split
hr
santand
es
object
studi
mechan
reduc
suscept
carbapenem
esbl
produc
k
pneumonia
obtain
patient
dubrava
univers
hospit
zagreb
croatia
isol
meropenem
therapi
method
esblproduc
k
pneumonia
determin
doubl
disk
assay
isol
blood
cultur
patient
cardiac
transplant
patient
treat
meropenem
twice
six
week
two
week
later
k
pneumonia
reduc
suscepept
carbapenem
isol
anal
swab
mic
determin
broth
microdilut
accord
clsi
modifi
hodg
test
mht
use
screen
product
carbapenemas
mbl
etest
use
screen
product
metalloblactamas
presenc
blashv
blatem
blactxm
blamir
blacmi
bladha
blaimp
blavim
determin
pcr
obtain
amplicon
sequenc
genet
related
strain
investig
use
pfge
studi
porin
content
strain
outer
membran
protein
omp
extract
separ
sdspage
result
initi
isol
suscept
ertapenem
mic
mgl
meropenem
mic
mgl
imipenem
mic
mgl
mic
carbapenem
strain
obtain
meropenem
treatment
ertapenem
mic
mgl
meropenem
mic
mgl
imipenem
mic
mgl
pfge
show
two
strain
highli
relat
strain
shown
possess
gene
mht
neg
strain
pcr
reaction
primer
specif
ampc
kpc
oxacillinas
neg
isol
produc
ompa
like
protein
initi
isol
express
one
singl
porin
second
isol
produc
two
major
porin
k
pneumonia
conclus
k
pneumonia
decreas
carbapenem
suscept
isol
surveil
cultur
anal
swab
prolong
meropenem
therapi
sinc
carbapenemas
produc
strain
carbapenem
resist
attribut
due
hyperproduct
ctxm
blactamas
combin
complet
porin
loss
studi
highlight
need
establish
antimicrobi
resist
survel
network
k
pneumonia
monitor
trend
new
type
resist
mechan
isol
tgctc
tgclev
tgccl
tclev
tccl
levcl
minsk
smolensk
ru
object
purpos
research
evalu
acinetobact
baumannii
antibiot
resist
level
hospit
republ
belaru
method
subject
studi
group
patient
clinic
laboratori
document
nosocomi
infect
caus
baumannii
patient
treat
minsk
hospit
decemb
juli
total
number
research
patient
male
middl
age
year
old
pathogen
identif
antibiot
resist
surveil
perform
microbiolog
laboratori
institut
antimicrobi
chemotherapi
russian
feder
strain
collect
differ
specimen
sourc
patient
exclud
isol
identifi
convent
method
antimicrobi
resist
evalu
diskdiffus
method
determin
accord
guidelin
nation
committe
clinic
laboratori
standard
nccl
usa
intermedi
suscept
isol
recogn
resist
result
none
test
antibiot
achiev
high
activ
suscept
nosocomi
isol
baumannii
examin
strain
resist
ceftazidim
ciprofloxacin
amikacin
respect
suscept
gentamicin
carbapenem
rel
higher
also
collect
isol
suscept
gentamicin
imipenem
meropenem
differ
suscept
carbapenem
document
three
case
two
strain
imipenemsuscept
one
strain
meropenemsuscept
interest
collect
isol
suscept
gentamicin
also
activ
carbapenemresist
strain
conclus
baumannii
isol
minsk
hospit
character
high
resist
studi
antibiot
found
carbapenem
highest
activ
nosocomi
strain
baumannii
seem
gentamicin
activ
rel
high
commonli
use
last
ten
year
countri
howev
resist
level
antimicrobi
extrem
high
v
velinov
petrov
n
hadjieva
kantardjiev
sofia
bg
object
daptomycin
cyclic
lipopeptid
potent
activ
broad
spectrum
gramposit
bacteria
current
use
treatment
complic
skin
skin
structur
infect
bacteremia
includ
right
side
endocard
evalu
vitro
activ
new
compound
clinic
strain
staphylococci
enterococci
collect
bulgarian
medic
center
nation
refer
laboratori
control
monitor
antimicrobi
resist
nation
center
infecti
parasit
diseas
sofia
method
total
fresh
nondupl
clinic
strain
includ
staphylococcu
aureu
mrsa
enterococcu
spp
enterococcu
faecium
e
faecali
e
avium
differ
medic
center
test
suscept
refer
agar
microdilut
method
accord
clinic
laboratori
standard
institut
guidelin
interpret
criteria
result
aureu
strain
inhibit
daptomycin
mic
mgl
among
test
e
faecium
strain
highest
daptomycin
mic
valu
mgl
mgl
among
e
faecali
e
avium
highest
mic
valu
mgl
tabl
conclus
daptomycin
show
excel
vitro
activ
staphylococci
enterococci
collect
nation
refer
laboratori
control
monitor
antimicrobi
resist
appear
excel
therapeut
option
seriou
infect
caus
methicillinresist
staphylococci
vancomycinresist
enterococci
nation
studi
resist
bacteria
found
bulgaria
test
strain
suscept
daptomycin
establish
local
preval
vitro
suscept
essenti
vitro
antibacteri
suscept
drug
interact
studi
order
predict
potenti
local
efficaci
promot
appropri
use
defin
place
amongst
avail
antibiot
method
major
hospit
belgium
luxemburg
collect
clinic
relev
consecut
isol
studi
list
gram
posit
gram
neg
pathogen
month
period
januari
novemb
minim
inhibitori
concentr
mic
determin
use
microdilut
method
sensititr
pathogen
origin
ward
infect
maximum
urinari
isol
per
hospit
e
coli
klebsiella
spp
enterobact
spp
screen
extend
spectrum
blactamas
esbl
activ
use
local
methodolog
result
tigecyclin
activ
agent
test
gram
posit
pathogen
cumul
refer
european
committe
antimicrobi
suscept
test
eucast
breakpoint
e
faecali
n
e
faecium
n
aureu
mssa
n
mrsa
n
tigecyclin
activ
gram
neg
pathogen
well
cumul
eucast
breakpoint
baumannii
n
e
coli
esbl
n
klebsiella
spp
esbl
n
enterobact
spp
esbl
n
conclus
tigecyclin
continu
show
excel
vitro
activ
gram
posit
reliabl
activ
gram
neg
pathogen
collect
consecut
daili
practic
belgium
luxemburg
result
enabl
belgian
luxemburg
physician
use
tigecyclin
appropri
hospit
patient
e
georgiad
n
vavatsichristaki
tj
walsh
e
roilid
thessaloniki
gr
bethesda
us
object
chronic
pseudomona
aeruginosa
pa
airway
infect
remain
primari
caus
morbid
mortal
cystic
fibrosi
cf
patient
growth
state
pa
cf
airway
consist
bacteri
biofilm
bf
differ
exhibit
convent
suscept
test
condit
within
bf
pa
cell
protect
polymorphonuclear
neutrophil
pmn
exhibit
high
level
resist
antimicrobi
agent
examin
vitro
activ
pmn
alon
combin
amikacin
amk
pa
bf
compar
freeliv
plankton
pl
counterpart
method
two
clinic
pa
isol
resist
amkr
clsi
mic
mgl
suscept
amk
clsi
mic
mgl
deriv
two
cf
patient
grown
incub
cationadjust
muellerhinton
broth
flatbottom
plastic
plate
constant
shake
h
order
form
bf
pmn
healthi
donor
effector
target
e
ratio
incub
h
alon
combin
mgl
amk
percent
damag
bf
pl
assess
metabol
xtt
assay
damag
indic
drug
suscept
synergi
conclud
observ
bacteri
damag
significantli
higher
expect
sum
damag
respect
wherea
addit
defin
observ
bacteri
damag
significantli
higher
compon
synergi
achiev
anova
n
dunnett
test
perform
result
pmn
induc
lower
percent
damag
bf
pl
cell
isol
ratio
vs
p
amkr
vs
p
amk
amk
mgl
amk
vs
mgl
isol
vs
amkr
vs
amk
induc
lower
damag
p
bf
pl
cell
combin
effect
pmn
variou
concentr
amk
isol
damag
bf
lower
damag
pl
cell
p
synergi
observ
pmn
combin
amk
mgl
amkr
amk
isol
bf
pl
cell
conclus
bf
resist
suscept
isol
significantli
less
suscept
pmn
amk
pl
cell
pl
bf
growth
form
resist
pa
less
suscept
amk
suscept
organ
synergi
exhibit
pmn
amk
bf
pl
cell
fosfomycin
issu
emerg
antimicrobi
resist
p
rafailidi
kastori
kapask
falaga
athen
gr
object
reevalu
older
antimicrobi
agent
may
provid
least
temporari
solut
challeng
advanc
antimicrobi
drug
resist
among
common
bacteri
pathogen
fosfomycin
use
rare
treatment
system
infect
despit
substanti
antimicrobi
activ
common
pathogen
emerg
mutat
resist
agent
concern
aim
evalu
magnitud
issu
emerg
bacteri
resist
fosfomycin
method
perform
systemat
review
relev
publish
vitro
studi
clinic
studi
studi
examin
trend
resist
time
includ
result
vitro
studi
identifi
develop
bacteri
resist
fosfomycin
exposur
agent
observ
variou
method
escherichia
coli
isol
staphylococcu
aureu
isol
serratia
spp
isol
pseudomona
aeruginosa
isol
klebsiella
pneumonia
isol
clinic
studi
identifi
failur
fosfomycin
therapi
associ
emerg
resist
agent
observ
patient
variou
type
infect
receiv
fosfomycin
therapi
studi
examin
resist
trend
period
year
absolut
differ
suscept
rate
fosfomycin
pathogen
examin
mainli
e
coli
within
percentil
unit
develop
mutat
resist
fosfomycin
appear
frequent
vitro
particularli
pathogen
e
coli
howev
clinic
relev
phenomenon
appear
minor
signific
support
research
fosfomycin
use
system
infect
stenotrophomona
maltophilia
clinic
isol
c
todd
cl
marodi
middlesbrough
uk
object
stenotrophomona
maltophilia
emerg
hospit
pathogen
suscept
test
difficult
affect
temperatur
medium
though
antibiot
shown
effect
treat
patient
good
evid
support
relationship
laboratori
suscept
test
clinic
outcom
due
lack
clinic
trial
standardis
suscept
test
aim
studi
vitro
interact
among
variou
antimicrobi
clinic
isol
use
etest
method
specif
modifi
project
method
maltophilia
clinic
isol
collect
period
month
ident
confirm
isol
refriger
use
day
prior
experi
isol
refer
strain
sub
blood
agar
provid
fresh
growth
mcfarland
suspens
prepar
isol
inocul
muller
hinton
agar
plate
mark
templat
appropri
cotrimoxazol
sxt
ceftazidim
cz
strip
appli
design
templat
area
use
steril
techniqu
plate
left
room
temperatur
hour
sxt
strip
templat
cz
templat
remov
strip
ciprofloxacin
cip
moxifloxacin
mx
minocyclin
mn
chloramphenicol
c
appli
empti
slot
templat
strip
piperacillintazobactam
pt
ticarcillinclavulin
tim
aztreonam
atm
amoxicillinclavulin
amc
appli
templat
scale
adjust
plate
incub
hour
mic
read
inhibit
sxt
complet
inhibit
cz
experi
standardis
refer
strain
nation
collect
type
cultur
colindal
result
sxt
group
combin
sxt
mx
effect
sxt
alon
cz
group
combin
cz
pt
tim
atm
effect
cz
alon
tabl
synergist
result
yield
project
appear
activ
vitro
good
evid
avail
suggest
relationship
clinic
outcom
call
investig
clinic
trial
differ
antibiot
combin
could
test
find
altern
effect
treatment
difficult
treat
infect
object
chose
promis
wide
use
medicin
plant
uzbekistan
use
tradit
local
inhabit
treat
condit
like
associ
microorgan
evalu
potenti
antimicrobi
activ
order
confirm
popular
use
detect
new
sourc
antibacteri
agent
method
plant
materi
g
extract
methanol
extract
dissolv
vv
solut
dmso
creat
concentr
mgml
stock
solut
preliminari
antimicrobi
activ
extract
carri
disc
diffus
test
plant
extract
show
inhibitori
effect
investig
mic
use
broth
microdilut
method
compar
purpos
standard
antibiot
disc
viz
tetracyclin
mgdisc
ampicillin
mgdisc
use
posit
dmso
vv
neg
control
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
matricaria
chamomilla
l
comparison
vitro
suscept
n
patient
conclus
studi
popul
pt
bacteraemia
differ
clinic
stage
sepsi
antibiot
monotherapi
show
vitro
activ
patient
enrol
thu
leav
least
pt
without
adequ
therapi
thu
combin
therapi
eg
broadspectrum
blactam
antibiot
fluoroquinolon
seem
warrant
patient
communityacquir
sepsi
especi
pneumonia
moxifloxacin
potent
therapeut
option
rapid
detect
extendedspectrum
blactamas
produc
bacteria
mean
flow
cytometri
mj
fariaramo
f
font
carvalho
ag
rodrigu
c
pina
vaz
porto
pt
object
reliabl
detect
extendedspectrum
blactamas
esbl
produc
bacteria
repres
major
clinic
challeng
inappropri
treatment
empir
administr
unspecif
wide
spectrum
antibiot
lead
apart
therapeut
failur
promot
multiresist
organ
phenotyp
detect
method
take
least
hour
provid
result
consid
unspecif
thu
demand
addit
confirmatori
test
molecular
method
expens
timeconsum
sever
gene
involv
bacteri
resist
flow
cytometri
allow
rapid
analysi
larg
number
individu
cell
use
light
scatter
fluoresc
measur
aim
develop
flow
cytometr
protocol
provid
easi
fast
reliabl
detect
esbl
produc
method
forti
clinic
strain
escherichia
coli
klebsiella
pneumonia
classifi
posit
n
neg
n
esbl
produc
phenotyp
method
test
strain
genet
type
belong
common
esbl
genotyp
shv
tem
ctxm
use
control
bacteri
strain
incub
mullerhinton
broth
expos
cefotaxim
ceftazidim
sever
concentr
one
two
hour
without
clavulan
acid
esblinhibitor
bacteri
suspens
analys
flow
cytometri
stain
thirti
minut
bi
acid
trimethin
oxonol
fluoresc
dye
penetr
cell
membran
result
membran
depolar
result
esbl
posit
strain
show
increas
intens
fluoresc
incub
clavulan
acid
flow
cytometri
method
abl
provid
fast
soon
one
hour
treatment
correct
classif
strain
conclus
flow
cytometri
prove
excel
tool
accur
specif
rapid
detect
common
esbl
produc
bacteria
avoid
routin
delay
high
cost
product
antimicrobi
cytotox
activ
higher
activ
reactant
therefor
appli
process
synthesi
new
azol
method
laccas
obtain
ligninolyt
fungu
pycnoporu
cinnabarinu
pcl
reaction
mixtur
analyz
use
hplc
system
dad
column
mass
spectrometri
ms
nuclear
magnet
reson
nmr
spectroscopi
product
isol
solid
phase
extract
dri
lyophil
antifung
suscept
test
perform
modifi
method
edi
result
use
model
substanc
derivat
pcl
laccasecatalyz
transform
paradihydroxyl
substrat
acid
methyl
ester
acid
ethyl
ester
quinon
nucleophil
attack
azol
occur
result
cncoupl
heteromolecular
product
respect
yield
structur
confirm
ms
nmr
analysi
antifung
activ
b
candida
speci
exceed
reactant
tabl
vitro
antimicrobi
activ
amelanocyt
stimul
hormon
mechan
action
potent
human
pathogen
candida
albican
p
k
mukhopadhyay
new
delhi
object
establish
amelanocyt
stimul
hormon
amsh
novel
agent
control
candida
albican
infect
examin
vitro
antimicrobi
activ
amsh
vari
sever
paramet
viz
fungal
cell
densiti
ph
ionic
composit
c
albican
strain
antifung
activ
amsh
also
examin
pathogen
hyphal
form
understand
mechan
action
amsh
c
albican
cell
perform
membran
permeabil
atp
efflux
assay
result
show
amsh
possess
signific
rapid
antifung
activ
pathogen
hyphal
nonpathogen
yeast
form
c
albican
amsh
exhibit
kill
yeast
hyphal
form
hr
antifung
activ
amsh
depend
fungal
cell
densiti
kill
c
albican
ion
select
ph
chang
increas
candidacid
activ
amsh
also
found
amsh
ad
c
albican
hyphal
condit
hyphal
format
inhibit
membran
permeabil
assay
found
signific
membran
permeabil
observ
incub
amsh
suggest
candidacid
activ
membran
damag
atp
efflux
assay
reveal
incub
c
albican
lethal
dose
amsh
consider
amount
atp
efflux
furthermor
presenc
energi
metabol
inhibitor
azid
carbonyl
cyanid
mchlorophenylhydrazon
substanti
decreas
atp
efflux
conclus
observ
suggest
candidacid
activ
amsh
may
mediat
energi
deplet
membran
damag
thu
conclud
amsh
emerg
excel
therapeut
agent
potent
human
pathogen
c
albican
antibiot
suscept
includ
tigecyclin
malditof
ms
e
coli
aureu
isol
e
ro
jenkin
minassian
northampton
leicest
uk
object
test
tigecyclin
esbl
produc
e
coli
mrsa
isol
compar
result
etest
programm
carri
antibiot
suscept
commonli
use
antibiot
use
vitek
analys
carri
malditofm
isol
evalu
potenti
discrimin
organ
method
total
mssa
mrsa
esblproduc
e
coli
nonesbl
produc
e
coli
isol
obtain
northampton
hospit
counti
variou
specimen
type
presumpt
identif
isol
chromogen
agar
oxoid
confirm
mrsa
e
coli
isol
identif
assess
antimicrobi
suscept
vitek
analysi
tigecyclin
etest
carri
confirm
esbl
e
coli
mrsa
isol
accord
manufactur
instruct
ab
biodisk
solna
sweden
maldi
analysi
organ
grown
columbia
blood
agar
plate
hors
blood
overnight
direct
inocul
techniqu
carri
emulsifi
singl
isol
coloni
use
loop
onto
maldi
target
well
left
dri
addit
ml
chca
matrix
malditofm
analysi
carri
use
laser
power
maximum
profil
per
minut
shot
per
profil
result
mssa
sensit
antibiot
reduc
suscept
penicillin
mrsa
isol
show
increas
resist
antibiot
eg
ciprofloxacin
sensit
vancomycin
teicoplanin
linezolid
esbl
producing
coli
isol
sensit
meropenem
ertapenem
sensit
piperacillin
tazobactam
tigecyclin
exhibit
potenc
mrsa
esbl
produc
e
coli
isol
mic
valu
less
mgl
tigecyclin
result
compar
etest
programm
eg
spain
canada
maldi
fingerprint
deriv
isol
produc
rich
peak
high
reproduc
hierarch
cluster
analysi
categor
maldi
spectra
precis
group
accord
antibiot
sensit
pattern
aureu
e
coli
isol
well
blactamas
product
conclus
studi
highlight
problem
antibiot
resist
potenc
tigecyclin
resist
isol
furthermor
malditofm
shown
rapid
method
identif
bacteria
speci
subspeci
level
use
character
accord
antibiot
suscept
pattern
staphylococcu
pseudintermediu
healthi
dog
spain
e
c
lozano
f
ruizlarrea
zarazaga
c
torr
es
object
identifi
character
methicillinresist
coagulaseposit
staphylococci
cp
recov
healthi
dog
spain
method
sampl
extern
nare
healthi
dog
obtain
la
rioja
spain
marchaugust
follow
enrich
nutrient
broth
nacl
sampl
cultur
orsab
plate
oxoid
methicillinresist
cp
recoveri
onesampl
suscept
antibiot
test
diskdiffus
agar
method
molecular
identif
isol
perform
amplif
nuc
gene
intermediu
discrimin
pseudintermediu
intermediu
done
pcrrflp
pta
gene
digest
either
mboi
alui
identif
confirm
sequenc
soda
gene
methicillinresist
isol
test
meca
gene
pcr
sccmec
type
perform
pcr
presenc
resist
gene
test
pcr
leukotoxin
exfoli
toxin
gene
intermediu
luksilukfi
siet
respect
well
lukslukfpv
eta
etb
hla
hlb
hld
hlg
gene
investig
pcr
result
methicillinresist
staphylococcu
pseudintermediu
mrsp
isol
studi
sampl
methicillinresist
cp
speci
recov
comparison
restrict
pattern
use
mboi
versu
alui
show
speci
identif
test
isol
type
sccmecv
isol
sccmec
iii
isol
nontyp
isol
although
ccrc
gene
detect
multiresist
phenotyp
least
famili
antibiot
follow
resist
gene
detect
number
isol
meca
blaz
ermb
tet
k
tet
aph
aac
aph
ant
str
dfra
dfrd
dfrg
dfrk
cat
erma
ermc
mph
c
mrsa
msrb
lina
vga
tet
l
tet
ant
ant
fexa
cfr
gene
neg
mrsp
isol
harbour
exfoli
toxin
gene
siet
leukocidin
gene
luksi
lukfi
pantonvalentin
leukocidin
gene
lukslukf
toxin
detect
two
mrsp
pcr
toxin
gene
neg
conclus
mrsp
rel
common
colon
healthi
dog
frequent
harbour
high
number
antibiot
resist
gene
virul
gene
repres
public
health
treatment
concern
siet
toxic
gene
present
isol
role
diseas
requir
studi
result
spa
type
major
mrsa
assign
among
blood
isol
strain
assign
contain
sccmec
type
iv
character
sccmec
type
strain
assign
differ
spa
type
strain
harbour
pvl
toxin
gene
strain
isol
pusexud
respiratori
tract
assign
harbour
sccmec
type
iv
character
contain
sccmec
type
strain
assign
differ
spa
type
harbour
sccmec
type
ii
iv
one
strain
isol
exud
assign
harbour
sccmec
type
iv
pvl
posit
isol
suscept
major
differ
regard
erythromycin
vs
gentamycin
vs
rifampicin
vs
clindamycin
resist
induc
strain
constitut
strain
conclus
studi
common
wellestablish
old
spa
type
italian
hospit
outnumb
new
strain
less
resist
antibiot
although
isol
resembl
prototyp
camrsa
differ
latter
lack
pvl
gene
multidrug
resist
infact
isol
belong
welladapt
hospit
clone
recent
emerg
europ
pvl
posit
strain
studi
belong
camrsa
european
clone
confirm
camrsa
infrequ
itali
n
coplu
h
bayrak
buyukguclu
turan
h
sakar
n
balaban
e
guner
u
cinar
caliskan
b
yalcin
eksioglu
n
atakan
kilic
b
esen
ankara
tr
object
epidemiolog
aureu
infect
chang
worldwid
mrsa
frequent
found
commun
associ
ca
pathogen
aim
studi
assess
risk
ca
aureu
infect
infect
control
record
identifi
two
group
inpati
one
new
posit
mrsa
blood
cultur
one
new
posit
mssa
blood
cultur
consid
bsi
acquir
inhospit
cultur
taken
hour
admiss
taken
less
hour
patient
hospit
within
last
month
record
data
pertin
wide
accept
risk
factor
staphylococcu
aureu
colon
infect
consid
event
day
posit
cultur
date
use
electron
pharmaci
record
obtain
detail
data
intraven
antibiot
use
month
cultur
date
result
identifi
patient
new
namrsa
bsi
patient
new
namssa
bsi
elig
analysi
univari
analysi
signific
differ
note
age
nurs
home
resid
presenc
chronic
wound
rate
hemodialysi
intub
enter
feed
receipt
presenc
indwel
urinari
cathet
hour
receipt
least
antibiot
qualit
quantit
use
penicillin
blactam
antibiot
whole
qualit
use
aminoglycosid
fluoroquinolon
quantit
use
cephalosporin
clindaycin
blactamblactamas
inhibitor
model
multivari
analysi
includ
either
quantit
qualit
use
total
antibiot
individu
class
independ
predictor
namrsa
bsi
prior
receipt
least
antibiot
siginific
differ
outcom
note
conclus
compar
analysi
strictli
defin
patient
group
deriv
highli
homogen
popul
conclud
prior
receipt
least
antibiot
strongest
predictor
subsequ
namrsa
bsi
individu
antibiot
usag
tradit
risk
factor
namrsa
infect
period
time
suscept
strain
analys
similar
one
period
time
conclus
replac
gener
cephalosporin
gener
cephalosporin
resum
suscept
antibiot
problemat
pathogen
e
coli
k
pneumonia
p
aeruginosa
month
remov
gener
cefalosporin
ceftazidim
cefotaxim
hospit
util
lead
reduct
carbapenem
util
financi
benefit
c
j
dellamonica
l
marcq
n
molinari
sotto
nice
fr
object
assess
impact
intervent
design
improv
document
reassess
inpati
empir
antibiot
prescript
qualiti
prescript
method
prospect
intervent
studi
two
ward
intern
medicin
medic
intens
care
unit
icu
one
french
univers
hospit
intervent
consist
qualiti
improv
project
led
one
doctor
ward
aim
improv
document
four
process
measur
medic
record
antibiot
plan
review
diagnosi
adapt
microbiolog
result
ivpo
switch
result
antibiot
prescript
assess
intern
medicin
ward
icu
intervent
reassess
antibiot
prescript
often
document
icu
intervent
vs
p
intern
medicin
ward
vs
p
preval
appropri
antibiot
prescript
statist
differ
two
ward
intervent
vs
p
vs
p
respect
better
document
reassess
antibiot
prescript
achiev
one
ward
lead
better
qualiti
antibiot
prescript
object
aim
evalu
potenti
inaccuraci
administ
desir
dose
drug
teaspoon
tablespoon
collect
differ
teaspoonstablespoon
avail
household
area
attica
greec
measur
volum
capac
ml
result
total
teaspoon
tablespoon
provid
femal
mean
age
year
studi
particip
utensil
fill
water
volum
capac
teaspoon
rang
ml
mean
volum
ml
median
ml
standard
teaspoon
use
volum
rang
ml
among
total
studi
particip
subset
studi
particip
fill
teaspoon
paracetamol
syrup
mean
volum
conclus
teaspoon
tablespoon
unreli
dose
devic
thu
use
longer
recommend
object
hospit
high
rate
mrsa
esbl
escherichia
coli
klebsiella
multidrugresist
acinetobact
high
ceftriaxon
fluoroquinolon
usag
rise
carbapenem
piperacillintazobactam
usag
daili
antibiot
order
averag
week
make
manual
review
feedback
labori
method
hospit
comprehens
inform
technolog
system
includ
electron
inpati
medic
record
eimr
design
arusc
integr
doctor
work
process
guid
antibiot
use
adopt
evidencebas
medicin
realtim
data
result
doctor
launch
arusc
eimr
select
empir
definit
prophylact
antibiot
infecti
diseas
id
condit
treat
enter
data
unavail
system
doctor
view
antibiot
recommend
includ
renal
dose
adjust
durat
therapi
allergi
antibiot
toxic
monitor
therapeut
duplic
antibiot
microbiolog
data
summari
arusc
check
healthcareassoci
infect
prior
antibioticresist
bacteria
ill
sever
influenc
antibiot
select
provid
clue
diagnosi
investig
referr
select
id
condit
interpret
posit
microbiolog
cultur
empir
definit
antibiot
use
arusc
provid
guidanc
treat
cultureposit
infect
use
narrowspectrum
cultureguid
antibiot
stepdown
therapi
cultureneg
infect
improv
recommend
referr
investig
nonimprov
cultureneg
infect
advis
antibiot
multipl
bacteria
includ
rout
durat
base
id
condit
cultur
site
clinic
respons
doctor
abl
overrid
arusc
usag
arusc
rose
episod
week
one
week
overrid
rang
per
week
daili
usag
rang
week
day
weekend
screen
shot
arusc
action
data
efficaci
safeti
present
voluntari
arusc
use
hamper
error
doctor
mindset
mandatori
arusc
use
may
need
achiev
signific
reduct
overal
broadspectrum
antibiot
use
evalu
arusc
way
result
show
ab
nh
prescrib
gener
practition
gp
specialist
anoth
prescrib
n
substanc
major
prescrib
indic
n
ab
gp
specialist
empir
treatment
respect
specialist
prescrib
significantli
frequent
ab
microbiolog
document
infect
gp
p
result
ab
treatment
n
show
gp
prescrib
significantli
frequent
extendedspectrum
blactam
penicillin
specialist
p
gp
prescript
amoxicillin
compar
prescript
specialist
combin
penicillin
blactamas
inhibitor
prescrib
similar
amount
gp
specialist
respect
p
also
case
prescript
quinolon
p
specialist
prescrib
cephalosporin
slightli
often
gp
respect
p
final
gp
specialist
prescrib
antimicrobi
almost
equal
proport
respect
p
gp
opt
case
oral
ab
oral
administr
also
predomin
rout
administr
specialist
although
combin
substanti
proport
parenter
ab
administr
caus
signific
differ
gp
specialist
p
conclus
compar
specialist
gp
prescrib
compar
class
ab
nh
except
extendedspectrum
blactam
agent
eg
amoxicillin
probabl
gp
prescrib
empir
ab
specialist
prescrib
frequent
parenter
ab
administr
compar
gp
background
presenc
antimicrobi
compound
environ
may
exert
select
pressur
bacteria
contribut
emerg
dissemin
antimicrobi
resist
antimicrobi
agent
use
extens
hospit
previou
report
parent
drug
relat
metabolit
hospit
effluent
make
signific
point
sourc
pharmaceut
environ
aim
research
examin
hospit
effluent
two
antimicrobi
ciprofloxacin
trimethoprim
method
effluent
sampl
collect
hospit
sewer
municip
sewer
point
upstream
downstream
hospit
effluent
discharg
intak
effluent
untreat
stage
secondari
wast
water
treatment
plant
primari
treat
effluent
stage
post
return
effluent
stage
final
treat
effluent
stage
effluent
filter
use
glassfib
filter
acidifi
ph
preconcentr
use
solid
phase
extract
mixedmod
revers
phasestrong
cation
exchang
sorbent
analysi
liquid
chromatographi
singl
tandem
mass
spectrometri
use
secondari
product
ion
scan
mode
ciprofloxacin
parent
mz
ion
mz
detect
effluent
sampl
indic
either
rapid
degrad
sorption
solid
materi
log
p
insuffici
sensit
method
trimethoprim
parent
mz
ion
mz
howev
detect
effluent
hospit
parent
fragment
ion
detect
concentr
trimethoprim
hospit
effluent
estim
ngl
conclus
trimethoprim
detect
subinhibitori
concentr
hospit
effluent
sampl
ireland
implic
find
emerg
spread
antimicrobi
resist
merit
investig
may
appropri
consid
measur
mitig
discharg
antimicrobi
substanc
hospit
object
intern
surviv
sepsi
campaign
ssc
triag
system
identifi
patient
sepsi
ensur
rapid
initi
empir
antimicrobi
therapi
besid
diagnost
purpos
cultur
microbiolog
collect
enabl
deescal
broad
spectrum
therapi
evalu
cultur
collect
complianc
local
antimicrobi
guidelin
implement
ssc
vitro
suscept
isol
pathogen
recommend
therapi
prescrib
therapi
evalu
method
adult
patient
diagnos
sepsi
emerg
depart
ed
radboud
univers
nijmegen
medic
centr
novemb
may
includ
electron
medic
chart
review
collect
clinic
diagnosi
ed
prescrib
therapi
cultur
collect
cultur
result
suscept
result
retriev
laboratori
inform
system
cultur
result
evalu
clinic
signific
empir
therapi
classifi
accord
guidelin
therapi
agt
accord
guidelin
therapi
ngt
mrsa
rapid
test
could
reduc
time
spent
laboratori
staff
microbiologist
clinician
work
review
result
prevent
unnecessari
antistaphylococc
antibiot
commenc
allow
earlier
institut
optim
antibiot
therapi
mssamrsa
must
conjunct
infect
control
teach
correct
techniqu
take
bc
reduc
rate
contamin
first
instanc
method
prestudi
period
month
observ
sequenti
bc
test
genexpert
cepheid
machin
differenti
coagulas
neg
staphylococci
cn
mssa
mrsa
hour
relev
gram
stain
period
standard
questionnair
fill
last
mrsa
screen
current
antibiot
advic
given
clinician
base
clinic
pictur
document
includ
chang
made
prior
pcr
cultur
result
consult
duti
blind
pcr
result
pcr
result
review
chang
made
manag
appropri
time
review
singl
patient
contact
clinician
input
data
assess
result
see
tabl
failur
pcr
kit
caus
known
mismatch
pcr
result
cultur
result
occur
repeat
pcr
concur
cultur
result
deal
initi
gram
stain
took
averag
conclus
throughout
studi
substanti
number
bc
misinterpret
microbiologist
clinician
mssa
identifi
test
obtain
delay
best
treatment
time
spent
phone
contamin
bc
equat
averag
consult
salari
bc
month
test
save
bed
nightsmonth
would
make
test
cost
effici
bed
importantli
reduc
rate
contamin
key
best
practic
would
turn
reduc
number
bc
would
requir
test
thought
signific
isol
cultur
thought
signific
cultur
e
g
jankoska
grdanoska
k
icev
skopj
mk
introduct
streptococcu
group
b
gb
part
normal
flora
gut
harmlessli
colon
genit
tract
healthi
women
object
studi
evalu
rapid
simpl
assay
speedoligo
chromatographi
test
vircel
detect
gb
vagin
smear
pregnant
women
studi
involv
pregnant
week
gestat
doubl
vagin
swab
pregnant
women
analyz
first
one
inocul
columbia
blood
agar
incub
h
suspici
coloni
use
perform
bacitracin
suscept
test
identif
gb
second
swab
use
proceed
speedoligo
gb
assay
bacteri
dna
extract
elut
swab
sampl
solut
provid
kit
follow
heat
minut
centrifug
rpm
minut
microl
dna
templat
use
pcr
purpos
use
microl
reconstitut
pcr
mix
contain
need
amplif
specif
cfb
gene
gb
princip
test
pcr
reaction
perform
termocycl
follow
temperatur
profil
cycl
min
cycl
consist
three
step
cycl
min
cycl
min
hole
amplif
time
less
minut
amplicon
detect
process
hybrid
dipstick
minut
posit
result
conform
accord
red
line
stick
result
swab
cultur
gb
reveal
posit
result
posit
speedoligo
assay
swab
use
speedoligo
assay
posit
gb
posit
cultur
two
posit
case
speedoligo
result
neg
cultur
comparison
rapid
simpl
assay
cultur
gold
standard
detect
gb
reveal
sensit
specif
conclus
speedoligo
gb
prove
rapid
sensit
specif
assay
detect
gb
base
nucleic
acid
amplif
techniqu
test
could
use
detect
colon
infect
gb
pregnant
women
hole
time
pregnanc
would
especi
import
pregnant
women
preterm
deliveri
ruptur
membran
high
fever
deliveri
object
protein
secret
system
virul
determin
mediat
interact
bacteria
eukaryot
host
cell
contribut
sever
infect
among
secret
system
known
date
type
ii
iii
iv
v
vi
report
p
aeruginosa
secret
system
intens
studi
small
number
refer
strain
except
type
iii
secret
system
lack
data
regard
distribut
relev
clinic
strain
studi
aim
identifi
gene
encod
compon
effector
protein
secret
system
p
aeruginosa
isol
acut
infect
method
p
aeruginosa
strain
isol
patient
hospit
highrisk
depart
intens
care
unit
hematolog
genotyp
perform
use
speipfg
reppcr
box
eric
primer
total
multiplex
pcr
assay
design
target
gene
encod
structur
secret
protein
secret
system
ivi
result
total
p
aeruginosa
strain
isol
patient
genotyp
use
reppcr
pfge
allow
assign
strain
cluster
strain
show
unrel
uniqu
profil
strain
possess
gene
encod
effector
associ
type
v
vi
secret
system
gene
encod
protein
secret
type
ii
found
clone
examin
except
gene
lapa
locat
region
genom
plastic
presenc
gene
encod
effector
protein
exo
exoy
exou
transport
type
iii
secret
system
certifi
strain
remain
one
seem
incompat
exo
exou
type
secret
system
haspa
apra
aprx
gene
present
strain
respect
type
iv
secret
system
preval
gene
trb
reppcr
result
confirm
pfge
support
reliabl
method
genotyp
reveal
presenc
clone
isol
hematolog
intens
care
unit
indic
crosstransmit
within
nosocomi
environ
remark
heterogen
distribut
secret
system
iiv
observ
suggest
genom
plastic
may
contribut
specif
p
aeruginosa
infect
object
helicobact
pylori
infect
risk
factor
develop
chronic
peptic
ulcer
gastric
cancer
purpos
studi
investig
frequenc
helicobact
pylori
vaca
genotyp
patient
gastric
duoden
ulcer
method
total
biopsi
specimen
patient
gastric
n
duoden
n
ulcer
collect
specimen
cultur
select
media
incub
microaerophil
atmospher
day
isol
character
speci
level
convent
biochem
test
extract
dna
isol
use
perform
polymeras
chain
reaction
base
simultan
analysi
caga
statu
allel
variat
signal
region
middl
region
vaca
gene
result
helicobact
pylori
isol
specimen
patient
vaca
gene
detect
isol
among
vaca
genotyp
common
helicobact
pylori
isol
patient
gastric
ulcer
duoden
ulcer
studi
demonstr
vaca
slml
common
genotyp
helicobact
pylori
patient
peptic
ulcer
vaca
allel
bacterium
associ
ulcer
brazilian
children
c
taddei
f
oliveira
runga
e
harummyy
irino
k
brandt
carneirosampaio
sao
paulo
br
human
intestin
microbiota
play
import
role
bodi
healthi
differ
composit
relat
differ
level
environment
contamin
differ
endogen
factor
establish
microbiota
occur
first
two
year
life
object
studi
analyz
establish
fecal
microbiota
group
children
first
year
life
live
low
socioeconom
condit
paulo
brazil
base
rdna
gene
librari
analysi
method
fecal
sampl
collect
healthi
exclus
breastf
children
differ
time
point
day
month
life
bacteri
dna
extract
directli
sampl
rdna
librari
construct
use
bacterialspecif
primer
randomli
select
clone
partial
sequenc
realtim
pcr
bifidobaterium
spp
perform
day
sampl
month
result
main
phylogenet
group
identifi
time
point
sampl
e
coli
clostridium
streptococcu
detect
high
rate
day
month
life
respect
month
age
high
rate
otu
classifi
uncultur
bacteria
detect
show
increas
divers
microbiota
bifidobacteria
detect
rdna
librari
present
sampl
analyz
real
time
pcr
conclus
molecular
approach
allow
analysi
fecal
microbiota
implant
group
children
sao
paulo
brazil
bacteri
profil
may
differ
describ
develop
countri
may
attribut
highli
contamin
environ
neonat
contamin
may
favor
hygien
habit
financi
support
fapespbrazil
eccmid
abstract
accept
public
k
majidzadeh
tehran
ir
object
ai
outbreak
one
major
problem
iranian
poultri
industri
associ
high
mortal
case
report
influenza
viru
wild
bird
recent
year
rais
specter
possibl
new
genet
modifi
ai
viru
method
studi
phylogenet
analysi
fulllength
matrix
gene
gene
isol
broiler
iran
tehran
provinc
sampl
collect
perform
accord
standard
method
suspect
clinic
broiler
specimen
tendayold
embryon
chicken
egg
inocul
incub
h
viral
rna
extract
infect
allanto
fluid
rtpcr
done
purifi
pcr
product
clone
plasmid
ta
subject
nucleotid
sequenc
bioinformat
studi
result
nucleotid
sequenc
influenza
virus
use
studi
avail
genbank
access
number
comparison
nucleotid
sequenc
isol
virus
reveal
substanti
number
silent
mutat
result
high
degre
homolog
amino
acid
sequenc
addit
cluster
iranian
isol
could
present
one
subgroup
high
degre
similar
gene
iranian
support
hypothesi
gene
origin
singl
predecessor
conclus
result
provid
use
molecular
epidemiolog
data
understand
dynam
evolut
year
iran
support
earlier
phylogenet
observ
object
sever
epidemiolog
studi
conduct
worldwid
order
estim
preval
human
papillomavirus
hpv
infect
aim
studi
evalu
preval
hpv
type
possibl
associ
grade
histolog
lesion
cohort
women
proceed
gynaecolog
clinic
alexandra
hospit
month
period
previou
abnorm
cytolog
find
use
highli
sensit
detect
method
base
nest
pcr
method
cervic
swab
collect
particip
hpv
dna
detect
carri
pcr
nest
pcr
use
kit
ab
analitica
detect
limit
method
copi
viral
genomeml
hpv
posit
sampl
genotyp
differ
hpv
type
revers
hybrid
specif
probe
amplifi
viral
region
acquir
nest
pcr
ab
analitica
padova
itali
object
enter
virus
report
caus
nonbacteri
acut
gastroenter
includ
rotavirus
norovirus
sapovirus
astrovirus
enter
adenovirus
purpos
studi
determin
preval
distribut
virus
respons
gastroenter
children
method
molecular
epidemiolog
studi
common
diarrheal
virus
conduct
afyon
citi
turkey
januari
novemb
one
hundr
fortyfour
faecal
sampl
children
year
age
mean
age
year
rang
month
neg
presenc
pathogen
bacteria
standard
cultur
method
test
novel
multiplex
rtpcr
method
detect
noroviru
rotaviru
group
sapovirus
sav
astrovirus
hastv
adenoviru
group
f
adenoviru
genu
intern
control
phage
rna
assay
onestep
rtpcr
reaction
base
detect
four
differ
fluorophor
realtim
abi
rtpcr
neg
sampl
also
examin
electron
microscopi
em
result
among
diarrheal
virus
detect
nov
gii
common
proport
wherea
group
rotaviru
adenoviru
f
adenoviru
gn
sav
hastv
also
found
respect
overal
sampl
posit
rtpcr
neg
sampl
suffici
volum
examin
em
posit
viru
group
c
rotaviru
reoviru
confirm
specif
pcr
addit
posit
found
seventeen
sampl
found
posit
one
viral
agent
sampl
contain
group
rotaviru
nov
gii
sequenc
bp
end
bristol
toronto
virginia
beachlik
gii
conclus
find
provid
evid
norovirus
lead
caus
gastroenter
highlight
need
implement
noroviru
rotaviru
elisa
detect
assay
associ
rapid
eia
rotaviru
adenoviru
eia
detect
clinic
diagnosi
nosocomi
prevent
gastroenter
viral
infect
paediatr
depart
noteworthi
group
c
rotaviru
first
report
turkey
proport
studi
introduct
herpesvirida
virus
wide
spread
among
human
popul
abil
establish
lifelong
latent
infect
immunocompet
individu
viru
reactiv
usual
harmless
undetect
human
herpesvirus
enterovirus
major
caus
agent
central
nervou
system
cn
viral
infect
common
clinic
symptom
caus
virus
make
necessari
optim
molecular
method
allow
multipl
sensit
rapid
identif
virus
object
improv
sensit
autom
system
simultan
detect
human
herpesvirus
vzv
cmv
ebv
enterovirus
echovirus
polioviru
cosxackieviru
clart
entherpex
method
viru
detect
perform
multiplex
rtpcr
improv
pcr
develop
array
detect
system
arraystrip
simultan
process
multipl
sampl
micropl
individu
strip
analyz
sampl
qcmd
sampl
order
determin
new
diagnost
paramet
kit
reproduc
repeat
sensit
specif
discrep
valid
sequenc
homemad
pcr
nestedpcr
furthermor
compar
result
kit
clart
entherpex
realtim
qpcr
result
result
determin
analyt
sensit
vzv
copi
valu
analyt
sensit
rang
copi
obtain
detect
rest
viral
specimen
analyz
diagnost
sensit
specif
behaviour
viru
valid
clinic
specimen
show
virus
show
sensit
higher
specif
higher
reproduc
higher
repeat
higher
conclus
clart
entherpex
use
tool
rapid
screen
simultan
detect
human
herpesvirus
enterovirus
clinic
set
abl
process
sampl
simultan
work
day
new
optim
version
kit
improv
amplif
detect
make
tool
highli
sensit
use
clinic
diagnost
purpos
object
coba
system
autom
platform
combin
sampl
prepar
realtim
pcr
detect
coba
hpv
test
multiplex
assay
detect
hpv
hpv
highrisk
carcinogen
hpv
genotyp
separ
report
dye
purpos
studi
investig
correl
coba
hpv
test
result
obtain
direct
test
cervic
cytolog
specimen
collect
surepath
lbc
medium
bd
diagnost
result
obtain
use
residu
process
cellpellet
surepath
sampl
method
conveni
sampl
pair
unprocess
pellet
surepath
lbc
cervic
specimen
collect
pool
cervic
cancer
screen
specimen
follow
cytolog
interpret
pair
unprocess
pellet
specimen
fraction
test
coba
hpv
test
data
analysi
includ
percent
agreement
pair
hpv
result
associ
cervic
cytolog
discord
result
pair
hpv
hpv
posit
result
valid
use
linear
array
la
hpv
genotyp
assay
roch
molecular
system
result
total
pair
specimen
test
includ
data
analysi
remain
deem
invalid
coba
due
specimen
inadequaci
overal
percent
total
agreement
unprocess
pellet
specimen
pair
percent
posit
agreement
pair
hpv
hpv
hpv
test
respect
unprocess
surepath
specimen
hpv
neg
thirteen
discord
hpv
pair
result
cytolog
result
show
equal
distribut
normal
lsil
ascu
find
total
specimen
notabl
hpv
posit
pair
specimen
associ
lsilascu
cytolog
oper
encount
signific
process
technic
difficulti
evalu
coba
system
conclus
first
report
describ
perform
coba
hpv
test
use
unprocess
surepath
lbc
specimen
comparison
result
obtain
follow
routin
concentr
process
perform
enhanc
cytolog
analysi
excel
overal
agreement
pair
surepath
specimen
studi
identifi
expand
util
coba
hpv
test
may
time
accommod
broader
rang
diagnost
algorithm
mucos
genit
genotyp
human
papillomaviru
hpv
classifi
alphapapillomaviru
genera
sever
group
relat
oncogen
potenti
wherea
associ
benign
lesion
howev
oncogen
nononcogen
group
close
relat
due
similar
envelop
gene
molecular
diagnost
base
gene
show
analyt
inaccuraci
crossreact
group
hybrid
captur
qiagen
express
result
test
highrisk
hr
lowrisk
lr
hpv
genotyp
posit
neg
work
show
signific
analyt
inaccuraci
mainli
due
crossreact
sever
untarget
hpv
genotyp
includ
cervic
specimen
obtain
women
undergo
routin
gynecolog
examin
recogn
hpv
posit
use
highand
lowrisk
probe
cocktail
specimen
genotyp
use
innolipa
hpv
innogenet
linear
array
hpv
roch
diagnost
capabl
recogn
differ
ahpv
genotyp
respect
fivehundredfourteen
sampl
correctli
identifi
hr
lr
probe
untarget
genotyp
frequent
found
hpv
genotyp
detect
frequenc
order
genotyp
untarget
preval
correspond
detect
jointli
hr
lr
probe
howev
detect
hr
probe
probabl
due
hpv
present
hr
cocktail
interestingli
includ
hybrid
captur
detect
hr
probe
also
low
risk
genera
next
recogn
hr
probe
conclud
low
specif
probe
could
use
recov
genotyp
primarili
untarget
properti
interest
detect
minor
genotyp
potenti
import
vaccin
individu
object
herp
simplex
virus
hsv
caus
sever
dissemin
infect
neonat
immunosuppress
patient
spread
central
nervou
system
result
potenti
fatal
case
enceph
mening
rapid
detect
infect
critic
sinc
mortal
morbid
significantli
decreas
antivir
therapi
start
earli
infect
effort
aid
diagnosi
develop
rapid
molecular
test
assay
use
integr
cycler
detect
csf
swab
specimen
studi
sought
determin
sensit
specif
newli
develop
assay
method
dilut
quantifi
viru
use
analyt
studi
determin
limit
detect
assay
analyt
specif
determin
test
panel
relat
pathogen
determin
whether
cross
reactiv
observ
clinic
sensit
determin
comparison
pcr
assay
develop
focu
diagnost
refer
laboratori
discord
sampl
analyz
dna
sequenc
result
analyt
assay
abl
detect
virus
copiesml
cross
reactiv
observ
pathogen
method
comparison
studi
show
assay
compar
assay
run
altern
platform
although
rapid
throughput
could
achiev
use
integr
cycler
conclus
assay
show
excel
sensit
specif
appear
effect
tool
diagnos
hsv
relat
diseas
small
footprint
integr
cycler
facilit
placement
laboratori
capac
rapid
cycl
aid
provid
expedit
diagnost
result
benefici
diseas
manag
result
ten
isol
shigella
recov
pediatr
case
identifi
boydii
select
studi
seven
isol
attribut
serotyp
wherea
remain
three
belong
serotyp
respect
six
drug
resist
phenotyp
defin
streptomycin
ampicillin
sulfamethoxazoletrimethoprim
preval
plasmid
analysi
result
seven
differ
plasmid
profil
three
dna
band
strain
one
share
ribotyp
pfge
differenti
four
group
result
indic
pfge
pattern
well
correspond
serotyp
antibiot
resist
test
plasmid
profil
analysi
appear
good
discriminatori
power
differenti
iranian
strain
boydii
human
papillomaviru
hpv
chlamydia
trachomati
ct
major
caus
sexual
transmit
diseas
clinic
consequ
highrisk
hpv
hr
hpv
infect
especi
hpv
type
hpv
hpv
includ
abnorm
pap
test
result
low
highgrad
cervic
intraepitheli
neoplasia
cervic
cancer
ct
may
sometim
cofactor
aim
studi
determin
preval
ct
agerel
profil
hr
hpv
infect
among
case
sexual
transmit
infect
counti
due
chronic
silent
infect
ct
fast
molecular
diagnost
adequ
therapi
infect
individu
crucial
step
ct
spread
control
threeyear
period
test
genitourinari
sampl
ct
gynaecolog
sampl
hr
hpv
normal
abnorm
cervic
cytolog
diagnosi
subsequ
ct
posit
sampl
analys
sequenc
amplifi
fragment
use
appli
biosystem
genet
analys
genotyp
sequenc
mutat
analysi
perform
use
abi
seqscap
softwar
compar
refer
sequenc
known
ct
serotyp
hr
hpv
posit
sampl
abnorm
cervic
cytolog
diagnosi
genotyp
linear
array
hpv
genotyp
test
roch
diagnost
determin
serotyp
ct
hpv
genotyp
distribut
compar
ct
hpv
distribut
pattern
region
world
associ
certain
hpv
genotyp
cervic
intraepitheli
neoplasia
determin
well
mix
infect
four
hpv
preval
ct
genotyp
osijekbaranya
counti
serotyp
e
concord
sweden
taiwan
data
follow
f
k
g
b
j
differ
sweden
taiwan
data
sequenc
gene
show
limit
variat
hpv
hpv
common
hr
hpv
genotyp
cervic
specimen
abnorm
cervic
cytolog
diagnosi
obtain
result
also
determin
mix
infect
four
hr
hpv
one
low
risk
hpv
obtain
result
ct
hpv
analys
ongo
project
could
use
tool
clinic
epidemiolog
character
circul
pathogen
commun
object
focu
studi
identif
lymphogranuloma
venereum
lgv
mean
lgvspecif
pmph
real
time
pcr
assay
use
lightcycl
sequenc
easili
identifi
lgv
strain
materi
method
sixteen
clinic
sampl
differ
anatom
site
cell
cervic
urethr
peni
rectal
ulcer
proctiti
sent
microbiolog
laboratori
basurto
hospit
bilbao
spain
genotyp
polymorph
membran
protein
h
gene
pmph
use
pcr
target
real
time
pcr
assay
base
uniqu
delet
region
occur
among
lgv
strain
two
set
pcr
primer
select
amplifi
lgv
serovar
set
pmph
amplifi
dna
fragment
anoth
lgv
amplifi
pcr
reaction
carri
volum
ml
perform
lightcycl
final
product
purifi
sequenc
use
bigdy
termin
v
chemistri
accord
kit
instruct
sequenc
reaction
purifi
autoseq
sequenc
abi
genet
analyz
dna
sequenc
obtain
align
obtain
fulllength
sequenc
inform
sampl
queri
blast
databas
design
pmph
real
time
pcr
target
lightcycl
instrument
detect
lgv
dna
specimen
softwar
check
specif
amplifi
product
melt
curv
analysi
show
dissoci
curv
lgv
product
melt
sequenc
show
sequenc
three
lgv
case
ident
blast
search
reveal
type
conclus
result
suggest
pmph
real
time
pcr
use
sensit
detect
lgv
strain
could
prove
use
detect
lgv
clinic
specimen
sequencebas
use
lgv
specif
pmp
h
primer
discrimin
lgv
serovar
less
invas
c
trachomati
speci
help
detect
case
prevent
transmiss
lgv
object
evalu
use
raman
spectra
rs
gener
spectracel
ra
system
river
diagnost
bv
rotterdam
netherland
subspeci
evalu
outbreakassoci
salmonella
spp
ss
compar
standard
puls
field
gel
electrophoresi
pfge
serotyp
schema
rs
reflect
overal
molecular
constitu
bacteri
sampl
studi
laser
interrog
rapid
technic
simpl
type
gastrointestin
pathogen
high
degre
interlaboratori
compar
need
enhanc
outbreak
investig
method
rs
uniqu
ss
isol
human
anim
food
process
sourc
repres
pfge
clonal
group
defin
use
establish
guidelin
determin
triplic
studi
isol
harvest
overnight
growth
trypticsoy
agar
plate
suspend
steril
water
spun
heavi
suspens
load
onto
test
slide
spectral
fingerprint
record
specimen
averag
read
time
minut
analysi
rs
perform
use
squar
pearson
correl
coeffici
compar
result
pfge
tradit
serotyp
result
rs
test
outbreak
isol
display
cluster
compar
cluster
identifi
pfge
multipl
pfge
cluster
found
within
smaller
number
rs
cluster
case
compris
predomin
pfge
type
relat
subtyp
b
f
c
among
pfge
cluster
replic
concord
within
respect
rs
cluster
serotyp
less
discriminatori
either
ra
pfge
certain
serotyp
eg
enterica
sv
montevideo
enterica
sv
typhi
typhimurium
occur
among
multipl
pfge
rs
cluster
respect
conclus
epidemiolog
monitor
use
rs
determin
spectracel
ra
system
extrem
rapid
technic
unambigu
test
ss
outbreak
specimen
result
larg
concord
pfge
highli
reproduc
potenti
isol
process
one
work
shift
background
current
model
outer
membran
protein
omp
express
regul
e
coli
mainli
deriv
strain
preliminari
inform
suggest
may
appli
clinic
isol
may
difficult
understand
import
omp
antibiot
resist
relev
issu
aim
studi
compar
omp
pattern
multiresist
e
coli
e
coli
grown
differ
environment
condit
method
clonallyunrel
defin
reppcrpfg
multirresist
e
coli
cultur
difer
patient
produc
n
n
extendedsprectrum
blactamas
esbl
studi
e
coli
strain
use
control
omp
obtain
sonic
cell
treat
sarcosyl
concentr
centrifug
separ
sdspage
run
gel
poliacrilamid
urea
isol
grown
overnight
muellerhinton
broth
mh
nutrient
broth
nb
six
isol
repres
frequent
pattern
select
addit
studi
evalu
omp
expres
differ
condit
osmolar
bacteria
grown
nb
alon
nb
plu
sorbitol
temperatur
cultur
incub
nb
mh
ph
isol
grown
nb
mh
adjust
result
sdspage
show
differ
omp
pattern
clinic
isol
multirresist
e
coli
produc
esbl
respect
case
differ
observ
isol
grown
mh
nb
contrast
result
observ
ompf
express
downregul
mh
omp
pattern
clinic
isol
grown
sorbitol
differ
bacteria
grown
nb
alon
ompf
downregul
note
high
osmolar
medium
incub
caus
decreas
express
ompc
organ
includ
ompf
express
affect
grown
mh
signific
chang
observ
variat
express
ompf
also
observ
organ
grown
media
ph
conclus
omp
express
pattern
clinic
isol
multirresist
e
coli
usual
differ
pattern
observ
e
coli
clinic
isol
studi
osmolar
chang
significantli
affect
omp
express
high
temperatur
low
ph
affect
ompc
ompf
express
respect
object
sigma
transwab
liquid
medium
transport
swab
use
liquid
ami
transport
medium
base
origin
formul
ami
without
charcoal
intend
process
new
autom
plate
system
swab
foam
tip
allow
flow
liquid
medium
reagent
microorgan
thu
increas
sensit
recoveri
organ
preliminari
studi
use
principl
clsi
standard
inocul
swab
specifi
dilut
target
organ
hold
either
room
temperatur
preliminari
studi
organ
use
staphylococcu
aureu
haemophilu
influenza
b
haemolyt
streptococcu
fresh
overnight
cultur
use
case
organ
clinic
specimen
nctc
atcc
organ
method
mcfarland
standard
made
steril
salin
fresh
overnight
cultur
organ
use
tenfold
dilut
made
viabil
studi
mcfarland
dilut
lawn
appropri
agar
plate
ensur
organ
viabl
salin
dilut
use
growth
control
cfuml
dilut
use
inocul
swab
ml
use
tube
swab
place
inoculum
second
return
transport
media
swab
kept
room
temperatur
follow
hold
time
minut
zero
time
hour
hour
hour
hour
set
dilut
perform
duplic
complet
hold
time
swab
inocul
plate
appropri
organ
blood
agar
chocol
blood
agar
lawn
incub
appropri
atmospher
aerob
c
staphylococcu
aureu
b
haemolyt
streptococcu
c
haemophilu
influenza
plate
read
coloni
count
manual
hour
initi
result
show
recoveri
seen
organismdilutiontemperatur
combin
hour
hour
sigma
transwab
would
suitabl
transport
devic
organ
studi
done
data
present
organ
use
fastidi
organ
comparison
result
obtain
standard
transport
swab
devic
eurotubo
spain
technic
servic
consult
uk
object
accur
measur
antidiphtheria
toxoid
igg
level
immens
valu
determin
rate
immun
within
broad
popul
therefor
immun
statu
individu
may
risk
infect
especi
immun
decreas
time
absenc
booster
b
assess
immunis
schedul
efficaci
c
assess
immun
respons
vaccin
part
diagnost
protocol
primari
immunodefici
disord
five
commerci
avail
elisa
kit
measur
antidiphtheria
toxoid
igg
antibodi
evalu
perform
method
elisa
kit
manufactur
euroimmun
scimedx
serion
bind
site
virotech
evalu
intraand
interprecis
recoveri
nibsc
intern
refer
materi
measur
titr
preand
postvaccin
sampl
imprecis
five
assay
rang
intraassay
interassay
recoveri
nibsc
intern
refer
across
kit
specif
calibr
curv
vari
across
five
assay
evalu
normal
sera
sampl
show
signific
differ
exist
mean
valu
obtain
five
assay
accuraci
interpret
preand
postvaccin
measur
differ
among
five
assay
data
suggest
manufactur
depend
characterist
affect
perform
assay
may
result
differ
clinic
diagnost
interpret
cac
found
sensit
specif
c
glabrata
sensit
specif
c
krusei
sensit
specif
c
tropicali
c
kefyr
abl
calcul
togeth
speci
grow
form
colour
valu
found
respect
conclus
studi
cac
aid
cs
plate
show
similar
perform
respect
c
albican
identif
cac
cs
c
tropicali
result
cac
recommend
reliabl
medium
presumpt
identif
candida
speci
differenti
four
speci
c
albican
c
tropicali
c
glabrata
c
krusei
success
pp
zurich
ch
object
fungal
cultur
tradit
incub
week
longer
order
maxim
recoveri
slowli
grow
fungi
howev
data
support
scarc
purpos
studi
determin
optimum
incub
time
specimen
mould
yeast
suspect
method
dermatolog
nondermatolog
specimen
prospect
analyz
day
fungal
growth
first
note
record
result
total
fungal
isol
detect
day
detect
day
detect
day
ten
nondermatolog
specimen
posit
third
week
grew
fungu
consid
clinic
nonrelev
result
indic
specimen
sent
detect
yeast
mould
except
dermatophyt
system
dimorph
fungi
incub
period
week
suffici
wherea
dermatophyt
week
necessari
base
result
previou
literatur
algorithm
incub
time
fungal
cultur
propos
agalactia
strain
identifi
speci
level
good
log
score
investig
mass
spectra
differ
st
reveal
marker
characterist
two
st
respect
also
minor
variabl
insid
group
conclus
malditof
ms
profil
analysi
reliabl
tool
speci
identif
agalactia
also
signific
capabl
subspeci
identif
evalu
full
potenti
studi
necessari
object
perform
commerci
immunoassay
detect
herp
simplex
viru
type
type
antibodi
seemingli
inconsist
african
hivinfect
popul
herein
evalu
new
bioplex
immunoassay
system
biorad
laboratori
ca
usa
detect
herpesspecif
antibodi
method
sera
obtain
inform
consent
patient
follow
health
care
clinic
bangui
capit
citi
central
african
republ
countri
high
preval
infect
includ
adult
clinic
asymptomat
herp
diseas
ii
children
born
hivinfect
mother
clinic
asymptomat
herp
diseas
iii
patient
suffer
pcrproven
genit
ulcer
recurr
iv
patient
suffer
pcrproven
primari
genit
ulcer
sera
test
specif
antibodi
fulli
autom
beadbas
multiplex
immunoassay
bioplex
system
result
among
adult
clinic
asymptomat
herp
diseas
seroposit
respect
among
children
clinic
asymptomat
herp
diseas
seroposit
respect
observ
consist
natur
histori
infect
subsaharan
africa
demonstr
earli
acquisit
children
wherea
infect
appear
larg
acquir
later
age
sexual
life
among
patient
suffer
genit
recurr
seroposit
final
among
patient
suffer
primari
genit
ulcer
seroposit
inclus
thu
seroposit
appear
highli
sensit
predict
recurr
patient
clinic
symptomat
genit
ulcer
may
also
found
earli
seroconvert
patient
primari
genit
ulcer
comparison
bioplex
result
obtain
convent
herpesselect
glycoprotein
immunoassay
discuss
bioplex
immunoassay
system
provid
use
tool
hsv
typespecif
serolog
use
clinic
care
african
patient
suffer
herpect
genit
disord
well
intervent
studi
field
conceiv
control
genit
infect
repres
main
modulatori
cofactor
heterosexu
hiv
transmiss
subsaharan
africa
cdt
tcdc
gene
delect
nt
less
hour
system
requir
use
singleus
dispos
cartridg
host
process
dna
extract
pcr
result
sampl
neg
method
sampl
posit
method
sampl
neg
method
posit
method
gdh
tox
ab
gdh
tox
ab
discord
result
pcr
assay
detect
toxin
b
gene
patient
diagnos
clostridium
difficil
infect
conjunct
patient
clinic
histori
incid
cdi
use
method
use
method
comparison
two
method
done
use
mcnemar
test
continu
correct
p
differ
found
statist
signific
conclus
techlab
c
diff
quik
chek
test
detect
posit
result
diagnosi
c
difficil
infect
xpect
toxin
ab
immunochromatograph
assay
result
confirm
real
time
pcr
method
base
luminex
technolog
assay
develop
use
microspher
coat
pnp
specif
monoclon
antibodi
mab
detect
type
singl
well
urin
sampl
posit
specif
serotyp
base
cutoff
valu
establish
panel
control
urin
sampl
calcul
rel
standard
curv
run
assay
plate
although
design
qualit
assay
method
abl
quantifi
amount
pnp
sampl
qualifi
address
specif
accuraci
precis
assay
specif
signific
signal
detect
polysaccharid
pair
homolog
mabcoat
microspher
lower
limit
linear
rang
pgml
qualif
experi
show
assay
accept
accuraci
bia
ratio
precis
rsd
preliminari
assess
clinic
sampl
obtain
cap
patient
demonstr
assay
significantli
sensit
blood
cultur
identifi
spn
serotyp
conclus
result
demonstr
assay
noninvas
sensit
reproduc
method
detect
presenc
spn
polysaccharid
urin
potenti
use
diagnost
test
support
clinic
well
epidemiolog
evalu
pneumococc
diseas
result
vitek
card
contain
esbl
well
fail
detect
esbl
activ
also
etest
esbl
strip
cazcazcla
ctxctxcla
yield
indetermin
result
isol
ect
fail
isol
cazcazcla
disc
isol
ctxctxcla
disc
howev
synergi
observ
aztreonam
amoxicillincla
strain
dd
etest
method
fail
detect
carbapenem
resist
instanc
wherea
vitek
show
overal
good
perform
accompani
warn
carbapenemas
activ
trigger
expert
system
tabl
mht
reveal
carbapenemas
activ
isol
cd
assay
success
ul
object
aim
studi
evalu
feasibl
protein
marker
central
nervou
system
infect
serum
marker
use
rapid
diagnost
traumat
ischaem
damag
central
nervou
system
cn
cn
marker
would
great
improv
diagnost
perform
lumbar
punctur
illdefin
case
research
test
whether
level
higher
serum
spinal
fluid
patient
cn
infect
compar
without
method
test
child
patient
child
infecti
diseas
depart
patien
admit
due
suspect
cn
infect
healthi
control
patient
underw
standard
diagnost
procedur
includ
blood
sampl
lumbar
punctur
serolog
cultiv
pcr
patient
test
serum
spinal
fluid
electroimunoassay
method
cn
infect
confirm
patient
cn
infect
prove
standard
method
patient
patien
ad
control
group
valu
serum
spinal
fluid
compar
group
result
signific
differ
valu
found
group
patient
cn
infect
control
group
patien
confirm
cn
infect
level
cuttoff
valu
age
result
indic
protein
promis
marker
central
nervou
system
infect
oral
caviti
one
complex
heterogen
bodi
part
inhabit
predominantli
anaerob
microorgan
may
act
synergist
produc
seri
purul
infect
mix
origin
worth
note
pericoron
recent
increas
aid
dental
patient
pericoron
therefor
gener
dentist
oral
surgeon
import
continu
therapi
prevent
treatment
entiti
detect
identif
infecti
agent
caus
critic
guid
us
toward
correct
antibiot
avoid
unnecessari
use
antibiot
thu
avoid
risk
bacteri
resist
outsid
border
made
studi
detect
identif
microorgan
involv
pericoron
recent
studi
publish
franc
unit
state
america
highlight
predomin
anaerob
bacteria
microorgan
produc
condit
countri
studi
perform
true
numer
studi
relat
detect
identif
microorgan
lesion
oral
caviti
dental
cari
subprothes
stomat
periodont
diseas
pulpal
periap
infect
given
import
microbiota
associ
pericoron
fulli
justifi
studi
well
enabl
detect
identif
caus
agent
pericoron
also
serv
identifi
associ
microbi
speci
help
select
appropri
antimicrobi
therapi
treatment
infect
serv
start
point
background
studi
microflora
entiti
bifidobacterium
spp
b
adolescent
veillonella
spp
p
loeschii
p
melaninogenica
p
orali
accept
good
correl
find
disk
diffus
etest
antibiot
media
clindamycin
found
unaccept
high
frequenc
vme
conclus
disk
diffus
reliabl
method
evalu
suscept
moxifloxacin
erythromycin
howev
disk
diffus
inadequ
detect
clindamycin
resist
therefor
supplement
either
etest
broth
dilut
method
object
use
standard
method
test
sporocid
activ
new
hybrid
materi
base
polyvinyl
alcohol
pva
tetraethyl
orthosil
teo
embed
silver
nanoparticl
agnp
synthes
two
differ
method
allow
compar
result
obtain
choic
appropri
method
synthesi
method
hybrid
materi
basi
pva
teo
embed
agnp
differ
silver
concentr
mg
mg
mg
synthes
use
solgel
method
two
strategi
first
strategi
base
insitu
format
agnp
via
thermal
anneal
pvateo
hybrid
film
second
strategi
consist
form
agnp
pvateo
matrix
without
thermal
anneal
film
standard
paper
disk
mm
impregn
solut
allow
dri
room
temperatur
thermal
treat
materi
disk
anneal
h
thu
prepar
disk
use
test
sporicid
activ
hybrid
pvaagnpsteo
materi
pour
agar
method
test
microorgan
bacillu
subtili
atcc
b
subtili
result
obtain
tripl
test
sampl
show
test
hybrid
materi
embed
agnp
possess
sporicid
activ
synthes
materi
demonstr
sporicid
activ
b
subtili
use
silver
concentr
appear
inhibit
zone
rang
mm
differ
zone
differ
silver
concentr
rang
mm
regardless
method
pronounc
zone
inhibit
demonstr
hybrid
pvaagnpsteo
materi
highest
silver
concentr
mg
method
prove
sporicid
activ
extend
possibl
applic
hybrid
materi
coat
clean
room
like
surgeri
industri
laboratori
place
contamin
spore
cultur
could
affect
neg
ampcproduc
strain
phoenix
mec
reproduc
also
evalu
isol
daili
qc
monitor
strain
test
parallel
phoenix
system
clsirecommend
agar
dilut
refer
method
adm
bacteri
suspens
adjust
equival
mcfarland
standard
inocul
simultan
bd
phoenix
system
adm
phoenix
panel
contain
mec
place
bd
phoenix
instrument
incub
autom
read
complet
adm
plate
incub
hour
ambient
air
read
manual
mic
endpoint
determin
mecillinam
breakpoint
qc
strain
rang
base
recommend
current
clsi
standard
phoenix
mec
yield
essenti
ea
categor
ca
agreement
respect
compar
adm
major
error
vme
major
rate
respect
me
identifi
esblproduc
strain
singl
vme
confirm
plasmidmedi
ampc
produc
reproduc
daili
qc
rate
bd
phoenix
system
provid
accept
level
agreement
mecillinam
refer
agar
dilut
method
result
abl
detect
resist
antibiot
escherichia
coli
method
plasma
sampl
children
age
month
year
test
presenc
total
antihav
children
separ
four
age
group
group
year
n
group
year
n
group
year
n
group
year
n
overal
preval
total
antihav
ci
hav
preval
rate
accord
age
group
follow
group
group
group
group
hav
seropreval
among
month
year
old
children
reach
year
age
group
year
age
group
except
year
age
group
older
age
associ
higher
seropreval
hav
total
antihav
posit
term
age
group
significantli
differ
p
age
group
statist
signific
differ
gender
regard
antihav
posit
conclus
studi
find
indic
hepat
preval
children
tehran
iran
hepat
infect
import
public
health
problem
region
survey
also
show
tehran
region
moder
endem
hepat
infect
hav
prevent
vaccin
children
benefici
object
coronari
arteri
diseas
cad
major
caus
death
worldwid
infect
follow
inflamm
coronari
arteri
one
lead
basi
atherosclerosi
matter
ponder
recent
studi
evalu
antibodi
titer
helicobact
pylori
hp
patient
cad
compar
normal
coronari
arteri
subject
nca
associ
advers
cardiac
event
cad
year
follow
sinc
differ
vaccin
campaign
perform
success
local
peopl
support
campaign
also
measl
vaccin
rate
last
year
consecut
case
detect
immigr
famili
travel
histori
iran
august
secondari
case
detect
year
old
cousin
famili
nt
travel
brought
necess
find
unvaccin
children
district
part
social
mobil
studi
local
administr
chief
inform
field
work
last
day
complet
subdistrict
immigr
famili
live
dens
health
offici
visit
hous
left
invit
resid
away
studi
found
children
unvaccin
nt
get
health
care
came
last
month
month
old
delay
mmr
vaccin
measl
igm
found
neg
children
rash
measl
surveil
today
famili
reject
get
measl
vaccin
case
show
mild
reaction
vaccin
case
detect
applic
mistak
conclus
difficulti
live
diagnos
measl
clinic
first
case
caus
secondari
case
outbreak
took
physician
attent
diseas
agenda
nt
behind
differenti
diagnosi
object
describ
clinic
present
patient
confirm
infect
compar
patient
neg
viru
method
patient
present
hospit
flulik
symptom
sinc
begin
pandem
pharyng
sampl
pcr
test
obtain
sampl
obtain
surveil
phase
order
identifi
isol
patient
thu
prevent
spread
diseas
result
sampl
posit
neg
tabl
summar
symptom
patient
group
conclus
among
patient
posit
pcr
promin
symptom
malais
fever
gener
typic
clinic
present
like
lead
posit
test
ignor
though
fact
case
low
fever
mild
diseas
prove
posit
other
typic
clinic
present
neg
patient
strong
possibl
base
clinic
condit
posit
test
safeti
reason
eg
peopl
immunocomprimis
member
famili
like
neg
posit
object
report
number
chlamydia
trachomati
ct
associ
lymphogranuloma
venereum
lgv
increas
last
decad
around
year
small
outbreak
sinc
describ
europ
howev
spain
sporad
case
report
north
northeast
area
explor
presenc
serovar
associ
lgv
among
high
risk
popul
madrid
spain
use
molecular
method
detect
genotyp
ctlgv
associ
serovar
method
two
high
risk
popul
group
citi
includ
studi
sentinel
popul
ii
patient
attend
unit
sexual
transmit
infect
sti
two
public
hospit
urethr
cervix
rectal
swab
symptomat
patient
recov
six
month
mayoctob
two
commerci
pcrbase
method
abbott
molecular
beckton
dickinson
perform
routin
diagnost
ct
infect
inhous
taqman
real
timepcr
qpcr
base
delet
pmph
gene
use
specif
detect
lgv
relat
serovar
identifi
specif
serovar
nestedpcr
sequenc
ompa
gene
appli
result
sampl
sentinel
popul
groupii
yield
posit
ct
amplif
repres
analys
sampl
among
posit
sampl
show
also
specif
amplif
lserovar
one
urethr
five
rectal
swab
result
obtain
men
sex
men
multipl
sexual
partner
last
year
interestingli
four
patient
spanish
indic
spread
lgv
among
nativ
popul
four
hiv
posit
concomit
sti
three
gonococc
proctiti
two
infect
high
risk
papilomaviru
one
herp
simplex
infect
blast
analysi
sequenc
ompa
gene
show
concord
serovar
case
previous
describ
recent
outbreak
europ
conclus
knowledg
percentag
serovar
found
work
highest
valu
publish
spain
confirm
spread
serovar
across
europ
high
correl
ctposit
serovar
nativ
popul
suggest
serovar
alreadi
establish
among
spanish
popul
public
health
perspect
routin
surveil
lgv
may
import
assess
real
preval
high
risk
popul
object
aim
studi
evalu
occur
clostridium
difficil
coastal
environ
gulf
napl
southern
itali
expos
differ
degre
anthrop
pressur
sampl
seawat
sediment
mussel
zooplankton
investig
presenc
c
difficil
order
provid
first
ecolog
insight
environment
behaviour
bacteria
method
sampl
water
sediment
mussel
mytilu
galloprovinciali
zooplankton
taken
sampl
station
gulf
napl
septemb
sampl
enrich
clostridium
difficil
enrich
broth
supplement
sodium
taurochol
incub
day
anaerob
condit
incub
alcohol
shock
centrifug
perform
spore
select
result
pellet
streak
onto
c
difficil
agar
base
supplement
moxalactam
norfloxacin
hors
blood
incub
h
condit
rhizoid
coloni
sporeform
gram
posit
bacilli
nonhemolyt
posit
prolin
aminopeptidas
test
oxoid
identifi
miniatur
system
id
rapid
biomeriux
identifi
c
difficil
strain
challeng
detect
esotoxin
xpect
clostridium
difficil
toxin
ab
test
oxoid
result
work
shown
widespread
presenc
c
difficil
investig
marin
environ
total
sampl
taken
yield
isol
posit
rate
c
difficil
isol
sampl
water
zooplankton
mussel
respect
isol
found
water
zooplankton
sampl
collect
faecal
pollut
area
found
abl
produc
c
difficil
toxin
ab
isol
found
area
low
faecal
pollut
non
toxigen
presenc
c
difficil
mussel
certainli
relat
presenc
bacterium
water
mussel
filter
feeder
clarifi
wheter
c
difficil
associ
particul
organ
matter
also
member
plankton
microbi
commun
isol
c
difficil
epizoot
contamin
zooplankton
exoskeleton
never
report
studi
need
understand
zooplankton
enabl
spread
bacterium
environ
especi
area
low
absent
faecal
pollut
purpos
studi
physic
properti
dissolut
profil
commerci
sampl
artesun
amodiaquin
tablet
method
fifteen
gener
brand
artesun
five
gener
brand
amodiaquin
tablet
obtain
drug
retail
outlet
oyo
ogun
state
nigeria
tablet
subject
variou
compendia
test
includ
identif
weight
uniform
uniform
content
assay
activ
ingredi
uniform
diamet
addit
test
use
basi
assess
pharmaceut
equival
product
includ
hard
disintegr
time
dissolut
rate
data
obtain
analys
correl
analysi
chisquar
anova
result
thirteen
gener
brand
artesun
four
amodiaquin
brand
investig
import
two
brand
import
artesun
brand
found
contain
undetect
amount
artesun
anoth
sampl
contain
overag
amodiaquin
brand
pass
assay
test
stipul
usp
amodiaquin
tablet
tablet
disintegr
time
amodiaquin
product
rang
min
one
artesun
sampl
pass
disintegr
test
major
artesun
brand
test
significantli
differ
dissolut
profil
p
four
amodiaquin
tablet
brand
test
similar
dissolut
profil
percent
drug
releas
within
min
p
one
amodiaquin
brand
cc
demonstr
poor
dissolut
profil
meet
essenti
minimum
content
dissolut
within
detect
substandard
artesun
tablet
poorli
formul
amodiaquin
tablet
amongst
sampl
brand
studi
highlight
need
increas
drug
surveil
monitor
qualiti
antimalari
medicin
current
use
order
prevent
widespread
treatment
failur
clinic
immens
success
sever
patient
requir
urgent
cardiac
surgeri
oper
day
complet
regc
use
teicoplanin
prophylaxi
prontoderm
pack
requir
prescript
suppli
pac
user
friendli
info
leaflet
cheaper
patient
find
chlorhexidin
shower
cleans
prontoderm
foam
applic
shower
dri
skin
object
import
immedi
hand
decontamin
direct
patient
contact
well
accept
practis
mani
year
howev
comparitav
littl
research
look
risk
spread
infect
via
stethoscop
medic
equip
direct
contact
patient
examin
aim
audit
assess
bacteri
contamin
stethoscop
assess
effect
propos
clean
method
use
alcohol
wipe
method
forti
stethoscop
randomli
select
wide
rang
medic
personnel
intens
care
unit
icu
medic
high
depend
unit
mhdu
accid
emerg
e
medic
depart
md
stethoscop
swab
clean
alcohol
wipe
isopropyl
alcohol
sampl
sent
cultur
result
express
count
coloni
form
unit
cfu
per
ml
ringer
solut
use
prepar
swab
overal
result
show
stethoscop
clean
contamin
skin
flora
averag
contamin
cfu
contamin
report
skin
flora
includ
potenti
pathogen
staphylococcu
aureu
pseudomona
aerginosa
e
lowest
averag
contamin
per
stethoscop
cfu
clean
cfu
third
stethoscop
ituhdu
clean
averag
contamin
cfu
howev
stethoscop
grew
cfu
md
highest
number
contamin
stethoscop
averag
cfu
clean
follow
clean
result
show
stethoscop
grew
cfu
remain
stethoscop
account
last
grew
cfu
prior
clean
possibl
error
clean
process
conclus
audit
demonstr
import
clean
stethoscop
patient
contact
plausibl
vector
transmit
potenti
pathogen
infect
prove
effect
clean
method
errad
bacteri
contamin
cfu
case
whilst
focu
must
maintain
hand
wash
also
advis
clean
stethoscop
improv
staff
knowledg
vital
could
achiev
ward
poster
easi
access
alcohol
wipe
present
result
audit
research
requir
see
condit
improv
propos
intervent
look
specif
transmiss
hospit
acquir
infect
via
stethoscop
object
emerg
spread
antimicrobi
resist
becom
major
public
health
threat
antimicrobi
usag
key
factor
resist
allow
select
emerg
resist
pathogen
main
object
studi
provid
intens
care
unitspecif
nation
benchmark
data
antimicrobi
consumpt
resist
rate
rr
group
hospit
hygien
gisio
italian
societi
hygien
siti
invit
take
part
studi
project
use
integr
approach
unitbas
approach
surveil
antimicrobi
use
patientbas
approach
surveil
antimicrobi
resist
italian
icu
studi
conduct
novemb
april
includ
icu
patient
length
stay
longer
two
day
patientday
produc
total
defin
daili
dose
ddd
studi
period
antimicrobi
usag
densiti
ad
patient
day
ddd
unit
per
patientday
three
use
drug
group
penicillinsblactamas
inhibitor
ad
quinolon
ad
glycopeptid
ad
singl
frequent
prescrib
antimicrobi
agent
ampicillinsulbactam
ddd
ad
follow
levofloxacin
ddd
ad
fluconazol
ddd
ad
suscept
data
report
isol
frequent
infectionassoci
pathogen
pseudomona
aeruginosa
follow
acinetobact
baumannii
staphylococcu
aureu
candida
spp
account
rr
ceftazidimresist
baumannii
p
aeruginosa
respect
imipenemresist
baumannii
p
aeruginosa
respect
oxacillinresist
aureu
conclus
comparison
resist
pattern
prescrib
practic
differ
icu
underlin
need
local
adapt
guidelin
empir
antimicrobi
therapi
base
evid
link
antimicrobi
resist
consumpt
intern
benchmark
order
address
effect
control
measur
object
nosocomi
infect
drugresist
bacteria
becom
great
concern
medic
facil
ng
respect
highest
preval
observ
among
symptomat
asymptomat
male
ct
respect
ng
respect
among
symptomat
asymptomat
women
tv
respect
posit
ct
associ
p
valu
c
younger
age
year
vs
year
age
vs
two
partner
previou
six
month
vs
partner
vs
use
oral
contracept
previou
six
month
oral
contracept
vs
vs
conclus
preliminari
result
laboratorybas
surveil
system
sti
seem
suggest
import
data
circul
infect
among
individu
like
gener
popul
consult
sti
clinic
background
control
hospit
infect
new
way
improv
clean
process
need
cleantrac
clinic
hygien
monitor
system
employ
atp
detect
technolog
valid
rapid
review
panel
provid
rapid
quantifi
assess
qualiti
clean
process
part
structur
approach
hygien
monitor
hospit
recent
introduc
gener
ward
clinic
base
clean
schedul
design
infect
prevent
control
team
focu
staff
clean
patient
equip
abl
demonstr
done
document
object
use
cleartrac
technolog
tool
look
valu
implement
ward
base
clean
schedul
aim
improv
clean
standard
medic
equip
two
clinic
area
select
minor
surgeri
treatment
room
surgic
ward
ten
site
clinic
area
identifi
written
plan
produc
enabl
swab
taken
exact
site
time
everi
day
week
prior
schedul
implement
follow
introduct
schedul
swab
collect
daili
day
per
week
week
feedback
given
staff
first
two
week
postschedul
last
week
postschedul
daili
feedback
given
senior
nurs
manag
clean
staff
background
swab
site
identifi
area
clean
need
improv
upon
commenc
clean
schedul
focu
staff
clean
led
improv
document
clean
process
expect
howev
site
continu
give
high
signal
atp
swab
feedback
given
staff
clean
improv
site
low
atp
signal
eas
access
clean
particular
piec
equip
found
affect
likelihood
clean
take
place
exampl
xray
light
box
site
high
staff
box
remov
follow
discuss
staff
studi
identifi
benefit
introduc
clean
schedul
refocus
staff
need
vigil
clean
equip
patient
valu
document
equip
clean
practic
cleantrac
system
use
provid
tool
audit
clean
qualiti
lagrangexelot
r
porcher
wargnier
gallien
j
pavi
n
de
castro
j
molina
pari
fr
object
guidelin
prevent
transmiss
mycobacterium
tuberculosi
healthcar
set
success
properli
implement
may
also
result
unnecessari
isol
mani
patient
without
tuberculosi
signific
increas
hospit
cost
wish
assess
preval
identifi
predict
clinic
factor
cultureproven
tuberculosi
among
inpati
isol
suspect
pulmonari
tuberculosi
ptb
depart
also
wish
valid
previous
publish
clinic
decis
rule
cdr
predict
need
respiratori
isol
patient
specif
higher
signific
result
obtain
neg
predict
valu
characterist
enabl
us
propos
pcr
screen
order
rapidli
releas
suspect
mrsa
carrier
isol
hospit
admiss
genxpert
rapid
molecular
test
present
high
neg
predict
valu
use
effici
improv
patient
comfort
hospit
ward
manag
without
loss
secur
infect
control
howev
low
ppv
obtain
suggest
cultur
remain
necessari
assess
strain
viabil
object
rubella
common
communic
diseas
childhood
ordinarili
benign
children
adult
howev
develop
fetu
infect
may
seriou
still
import
accur
determin
immun
statu
women
reproduct
age
still
women
vaccin
rubella
viru
diagnos
confirm
recent
infect
relat
congenit
syndrom
hemagglutin
inhibit
hai
still
commonli
use
techniqu
laboratori
diagnosi
rubella
countri
e
g
germani
austria
howev
test
lengthi
labor
intens
poorli
adapt
autom
addit
consider
variat
one
laboratori
anoth
use
fulli
autom
electrochemiluminesc
immunoassay
eclia
improv
altern
hai
studi
describ
compar
laboratori
analysi
indirect
hemagglutin
elecsi
rubella
igg
assay
roch
modular
immunoassay
platform
method
total
serum
specimen
studi
retrospect
sera
test
commerci
hai
assay
siemen
medic
diagnost
marburg
germani
fulli
autom
elecsi
rubella
igg
assay
modular
analyt
roch
diacnost
mannhein
germani
discrep
sampl
addit
test
rubella
igm
immunoassay
roch
diagnost
mannheim
germani
resolv
viru
neutral
assay
determin
immun
statu
rel
sensit
detect
immun
assay
type
amount
indetermin
result
hai
compar
elecsi
rubella
igg
rel
specif
assay
detect
immun
rubella
viru
hai
elecsi
rubella
igg
assay
overal
correl
assay
conclus
iha
still
reliabl
method
screen
sera
immun
rubella
viru
today
fulli
autom
quantit
antibodi
immunoassay
like
elecsi
rubella
igg
assay
superior
refer
sensit
specif
grade
standard
stabil
assay
even
higher
result
better
compar
differ
lab
point
view
iha
replac
quantit
igg
assay
screen
prenat
sera
immun
rubella
viru
object
reduc
blood
cultur
contamin
rate
subsequ
long
term
mainten
reduct
prevent
instig
unnecessari
antimicrobi
therapi
achiev
reduct
paediatr
set
requir
differ
infect
control
intervent
adult
polici
report
describ
retrospect
observ
studi
consecut
paediatr
bacteraemia
patient
attend
tertiari
referr
paediatr
director
intens
infect
control
measur
introduc
reduc
contamin
rate
studi
period
cover
two
year
novemb
octob
infect
control
intervent
introduc
follow
high
rate
blood
cultur
contamin
rate
octob
point
intens
train
educ
carri
induct
regular
real
time
epidemiolog
feedback
medic
nurs
staff
implement
mainten
demograph
clinic
laboratori
data
review
posit
blood
cultur
studi
period
result
follow
induct
mainten
phase
infect
control
intervent
reduct
blood
cultur
contamin
coagulas
neg
staphylococci
achiev
mean
per
month
preintervent
per
month
post
intervent
pvalu
statist
signific
drop
overal
blood
cultur
taken
preand
post
intervent
per
month
respect
pvalu
isol
pathogen
except
yeast
pre
intervent
isol
year
post
intervent
isol
year
pvalu
also
statist
signific
decreas
coagulas
neg
staphylococc
bacteraemia
patient
indwel
long
line
preintervent
post
intervent
pvalu
despit
gross
total
parenter
administr
within
unit
actual
increas
period
find
infect
control
intervent
focus
educ
train
reduc
blood
cultur
contamin
rate
reduct
maintain
regular
realtim
epidemiolog
feedback
clinic
staff
e
ozturk
guven
celik
doganay
voss
kayseri
tr
nijmegen
nl
object
identifi
belief
percept
associ
hand
hygien
perform
two
differ
institut
limit
resourc
start
infect
control
programm
later
develop
institut
studi
conduct
two
differ
hospit
univers
hospit
uhospit
commun
hospit
chospit
citi
selfadminist
questionnair
question
drawn
questionnair
use
previous
studiesfrom
industri
countri
base
theori
plan
behavior
nurs
nurs
student
physician
medic
student
uhospit
nurs
chospit
includ
studi
result
questionnair
return
return
rate
highest
nurs
chospit
lowest
senior
physician
uhospit
respond
provid
demograph
inform
data
variou
behavior
norm
control
belief
determin
intent
respect
perform
hand
hygien
among
individu
profession
categori
greater
percentag
uhospit
nurs
respect
believ
healthcareassoci
infect
greater
mortal
rate
among
infect
patient
greater
howev
profession
categori
believ
good
hand
hygien
effect
prevent
infect
univari
analysi
receipt
structur
train
hand
hygien
perceiv
colleagu
adher
good
adher
model
good
practic
other
observ
adher
norm
belief
percept
hand
hygien
rel
easi
perform
control
belief
associ
good
hand
hygien
howev
multivari
analysi
high
self
report
adher
hand
hygien
independ
associ
receipt
structur
train
hand
hygien
perceiv
good
adher
colleagu
percept
hand
hygien
rel
easi
perform
observ
adher
conclus
countri
limit
resourc
intent
compli
associ
train
strong
norm
control
belief
also
two
differ
kind
institut
similar
hand
hygien
promot
campaign
citi
believ
nurs
differ
develop
countri
resourc
save
train
hcw
easi
access
hand
hygien
product
isol
identifi
test
antibiot
suscept
autom
system
franc
confirm
mic
determin
etest
ab
biodisk
sweden
descript
logist
regress
analys
perform
determin
risk
factor
ssi
p
valu
regard
signific
result
ssi
occur
oper
pathogen
isol
seventeen
gramneg
rod
five
gramposit
cocci
one
candida
albican
infect
polymicrobi
fourteen
patient
infect
coexist
anoth
site
isol
k
pneumonia
p
aeruginosa
e
coli
enterococcu
spp
coagulaseneg
staphylococci
isol
staphylococcu
aureu
six
strain
k
pneumonia
kpcproduc
five
strain
p
aeruginosa
multidrug
resist
gramposit
cocci
methicillinresist
glycopeptidessensit
risk
factor
signific
summar
tabl
conclus
despit
use
precautionari
antimicrobi
treatment
antisept
measur
rate
ssi
high
effort
control
ssi
focus
hospit
infect
surveil
program
modif
feasibl
factor
affect
significantli
develop
ssi
awar
risk
factor
certain
surgic
procedur
allow
target
prevent
measur
overal
studi
intervent
studi
two
crossov
trial
review
studi
perform
four
studi
done
europ
uk
studi
canada
one
studi
clusterrandomis
unblind
crossov
trial
studi
use
commerci
assay
nasal
sampl
test
studi
studi
mrsa
associ
least
anoth
site
eg
axilla
perineum
groin
skin
break
compar
cultur
screen
use
rapid
screen
test
associ
signific
decreas
mrsa
acquisit
rate
risk
ratio
ci
heterogen
among
studi
reduc
inclus
new
studi
conclus
cumul
metaanalysi
demonstr
substanti
variat
point
estim
addit
recent
publish
studi
confirm
rapid
screen
test
seem
effect
significantli
reduc
hospitalacquir
mrsa
acquisit
rate
compar
cultur
screen
tezer
tekc
h
cabadak
sen
ankara
tr
object
hand
hygien
essenti
prevent
nosocomi
infect
complianc
clinic
practic
often
low
studi
plan
determin
complianc
rate
hand
hygien
practic
impact
educ
program
hand
hygien
complianc
rate
durat
effect
educ
program
method
prospect
observ
studi
perform
turkiy
yuksek
ihtisa
educ
research
hospit
turkey
hand
hygien
complianc
effect
educ
program
durat
effect
hand
hygien
complianc
investig
observ
carri
weekday
work
hour
hand
hygien
practic
evalu
follow
procedur
patient
contact
patient
contact
environment
contact
high
risk
contact
contact
blood
bodi
fluid
complianc
medic
doctor
nurs
staff
evalu
result
hand
hygien
complianc
evalu
contact
month
period
initi
phase
studi
total
contact
observ
contact
hand
hygien
practic
proper
educ
program
overal
complianc
rate
improv
p
follow
month
complianc
rate
detect
four
month
intervent
complianc
rate
decreas
repeat
educ
intervent
complianc
rate
increas
nurs
staff
better
complianc
rate
medic
doctor
overal
versu
p
overal
hand
hygien
complianc
patient
contact
greater
patient
contact
vs
p
hand
hygien
complianc
high
risk
contact
detect
intervent
first
intervent
p
conclus
continu
educ
program
need
order
maintain
higher
complianc
rate
hand
hygien
practic
suggest
educ
intervent
repeat
everi
month
object
obtain
incid
nosocomi
catheterassoci
urinari
tract
infect
cauti
microbiolog
profil
bacteri
resist
intens
care
unit
icu
observ
effect
educ
intervent
cauti
rate
episod
decis
made
declin
search
focu
search
prevent
precipit
death
episod
local
sign
miss
due
neutropenia
togeth
two
group
account
case
three
infant
month
old
primari
pneumococc
bacteraemia
conclus
use
retrospect
chart
review
refer
found
posit
predict
valu
close
categori
focu
unknown
databas
high
proport
patient
unknown
focu
either
die
rapidli
sever
neutropenia
contribut
neg
prognost
impact
absent
focu
perhap
even
hidden
focu
object
report
describ
epidemiolog
microbiolog
survey
infect
occur
rehabilit
unit
clinic
epidemiolog
nosocomi
infect
powi
vap
uti
bsi
elig
criteria
epidemiolog
analysi
includ
code
belong
ten
main
group
infect
uti
low
respiratori
tract
intestin
bone
sepsi
candidiasi
bacteri
specifi
ssti
iatrogen
cardiovascular
valid
diagnosi
review
medic
chart
ru
perform
order
assess
sensit
multipl
regress
method
conclus
studi
show
high
incid
nosocomi
candidemia
especi
medic
ward
candidemia
found
involv
non
neutropen
elderli
patient
receiv
antibiot
therapi
one
half
popul
cvc
sever
underli
diseas
casecontrol
studi
warrant
defin
risk
factor
candidemia
popul
order
get
effect
prevent
strategi
k
j
eder
fill
h
ellemunt
innsbruck
introduct
pseudomona
aeruginosa
pa
remain
import
pathogen
cystic
fibrosi
cf
lung
chronic
pa
infect
associ
increas
morbid
mortal
infect
control
measur
earli
erad
regimen
effect
prevent
cross
infect
among
patient
object
aim
studi
investig
divers
pa
isol
sputum
singl
longterm
chronic
infect
patient
chang
genotyp
time
also
determin
possibl
cross
infect
pa
patient
term
present
studi
studi
carri
prospect
random
sputum
isol
n
collect
chronic
infect
patient
studi
period
month
cf
patient
categor
chronic
infect
pa
accord
modifi
leed
criteria
andor
antipseudomona
antibodi
includ
twenti
outpati
inpati
antibiot
therapi
record
cf
databas
avail
pseudomona
aeruginosa
isol
cultur
sputum
sampl
identifi
standard
method
strain
characteris
antibiot
resist
test
use
disc
diffus
etest
isol
analys
clonal
divers
use
random
amplifi
polymorph
dna
rapd
pcr
differ
primer
p
molecular
type
method
result
studi
period
patient
carri
multipl
pa
isol
four
patient
carri
isol
patient
isol
patient
isol
one
patient
isol
molecular
type
reveal
clonal
among
isol
test
found
transmiss
pa
isol
rapd
genotyp
among
patient
collect
one
patient
found
two
genotyp
differ
pa
one
sputum
sampl
great
genotyp
divers
found
repeat
sputum
sampl
patient
conclus
due
strict
patient
segregationinfect
control
polici
inoutpati
care
continu
educ
transmiss
pa
patient
innsbruck
cf
centr
intens
antibiot
use
seem
remark
impact
preemin
organ
multipl
strain
carrier
may
induc
adapt
mechan
genom
rearrang
phenotyp
alter
subset
chronic
infect
pa
patient
j
h
pai
j
kang
choi
seoul
kr
object
order
find
epidemiolog
clinic
characterist
clostridium
difficileassoci
diarrhoea
cdad
prospect
studi
perform
tertiari
hospit
korea
septemb
august
patient
diarrhea
stool
passag
day
day
diarrhea
hour
antibiot
usag
includ
stool
cultur
toxin
b
assay
direct
stool
toxin
pcr
perform
patient
cdad
defin
one
three
test
posit
clinic
characterist
cdad
case
studi
use
strain
cultur
multiplex
pcr
tcda
tcdb
binari
toxin
pcr
ribotyp
perform
result
incid
cdad
patientday
hospit
among
case
posit
cdadtest
hospitalacquir
cdad
hacdad
heath
careassoci
cdad
hcacdad
toxigen
carrier
mean
hospit
day
admiss
hacdad
occurr
day
hacdad
show
sever
diseas
sever
score
zar
et
al
cid
compar
characterist
hacdad
hcacdad
univari
analysi
sever
score
higher
hcacdad
p
blocker
use
hacdad
p
among
case
haand
hcacdad
improv
without
treatment
improv
treatment
relaps
treatment
die
lost
howev
among
fatal
case
cdadattribut
mortal
identifi
multiplexpcr
use
cultur
organ
isol
tcda
tcdbposit
isol
produc
binari
toxin
pcr
ribotyp
isol
show
divers
ribotyp
isol
common
ribotyp
compar
ribotyp
pair
strain
relaps
case
ribotyp
observ
case
differ
ribotyp
found
case
interv
relaps
day
day
respect
three
strain
identifi
among
isol
toxigen
carrier
hacdad
case
sever
score
two
case
higher
mean
valu
case
vs
conclus
incid
morbid
mortal
cdad
high
hospit
howev
strain
appear
thu
observ
incid
diseas
sever
spread
commun
hospit
necessari
object
aim
studi
determin
incid
etiolog
antibiot
resist
pattern
ventilatorassoci
pneumonia
vap
intens
care
unit
icu
anesthesiolog
cardiothorac
surgeri
b
kurtaran
tasova
gurel
inal
f
kibar
hs
object
surviv
improv
due
support
treatment
qualiti
main
caus
death
amongst
patient
infect
aim
studi
determin
type
infect
caus
microorgan
order
guid
antimicrobi
therapi
infect
control
method
hospit
infect
control
committe
data
review
retrospect
year
fist
nine
month
cdc
case
definit
nosocomi
infect
use
antimicrobi
suscept
determin
vitek
system
microbiolog
data
site
isol
extract
result
total
patient
follow
patient
day
pd
gener
hospit
infect
rate
distribut
summar
tabl
infect
rate
seen
higher
burn
unit
temporarili
close
bed
decreas
order
plan
revis
high
infect
rate
infect
rate
decreas
dramat
burn
infect
increas
increas
link
transfer
temporari
clinic
inappropri
condit
urinari
infect
rate
highest
decreas
time
thought
result
urinari
tract
infect
control
educ
hospit
blood
stream
infect
rate
gramneg
microorgan
tend
decreas
increas
preval
microorgan
pseudomona
aeruginosa
respect
acinetobact
baumannii
took
place
rate
respect
extend
spectrum
b
lactamas
rate
high
year
escherichia
coli
klebsiella
pneumonia
respect
staphylococcu
aureu
isol
meticillin
resist
antimicrobi
resist
also
remark
gramneg
especi
acinetobact
baumannii
spp
conclus
conclus
high
overal
infect
resist
rate
seen
hospit
infect
rate
caus
microorgan
tend
influenc
physic
condit
infect
control
measur
complianc
also
overal
hospit
implement
unit
base
gener
standard
establish
support
reinforc
hospit
administr
order
decreas
hospit
infect
method
perform
retrospect
cohort
studi
high
complex
hospit
citi
includ
patient
bloodstream
infect
bi
icu
identifi
antimicrobi
resist
surveil
system
systemat
chart
review
perform
sever
ill
comorbid
type
infect
therapi
demograph
variabl
collect
attribut
mortal
analyz
post
hoc
committe
time
event
date
model
result
methicillinresist
staphylococcu
aureu
mrsa
methicillinsuscept
mssa
icu
document
gross
mortal
attribut
mortal
aureu
bacteremia
mrsabi
attribut
mortal
vs
mssabi
log
rank
test
p
surviv
function
mrsa
mssa
figur
multivari
adjust
proport
hazard
model
independ
predictor
attribut
mortal
charlson
comorbid
index
septic
shock
adequ
clinic
respons
day
earli
chang
antimicrobi
therapi
meticillin
resist
inappropri
initi
therapi
observ
signific
predictor
attribut
mortal
conclus
mrsabi
show
differ
surviv
function
compar
mssabi
high
gross
attribut
mortal
patient
bi
aureu
icu
mortal
predictor
comorbid
sever
earli
treatment
earli
respons
object
assess
preval
vaginali
infect
symptomat
asymptomat
women
attend
major
gynecolog
hospit
athen
greec
evalu
four
method
diagnosi
vaginali
infect
method
specimen
collect
consecut
women
attend
outpati
clinic
alexandra
hospit
period
two
hundr
fiftyf
symptomat
asymptomat
three
hundr
fiftyeight
greek
immigr
women
complet
questionnair
includ
demograph
data
medic
histori
behavioralsexu
inform
presenc
vaginali
vagin
sampl
assess
use
wet
mount
cultur
modifi
diamond
medium
antigen
detect
two
pcr
assay
target
differ
region
vaginali
genom
specimen
consid
posit
vaginali
found
posit
either
cultur
pcr
kappa
test
agreement
diagnost
test
also
determin
result
twentythre
women
found
posit
vaginali
infect
preval
symptomat
women
asymptomat
one
vaginali
frequent
detect
immigr
greek
women
gardnerella
vaginali
infect
significantli
frequent
women
infect
vaginali
pcr
sensit
method
follow
cultur
wet
mount
latex
agglutin
kappa
index
cultur
wet
mount
cultur
latex
agglutin
cultur
pcr
present
studi
indic
rel
low
percentag
trichomoniasi
femal
popul
live
athen
infect
preval
among
immigr
major
infect
women
asymptomat
pcr
found
consider
improv
diagnost
yield
compar
convent
diagnost
method
f
perez
p
capon
n
moran
g
martin
j
carton
oviedo
es
introduct
taeniasi
infect
human
adult
tapeworm
taenia
saginata
taenia
solium
human
taeniasi
public
health
problem
affect
endem
area
describ
clinic
epidemiolog
characterist
sever
episod
taeniasi
associ
consumpt
wild
boar
meat
asturia
spain
studi
clinicalepidemiolog
characterist
autochtn
taeniasi
diagnos
tropic
medicin
unit
hospit
universitario
central
de
asturia
region
northern
spain
parasitolog
diagnost
base
examin
three
formalineth
concentr
stool
sampl
examin
proglottid
bodi
segment
avail
patient
follow
one
year
diagnost
parasitolog
screen
everi
month
diseas
cure
two
consecut
test
neg
result
studi
patient
present
taenia
spp
egg
stool
sampl
women
mean
age
year
rang
patient
report
eaten
undercook
meat
wild
boar
averag
day
prior
onset
symptom
two
patient
urticari
clinic
three
abdomin
pain
rest
asymptomat
except
broadcast
tapeworm
stool
patient
eosinophilia
mean
cellsmm
limit
patient
treat
praziquantel
mgkg
oral
space
week
apart
parasitolog
control
neg
patient
conclus
taeniasi
major
public
health
problem
asturia
consid
errad
recent
resurg
associ
consumpt
wild
boar
meat
need
epidemiolog
control
prevent
emerg
aparit
diseas
rodriguez
c
seco
r
ortega
n
moran
g
martin
p
capon
j
carton
oviedo
es
introduct
appear
rash
haematolog
hepat
toxic
one
frequent
limit
sideeffect
treatment
benznidazol
bnz
slowli
escal
dose
use
tropic
diseas
treatment
like
loiasi
explor
efficaci
safeti
strategi
reduc
incid
complic
method
twelv
patient
diagnos
chaga
diseas
tropic
medicin
unit
hospit
universitario
central
de
asturia
treat
bnz
slowli
escal
dose
begin
mg
daili
fir
day
increas
dose
mg
day
full
daili
dose
mg
mgkgday
combin
addit
dexchlorpheniramin
slowli
escal
dose
patient
revis
everi
day
patient
realiz
exhaust
questionnair
apparit
advers
effect
revis
made
determin
blood
count
liver
function
test
treatment
continu
day
patient
discontinu
treatment
patient
describ
apparit
rah
cutan
diseas
treatment
blood
count
liver
function
test
chang
end
treatment
two
patient
report
nausea
first
day
treatment
advers
effect
conclus
incid
rash
complic
first
week
treatment
bnz
diminish
ad
histamin
antagonist
week
standard
recommend
use
slowli
escal
dose
incid
advers
effect
haematolog
hepat
decreas
use
slowli
scalat
dose
necessari
studi
to
proven
slowli
dose
pharmacokinet
safe
gender
femal
male
polymeras
chain
reaction
avail
case
posit
neg
chest
radiographi
normal
patient
found
abnorm
ekg
mainli
branch
block
patient
need
pacemak
echocardiographi
abnorm
patient
one
patient
die
due
termin
cardiomyopathi
colon
barium
enema
perform
patient
found
megacolon
contrast
radiographi
esophagu
done
patient
abnorm
conclus
chaga
diseas
emerg
diseas
europ
migratori
movement
caus
import
morbid
young
popul
situat
requir
improv
clinic
diagnost
knowledg
determin
prioriti
prevent
assistenci
need
background
central
southeastern
uganda
buikw
south
health
subdistrict
hsd
locat
acut
form
sleep
sick
caus
trypanosoma
brucei
rhodesiens
predomin
report
incid
b
rhodesiens
sleep
sick
last
function
treatment
centr
buikw
south
hsd
southeastern
uganda
period
treatment
outcom
structur
popul
affect
function
sleep
sick
control
programm
area
method
sleep
sick
data
collect
retrospect
buikw
sleep
sick
treatment
centr
avail
sleep
sick
regist
case
definit
base
clinic
laboratori
diagnosi
record
case
includ
data
analys
epiinfo
programm
result
period
case
sleep
sick
diagnos
treat
number
patient
age
year
year
year
patient
diagnos
earli
stage
diseas
exclud
presenc
microfilaria
bs
treatment
suramin
initi
recov
except
men
escap
hospit
patient
diagnos
late
stage
diseas
therapi
melarsoprol
treat
die
refer
health
unit
case
fatal
rate
late
stage
diseas
case
fatal
rate
median
interv
diagnosi
death
day
highest
incid
earli
nineti
case
incid
decreas
due
closur
treatment
center
lack
supervis
motiv
healthcar
worker
diseas
start
reemerg
new
case
diagnos
conclus
sleep
sick
still
remain
seriou
public
health
problem
sinc
prevent
educ
activ
control
neglect
diseas
function
appropri
reemerg
easili
object
protist
blastocysti
found
digest
tract
human
worldwid
distribut
clinic
signific
remain
unresolv
nine
major
distinct
subtyp
st
blastocysti
identifi
base
gene
sequenc
recent
studi
suggest
associ
subtyp
blastocysti
acut
diarrhea
irrit
bowel
syndrom
howev
data
avail
regard
preval
genet
divers
blastocyti
franc
probabl
due
difficulti
point
blastocysti
human
fece
anaerob
cultur
fresh
stool
sampl
remain
gold
standard
method
heavi
set
epidemiolog
studi
direct
microscopi
fecal
smear
frequent
use
exhibit
poor
sensibl
compar
cultur
aim
studi
develop
sensit
real
time
pcr
assay
detect
blastocysti
directli
stool
pcr
use
estim
preval
blastocysti
patient
clermont
ferrand
hospit
franc
compar
microscopi
cultur
method
coupl
primer
design
amplifi
bp
length
fragment
gene
blastocysti
real
time
pcr
assay
perform
use
sybr
green
detect
dna
extract
genotyp
test
repeat
reproduc
limit
detect
determin
fecal
sampl
final
stool
sampl
hospit
patient
test
blastocysti
use
direct
microscopi
fecal
smear
cultur
jone
medium
real
time
pcr
assay
develop
result
success
amplifi
dna
extract
subtyp
lower
limit
detect
blastocysti
per
gram
stool
prospect
clinic
studi
among
patient
posit
sampl
detect
use
microscop
analysi
use
cultur
use
real
time
pcr
assay
three
sampl
posit
pcr
indic
better
sensit
method
specif
st
determin
check
sequenc
pcr
product
gener
popul
industri
countri
preval
blastocysti
often
consid
sensit
quantit
pcr
assay
blastocysti
detect
stool
sampl
result
show
use
molecular
pcrbase
diagnost
approach
obtain
relev
data
epidemiolog
featur
blastocysti
kakar
byotra
new
delhi
object
studi
clinic
profil
patient
confirm
dengu
fever
studi
laboratori
profil
patient
dengu
fever
studi
mortal
patient
enrol
patient
age
year
studi
includ
confirm
case
dengu
fever
way
posit
dengu
igm
antibodi
andor
dengu
antigen
total
patient
enrol
studi
period
two
month
complet
clinic
biochem
profil
record
per
preset
performa
studi
show
male
femal
mean
age
year
patient
admit
initi
platelet
count
less
patient
fever
mean
durat
day
mean
age
patient
year
patient
complaint
nausea
bodi
ach
vomit
patient
record
either
itch
skin
rash
patient
sever
bleed
form
requir
urgent
intervent
form
blood
platelet
transfus
patient
minor
bleed
form
gum
bleed
petechi
rash
bleed
form
nose
one
episod
malena
patient
die
due
bleed
aspir
hypotens
one
patient
concomit
vivax
malaria
patient
rais
transaminas
rang
time
time
upper
limit
patient
featur
hepatomegali
gall
bladder
wall
oedema
pleural
effus
ascit
patient
respond
therapi
form
iv
fluid
platelet
transfus
case
bleed
platelet
count
acetaminophen
symptomat
care
patient
requir
platelet
transfus
total
patient
requir
multipl
platelet
transfus
patient
recov
within
mean
durat
day
dengu
fever
specif
age
sex
preponder
patient
present
fever
bodi
ach
nausea
major
patient
present
elev
liver
enzym
self
limit
phenomenon
dengu
fever
studi
low
mortal
show
particular
strain
self
limit
diseas
major
case
support
treatment
given
appropri
platelet
transfus
requir
approxim
patient
major
bleed
seen
major
case
adequ
support
treatment
vitro
suscept
test
acanthamoeba
sp
isol
clinic
specimen
chlorhexidin
propamidin
isethion
gentamicin
chloramphenicol
mk
abd
gh
shirley
tang
n
anisah
n
putri
yusof
r
noraina
norazah
kuala
lumpur
object
acanthamoeba
kerat
one
sever
potenti
sightthreaten
ocular
parasit
infecti
diseas
recogn
challeng
among
ocular
infect
vitro
suscept
test
acanthamoeba
isol
may
prove
benefici
applic
earli
treatment
regimen
studi
conduct
determin
effect
drug
therapeut
dose
minimum
cysticid
concentr
mcc
drug
method
serial
doubl
dilut
chlorhexidin
diglucon
mgml
mgml
propamidin
isethion
brolen
mgml
mgml
gentamicin
mgml
mgml
perform
microtit
plate
test
acanthamoeba
isol
isol
kerat
case
exposur
cyst
drug
hour
cyst
wash
free
drug
centrifug
deposit
cyst
cultur
onto
nonnutri
agar
plate
overlaid
heatkil
escherichia
coli
replic
growth
trophozoit
cyst
expos
dilut
observ
record
microscop
day
determin
mcc
drug
effect
drug
therapeut
dose
cyst
test
directli
without
doubl
dilut
result
chlorhexidin
diglucon
propamidin
isethion
brolen
success
exhibit
cysticid
activ
therapeut
dose
gentamicin
chloramphenicol
minimum
cysticid
concentr
mcc
chlorhexidin
rang
mgml
mgml
propamidin
isethion
rang
mgml
mgml
gentamicin
rang
mgml
mgml
mean
mcc
chlorhexidin
propamidin
isethion
gentamicin
acanthamoeba
isol
mgml
mgml
mgml
respect
vitro
sensit
test
enabl
determin
mcc
drug
acanthamoeba
isol
use
screen
new
antiacanthamoeb
therapeut
agent
chlorhexidin
diglucon
propamidin
isethion
brolen
proven
effect
anti
acanthamoeb
agent
object
preval
cryptosporidium
risk
factor
zoonot
transmiss
najafabad
isfahan
iran
dairi
farm
examin
materi
method
sampl
specimen
process
one
fecal
sampl
collect
calv
less
month
old
dairi
farm
around
najafabad
isfahan
provinc
central
iran
well
individu
work
farm
household
member
septemb
march
fecal
sampl
collect
calv
human
respect
specimen
place
plastic
vial
brought
immedi
laboratori
store
analysi
sampl
stain
modifi
ziehlneelsen
method
examin
bright
field
microscopi
dna
extract
fecal
sampl
subject
six
cycl
freezethaw
liquid
nitrogen
water
bath
ruptur
oocyst
dna
isol
aliquot
frozen
stool
rrna
gene
amplif
sequenc
twostep
nest
pcr
protocol
use
amplifi
rrnagen
bp
pcr
product
analyz
agaros
gel
visual
ethidium
bromid
stain
result
cryptosporidium
identifi
stool
preval
farm
worker
household
member
furthermor
calf
sampl
posit
base
rrna
gene
amplif
sequenc
cryptosporidium
parvum
identifi
posit
farm
worker
posit
household
member
posit
calv
infect
c
parvum
indic
possibl
zoonot
transmiss
farm
univari
analysi
potenti
risk
factor
reveal
contact
calv
p
signific
risk
factor
c
parvum
infect
consider
neg
associ
observ
c
parvum
infect
clean
shoesboot
daili
work
p
hand
wash
p
use
pipe
water
p
multivari
analysi
logist
regress
contact
calv
signific
conclus
zoonot
transmiss
c
parvum
due
contact
calv
predomin
among
farm
worker
household
member
region
appropri
health
measur
must
appli
control
infect
decreas
zoonot
transmiss
parasit
l
galimberti
v
acquaviva
l
milazzo
e
gianelli
corbellino
galli
milan
object
describ
preval
hospit
clinic
spectrum
fever
return
travel
migrant
itali
method
retrospect
chart
review
febril
ill
develop
within
month
stay
tropic
hospitalis
infecti
diseas
clinic
milan
itali
result
near
hospit
admiss
studi
period
due
fever
travel
migrant
return
tropic
men
median
age
year
rang
year
italian
citizen
extraeuropean
migrant
classifi
visit
friend
rel
shown
figur
malaria
common
specif
etiolog
diagnosi
found
ill
return
travel
fever
fiftythre
percent
malaria
case
diagnos
migrant
caus
fever
vari
region
visit
malaria
acquir
subsaharan
africa
ci
dengu
fever
acquir
latin
america
indian
subcontin
southcentr
asia
case
time
present
travel
dengu
account
earli
present
travel
fever
vaccin
prevent
infect
sixteen
percent
patient
acut
viral
infect
exclud
viral
hepat
account
caus
fever
conclus
period
number
patient
return
tropic
area
admit
fever
univers
hospit
northern
itali
remain
stabl
malaria
remain
frequent
diagnosi
account
near
hospit
dengu
fever
frequent
tropic
infect
besid
malaria
time
present
travel
region
visit
provid
import
clue
toward
establish
correct
diagnosi
toxocara
cani
infect
uncommon
develop
countri
howev
sporad
case
possibl
system
involv
requir
consid
diagnost
possibl
case
report
old
previous
healthi
femal
urban
surround
present
clinic
prolong
lowgrad
fever
abdomin
pain
sever
lumboishialgia
paraesthesia
prurit
rash
gener
lymphadenopathi
liver
damag
anamnest
data
concern
recent
travel
contact
anim
complet
laboratori
examin
reveal
hypereosinophilia
elev
liver
enzym
ast
alt
hyperbilirubinemia
histolog
nonspecif
lymph
node
infiltr
without
radiolog
find
focal
infect
toxocara
cani
infect
confirm
posit
serolog
test
test
includ
virolog
hepat
b
c
hiv
herpesvirida
coxsacki
bacteri
cultur
includ
serolog
b
burgdorferi
brucella
test
tuberculosi
stool
test
avail
immunoserolog
parasit
neg
day
treatment
albendazol
mg
twice
day
patient
afebril
without
physic
complaint
includ
normal
level
liver
enzym
leukocyt
formula
case
viscer
larva
migran
mild
selflimit
may
mimic
mani
differ
condit
avail
treatment
option
effect
suspect
patient
hypereosinophilia
liver
damag
preval
cryptosporidium
immunocompet
children
acut
diarrhoea
upper
normandi
northwestern
franc
g
gargala
f
dall
bonnin
f
louillet
michelet
e
mallet
l
rouen
dijon
fr
object
intestin
protozoa
cryptosporidium
increasingli
recogn
major
caus
diarrheal
diseas
howev
incid
cryptosporidiosi
children
unknown
franc
studi
conduct
assess
signific
cryptosporidium
caus
agent
gastroenter
immunocompet
children
uppernormandi
franc
studi
conduct
januari
novemb
period
studi
stool
specimen
children
age
year
immunocompet
acut
diarrhea
prospect
screen
presenc
cryptosporidium
oocyst
patient
attend
pediatr
depart
rouen
univers
hospit
uppernormandi
northwestern
franc
whose
stool
examin
hospit
parasitolog
laboratori
patient
attend
gener
practition
whose
stool
examin
privat
clinic
laboratori
saint
en
caux
km
rouen
presenc
cryptosporidium
assess
microscopi
semiquantit
result
obtain
hein
stain
faecal
smear
cryptosporidium
speci
genotyp
determin
base
polymeras
chain
reaction
pcr
target
rrna
gene
follow
rrna
gene
fragment
sequenc
result
twenti
three
children
seen
rouen
univers
hospit
saint
en
caux
respect
report
excret
oocyst
maximum
case
report
children
age
year
genotyp
reveal
posit
stool
c
homini
c
parvum
respect
children
vomit
dehydr
symptom
includ
fever
abdomin
pain
case
report
juli
octob
four
six
c
homini
case
report
travel
outsid
franc
prior
ill
compar
c
parvum
conclus
report
avail
frequenc
cryptosporidiosi
immunocompet
children
franc
studi
demonstr
public
health
import
parasit
uppernormandi
cryptosporidiosi
like
unrecogn
underdiagnos
diagnost
test
cryptosporidium
rare
order
even
patient
symptom
consist
cryptosporidiosi
lead
lack
specif
prevent
initi
limit
overal
health
impact
cryptosporidiosi
strain
isol
infect
sarbu
csutak
pelinescu
stoica
e
enachesoar
p
cornea
tanas
r
ghindea
negruta
vassu
bucharest
ro
estim
candida
speci
account
fungal
infect
select
microbi
strain
larg
antifung
activ
could
repres
import
altern
treatment
object
antifung
activ
studi
lactic
acid
bacteria
lab
metschnikowia
pulcherrima
yeast
strain
candida
albican
cc
candida
parapsilosi
candida
tropicali
strain
isol
vagin
oral
infect
enhanc
antifung
activ
pulcherrima
strain
use
sodium
bicarbon
calcium
chlorid
method
studi
strain
lactic
acid
bacteria
isol
sourdough
newborn
faec
ferment
milk
plant
select
lab
strain
made
cultiv
mr
gram
stain
catalas
test
strain
screen
candida
growth
inhibit
capac
use
spot
agar
method
antifung
killer
activ
test
spote
three
pulcherrima
strain
plate
flood
candida
isol
test
cell
suspens
mix
result
nine
lab
strain
select
high
antifung
activ
candida
isol
api
biolog
reppcr
analysi
allow
us
place
lab
strain
lactobacillu
pediococcu
weissela
enterococcu
genera
antifung
activ
correl
biosynthesi
organ
acid
three
pulcherrima
strain
show
high
killer
activ
cc
weakest
action
record
best
result
antifung
activ
obtain
three
strain
wide
halo
growth
inhibit
signific
result
observ
cc
case
form
shallow
halo
strain
sensibl
activ
mixtur
clear
halo
obtain
cc
plate
three
pulcherrima
strain
weeker
result
record
strain
antifung
activ
nine
lab
select
strain
correl
biosynthesi
organ
acid
import
killer
antifung
activ
three
pulcherrima
strain
observ
cc
enhanc
mixtur
show
higher
antagonist
potenti
candida
isol
test
fungaemia
c
krusei
acquisit
voriconazol
resist
vivo
e
ricardo
fariaramo
ap
silva
ag
rodrigu
c
pinavaz
porto
pt
fluconazol
prophylaxi
associ
increas
preval
c
krusei
c
glabrata
strain
c
krusei
show
intrins
resist
fluconazol
usual
azol
voriconazol
c
krusei
blood
isol
recov
leukemia
patient
two
month
period
submit
voriconazol
therapi
increas
minim
inhibitori
concentr
mic
valu
voriconazol
regist
among
consecut
isol
final
develop
resist
phenotyp
object
aim
clarifi
acquir
resist
mechan
rais
hypothesi
resist
due
overespress
efflux
pump
method
two
clinic
c
krusei
isol
studi
one
suscept
mic
one
resist
mic
voriconazol
agar
disk
diffus
assay
perform
order
studi
synergist
effect
tacrolimu
describ
efflux
blocker
voriconazol
resist
c
krusei
isol
describ
ricardo
e
et
al
tenfold
dilut
rang
assay
voriconazol
ad
yepd
agar
plate
supram
valu
mgml
order
induc
resist
suscept
strain
expos
vitro
subinhibitori
concentr
voriconazol
everi
day
cultur
broth
transfer
new
fresh
medium
voriconazol
suscept
profil
voriconazol
assay
acquisit
resist
flow
cytometri
assay
use
rhodamin
efflux
pump
fluoresc
substrat
perform
order
compar
resist
isol
vivo
vitro
induc
suscept
isol
regard
role
efflux
pump
c
krusei
resist
result
agar
disk
diffus
assay
show
growth
inhibit
around
disk
impregn
highest
concentr
day
incub
suscept
strain
voriconazol
mic
valu
resist
strain
show
less
intens
fluoresc
stain
compar
suscept
isol
conclus
synergist
effect
observ
voriconazol
highest
concentr
resist
strain
accumul
less
intracellular
suscept
strain
mean
prolong
exposit
voriconazol
vivo
vitro
induc
resist
associ
efflux
pump
activ
candida
sp
e
enachesoar
vassu
brezeanu
c
cristescu
v
cristescu
bucharest
ro
object
aim
studi
investig
action
nonsteroid
antiinflammatori
drug
nsaid
sodium
diclofenac
aspirin
piroxicam
cell
viabil
plankton
cell
candida
albican
candida
krusei
strain
possibl
ultra
structur
chang
c
albican
cell
treat
diclofenac
method
four
strain
c
albican
one
c
krusei
use
studi
strain
isol
pharyng
excreta
isol
identifi
convent
molecular
type
amplif
arn
ribosom
gene
restrict
enzym
dde
cfo
hind
iii
test
viabil
cell
presenc
three
nsaid
done
serial
dilut
method
standard
method
electron
microscopi
use
studi
ultra
structur
chang
c
albican
cell
induc
diclofenac
treatment
result
studi
identifi
strain
convent
molecular
type
show
us
four
strain
c
albican
speci
one
strain
c
krusei
cell
viabil
test
show
us
valu
c
albican
strain
treat
sodium
diclofenac
plasmat
concentr
microgml
c
krusei
strain
presenc
aspirin
mm
viabil
cell
c
albican
strain
piroxicam
c
krusei
strain
cell
viabil
aspirin
piroxicam
respect
electron
microscopi
studi
stood
ultra
structur
chang
c
albican
cell
treat
sodium
diclofenac
mm
mm
notic
chang
plasmalema
level
separ
cytoplasm
outer
layer
cell
wall
becam
electronotranspar
invagin
plasmat
membran
disorgan
cytoplasm
appear
complet
damag
small
part
cell
necrot
age
aspect
conclus
studi
stood
effect
nsaid
candida
albican
candida
krusei
strain
greater
inhibitor
effect
obtain
candida
cell
treat
diclofenac
result
electron
microscopi
studi
show
us
ultra
structur
chang
c
albican
cell
treat
diclofenac
think
use
nsaid
especi
sodium
diclofenac
specif
antifung
treatment
caus
suscept
candida
cell
facilit
action
antifung
drug
result
success
anticandida
therapi
primari
cutan
cryptococcosi
due
c
laurentii
renal
transplant
recipi
kulkarni
sinha
flynn
u
anandh
bangalor
object
present
renal
allograft
recipi
primari
cutan
cryptococcosi
pcc
cryptococcu
laurentii
probabl
caus
repeat
skin
injuri
inocul
inject
insulin
low
molecular
weight
heparin
thigh
method
identif
yeast
made
skin
biopsi
stain
gram
stain
india
ink
prepar
skin
biopsi
done
isol
cultur
sabourad
dextros
agar
serum
cryptococcu
latex
agglutin
test
also
done
speciat
done
use
mini
api
gram
stain
reveal
spheric
elong
bud
yeastlik
cell
without
pseudohypha
sabourad
dextros
agar
coloni
cream
colour
smooth
mucoid
textur
fungu
notabl
absent
blood
lung
serum
cryptococcu
latex
agglutin
test
neg
conclus
first
report
primari
cutan
cryptococcosi
due
c
laurentii
immun
compromis
host
report
patient
might
expand
exist
clinic
manifest
awar
high
index
suspicion
might
assist
earli
diagnosi
henc
institut
treatment
domingo
alarcon
lopezbrea
madrid
es
introduct
candida
spp
one
frequent
microorgan
isol
femal
genit
tract
infect
spite
theoric
incompat
bacteri
vaginosi
bv
certain
case
bv
candida
spp
also
present
aim
studi
aim
studi
see
preval
candidiasi
associ
bacteri
vaginosi
group
patient
district
madrid
f
ergin
yetkin
c
bulut
b
oral
g
ertem
n
demiroz
ankara
tr
object
nosocomi
candidiasi
great
risk
intens
care
patient
candida
infect
mainli
evolv
endogen
colon
thu
detect
colon
import
studi
evalu
candida
colon
intens
care
unit
patient
use
candida
colon
index
ci
aim
predict
valu
colon
index
invas
candidiasi
method
septemb
februari
patient
older
year
age
intens
care
unit
includ
studi
throat
nose
skin
axilla
urin
rectal
swab
cultur
taken
weekli
patient
also
tracheal
aspir
drain
central
vascular
cathet
cultur
taken
candida
colon
index
calcul
ratio
number
cultur
posit
site
number
site
cultur
result
candida
colon
found
patient
colon
patient
invas
candidiasi
develop
nine
patient
candidemia
five
urinari
tract
infect
four
colon
patient
surgic
intens
care
unit
icu
stay
longer
length
icu
invas
instrument
addit
candida
colon
diagnos
mostli
patient
bacteri
sepsi
expos
broad
spectrum
antibiot
colon
index
found
greater
patient
heavi
colon
ci
determin
one
nine
patient
invas
candidiasi
howev
nine
patient
develop
candid
infect
coloniz
infect
sensit
spesif
colon
index
determin
invas
candidiasi
found
respect
posit
predict
valu
neg
predict
valu
conclus
candida
colon
frequent
met
among
intens
care
patient
invas
candidiasi
intens
care
unit
set
thought
subsequ
colon
candida
colon
index
may
good
paramet
predict
invas
candida
infect
hadjipetrusheva
b
curcuc
trajkovska
hadjipetrusheva
jankijev
b
jaglikovski
skopj
mk
introduct
precis
identif
suscept
test
yeast
especi
candida
essenti
obtain
prompt
diagnosi
administ
proper
therapi
mind
actual
problem
resist
variou
antimycot
aim
identifi
yeast
isol
lower
respiratori
tract
lrt
urin
genit
sampl
use
novel
yeast
identifi
method
test
suscept
antimycot
total
yeast
isol
lrt
urin
genit
sampl
one
year
period
octob
evalu
convent
microbiolog
method
use
isol
yeast
identif
use
growth
chromogen
candida
albican
agar
calb
oxoid
uk
rapid
oxoid
uk
method
util
determin
yeast
enzym
provid
identif
result
hour
disc
diffus
test
perform
determin
suscept
nystatin
n
voriconasol
vor
fluconasol
fca
accord
clsi
standard
result
rapid
identifi
candida
albican
frequent
isol
strain
follow
c
glabrata
c
tropicali
c
crusei
one
isol
trichosporon
beigelii
turquois
colour
like
c
albican
calb
rodothorula
rubra
total
c
albican
suscept
test
antimycot
resist
n
strain
urinari
isol
n
fca
total
c
glabrata
strain
suscept
antimycot
resist
n
fca
show
strain
c
albican
c
glabrata
c
tropicali
respect
urinari
isol
isol
yeast
suscept
test
antimycot
conclus
rapid
fast
hour
simpl
identifi
method
meet
need
accur
reliabl
result
mycolog
diagnosi
suscept
test
reveal
voriconasol
still
good
antimycot
activ
test
strain
emerg
fluconasol
nystatin
resist
strain
therefor
especi
case
urinari
infect
fluconasol
oral
antimycot
achiev
high
urin
concentr
suscept
test
highli
recommend
day
rang
respect
eat
indic
fiftytwo
episod
median
day
rang
rest
episod
n
eat
indic
overal
ifi
incid
n
group
receiv
eat
twelv
patient
develop
ifi
comparison
noon
patient
group
receiv
eat
daysglob
mortal
group
receiv
eat
group
receiv
ifirel
mortal
null
group
receiv
eat
patient
group
receiv
eat
conclus
data
suggest
manag
patient
pfn
indic
eat
patient
select
basi
clinic
criteria
risk
profil
may
safe
avoid
overtreat
f
j
balbin
r
salesa
c
l
santand
es
object
cultur
convent
identif
remain
usual
basi
diagnosi
fungal
infect
long
respons
time
low
sensit
rate
object
studi
perform
molecular
identif
clinic
relev
fungi
identifi
speci
level
convent
approach
cultur
api
morpholog
criteria
compar
result
molecular
detect
fungi
invas
sampl
blood
cultur
method
preliminari
phase
strain
intern
collect
test
correctli
recogn
two
prospect
studi
done
parallel
one
year
sept
aug
cultur
difficulttoidentifi
fungi
yeast
mould
obtain
differ
clinic
sampl
identifi
molecular
method
ii
presenc
identif
fungi
invas
sampl
blood
bronchoalveolar
lavag
bronchoalveolar
brush
heart
valv
biopsi
joint
lung
brain
determin
use
convent
approach
compar
result
molecular
method
base
sequenc
intern
transcrib
spacer
region
complement
sequenc
btubulin
elong
factor
gene
intergen
spacer
ig
region
result
organ
object
identifi
molecular
method
concret
speci
genera
aspergillu
candida
trichosporon
scedosporium
alternaria
fusarium
microsporum
penicilium
sporotrichum
acremonium
sampl
object
ii
neg
cultur
molecular
method
mould
identifi
molecular
approach
two
case
organ
grew
cultur
joint
biopsi
heart
valv
patient
yield
scedosporium
apiospermum
addit
molecular
approach
identifi
aspergillu
sidowii
lung
biopsi
fumigatu
bronchoalveolar
brush
two
cultureneg
case
molecular
method
allow
identif
organ
either
cultur
clinic
sampl
hour
conclus
molecular
method
reduc
respons
time
identif
clinic
relev
fungi
includ
convent
identif
difficult
approach
consid
diagnosi
fungal
infect
clinic
laboratori
p
pr
hsueh
talwar
vm
co
v
rajadhyaksha
ml
ong
khon
kaen
th
taipei
citi
tw
noida
makati
citi
ph
mumbai
new
york
us
object
evalu
clinic
efficaci
safeti
anidulafungin
anid
treatment
asian
patient
proven
candidemia
phase
openlabel
multicentr
noncompar
studi
adult
acut
physiolog
chronic
health
evalu
apach
ii
score
patient
receiv
oncedaili
intraven
anid
singl
mg
load
dose
follow
mg
per
day
thereaft
day
subsequ
oral
voriconazol
allow
predetermin
condit
total
overal
treatment
durat
day
concomit
medic
system
antifung
permit
primari
endpoint
global
respons
defin
clinic
cureimprov
togeth
microbiolog
eradicationpresum
erad
end
therapi
eot
modifi
intenttotreat
mitt
popul
relationship
bdglucan
assay
result
respons
also
examin
safeti
toler
assess
throughout
studi
mean
age
enrol
patient
n
centr
india
philippin
taiwan
thailand
year
male
global
respons
rate
mitt
popul
n
eot
confid
interv
secondari
respons
rate
list
tabl
global
respons
rate
eot
candida
tropicali
c
albican
c
glabrata
c
parapsilosi
patient
central
venou
cathet
month
baselin
global
respons
rate
eot
global
respons
predefin
popul
follow
neutropen
patient
n
patient
age
year
n
patient
renal
insuffici
n
overal
mitt
popul
patient
clinic
respons
eot
lower
mean
bdglucan
level
baselin
clinic
failur
treatmentrel
advers
event
mild
moder
common
diarrhea
rash
subject
giannopoul
n
charalambaki
g
vrioni
k
konstantin
grafako
kyratsa
velegraki
f
klouvamolyvda
e
tsakri
athen
gr
object
fungaemia
repres
import
caus
morbid
mortal
critic
ill
patient
aim
studi
evalu
retrospect
analysi
fungaemia
intens
care
unit
icu
tertiari
care
hospit
method
patient
hospit
icu
longer
h
includ
studi
period
demograph
characterist
predispos
factor
incid
fungaemia
suscept
profil
therapi
outcom
analyz
laboratori
investig
perform
convent
method
chromogen
medium
api
use
identif
antifung
suscept
assess
mic
determin
use
broth
microdilut
method
accord
clsi
recommend
result
total
strain
isol
patient
mean
age
year
male
patient
pathogen
isol
blood
iv
cathet
cultur
predispos
factor
includ
cardiovascular
disord
n
diabet
mellitu
n
malign
n
respiratori
failur
n
burn
n
chronic
alcohol
consumpt
alcohol
cirrhosi
n
chronic
renal
failur
n
six
patient
suffer
hematolog
malign
one
hiv
posit
nonalbican
candida
strain
frequent
isol
n
c
parapsilosi
c
tropicali
c
glabrata
c
dubliniensi
thirti
strain
identifi
c
albican
thee
strain
saccharomyc
bullardii
one
strain
zygosaccharomyc
spp
one
rhodotorula
mucinanginosa
also
isol
antifung
agent
show
excel
activ
potenti
lethal
pathogen
howev
two
strain
c
glabrata
resist
itraconazol
fluconazol
three
strain
c
albican
resist
caspofugin
two
strain
c
tropicali
resist
itraconazol
r
mucinanginosa
sensit
amphotericinb
fluconazol
ketoconazol
patient
treat
amphotericinb
andor
caspofungin
case
fatal
conclus
candidemia
common
fungal
nosocomi
infect
among
icu
patient
high
mortal
rate
candida
nonalbican
preval
strain
earli
diagnosi
initi
antifung
therapi
well
control
underli
predispos
factor
potenti
cur
option
emerg
invas
infect
time
syphili
seroposit
median
count
rang
median
plasmat
hivrna
viru
load
logml
rang
logml
secondari
syphili
frequent
patient
primari
patient
latent
syphili
patient
symptomat
neurosyphili
patient
overal
patient
receiv
parenter
treatment
oral
day
lumbar
punctur
perform
neurolog
asymptomat
symptomat
patient
patient
deni
undergo
procedur
diagnos
neurosyphili
satisfactori
serolog
respons
observ
patient
month
follow
month
follow
respect
discuss
multipl
sexual
partner
unprotect
oral
sex
increas
age
among
msm
predomin
risk
factor
contribut
syphili
epidem
overal
high
rate
unprotect
sex
demonstr
increas
preval
unsaf
sexual
practic
among
msm
attribut
faith
antiretrovir
therapi
simplifi
regimen
mental
fatigu
aris
year
protect
sex
reduc
risk
hiv
therefor
essenti
prompt
diagnosi
treatment
contact
trace
occur
order
control
major
outbreak
expand
postexposur
prophylaxi
simultan
multipl
sourc
hiv
exposur
healthcar
worker
ig
v
papastamopoulo
georgiou
kotsianopoul
e
vrioni
samarko
skout
athen
gr
background
guidelin
postexposur
prophylaxi
pep
healthcar
worker
mostli
base
retrospect
data
expert
opinion
role
new
drug
class
pep
larg
undefin
report
extrem
case
highgrad
needlestick
exposur
healthcar
worker
serum
multipl
hivinfect
patient
tri
prematur
remov
respect
tube
autom
biochem
analyz
result
review
medic
record
sourc
patient
tabl
offer
healthcar
worker
expand
pep
regimen
includ
entri
inhibitor
enfuvirtid
refus
take
subcutan
inject
recommend
use
integras
inhibitor
raltegravir
inhibitor
maraviroc
commerci
avail
time
complet
therapi
without
problem
period
evalu
hiv
transmiss
month
incid
neg
believ
sever
import
issu
pertin
extrem
unusu
event
includ
choic
pep
case
exposur
potenti
resist
hiv
viru
es
use
newer
class
antiretrovir
drug
pep
theoret
advantag
pep
set
due
mechan
action
practic
differenti
label
specimen
hivinfect
patient
appli
long
time
sever
hospit
countri
method
ambulatori
inpati
n
malefemal
univers
hospit
confirm
nephropathia
epidemica
ne
follow
routin
blood
chemistri
sampl
peripher
blood
mononuclear
cell
pbmc
day
followup
convalesc
sampl
week
pbmc
store
rna
extract
use
rneasi
kit
quiagen
cdna
synthesi
perform
express
er
er
b
er
b
cx
mrna
splice
variant
er
b
quantit
estim
use
realtim
pcr
appli
biosystem
multipl
variabl
blood
chemistri
rel
express
level
er
mrna
sex
day
onset
diseas
relat
princip
compon
analysi
pca
simcap
v
result
er
express
higher
quantiti
er
b
cx
er
b
wild
type
could
detect
er
correl
rise
white
blood
cell
wbc
p
total
group
patient
n
divid
male
n
femal
n
correl
seen
er
urea
p
creactiv
protein
crp
p
wbc
p
male
patient
group
compar
correl
er
wbc
p
femal
patient
group
pca
show
distinct
dichotomi
male
femal
sampl
femal
sampl
tend
correl
higher
level
er
male
sampl
higher
level
er
b
cx
conclus
result
pca
indic
differ
clinic
present
men
women
ne
could
explain
men
women
receiv
clinic
diagnosi
ne
although
serolog
distribut
femal
associ
higher
level
er
male
er
b
cx
er
b
cx
known
dimer
er
therebi
prevent
normal
function
er
larger
studi
need
confirm
role
er
er
b
cx
diseas
r
yapar
kesk
hasanoglu
tasyaran
ankara
tr
introduct
crimeancongo
haemorrhag
fever
tickborn
viral
diseas
viru
acquir
bite
infect
tick
transmiss
also
may
occur
direct
aerosol
contact
blood
secret
infect
patient
healthcar
worker
increas
risk
acquir
infect
care
haemorrhag
patient
nosocomi
cchf
mortal
rate
higher
rout
respect
ribavirin
recommend
postexposur
prophylaxi
treatment
cchf
howev
controversi
case
report
june
femal
patient
diagnos
cchf
posit
pcr
result
refik
saydam
nation
public
health
agenc
develop
oral
mucos
vagin
bleed
melena
sixth
day
therapi
patient
confus
seizur
due
intracrani
haemorrhag
sixth
day
hospit
patient
exist
oral
nasal
haemorrhagi
increas
seizur
physician
interv
dispos
glove
patient
need
emerg
airway
manag
place
oral
airway
immedi
without
surgic
mask
eye
protect
patient
die
hour
widespread
bleed
five
day
intervent
femal
physician
present
fever
headach
myalgia
malais
temperatur
puls
beatsmin
blood
pressur
mmhg
laboratori
find
blood
biochem
test
normal
haemoglobin
gdl
leukocyt
kmcl
platelet
count
kmcl
oral
ribavirin
start
quickli
possibl
nosocomi
transmiss
ribavirin
dose
g
load
follow
gday
day
gday
day
histori
percutan
exposur
probabl
close
contact
aerosolis
blood
excret
suspect
rout
transmiss
diagnosi
confirm
rtpcr
followup
platelet
count
persist
decreas
liver
enzym
slightli
increas
fever
detect
third
day
haemorrhag
manifest
nt
develop
signific
side
effect
ribavirin
observ
patient
symptom
improv
seventh
day
admiss
conclus
prevent
transmiss
cchf
close
contact
haemorrhag
patient
droplet
contact
precaut
must
perform
although
controversi
earli
onset
ribavirin
found
effect
case
object
crimean
congo
hemorrhag
fever
cchf
sever
hemorrhag
fever
caus
nairoviru
belong
famili
bunyavirida
spread
zoonosi
human
main
role
tick
howev
transmiss
also
possibl
via
blood
tissu
bodili
fluid
infect
peopl
anim
nosocomi
transmiss
also
possibl
health
care
worker
one
major
risk
group
cchf
viru
acquisit
especi
care
patient
hemorrhag
differ
bodi
site
paper
report
cchf
two
health
care
worker
whose
contact
blood
bodi
fluid
patient
case
year
old
pregnant
nurs
ten
week
admit
clinic
sudden
onset
high
fever
myalgia
arthralgia
fatigu
care
patient
cchf
clinic
four
day
ago
shift
one
patient
die
cchf
patient
respiratori
symptom
renal
insuffici
although
nt
negativepressur
room
patient
isol
privat
room
healthcar
worker
use
barriernurs
techniqu
includ
dispos
glove
mask
goggl
handwash
use
alcohol
base
desenfectan
main
way
protect
isol
nurs
sent
serum
sampl
nation
refer
laboratori
cchf
test
next
day
diagnos
cchf
posit
pcr
inform
consent
ribavirin
treatment
given
follow
day
fever
continu
alanin
aminotransferas
lactat
dehydrogenas
creatin
phosphokinas
level
increas
five
day
clinic
laboratori
find
improv
discharg
medic
abortu
decis
case
year
old
male
resid
admit
clinic
complaint
two
day
nurs
admiss
care
patient
day
nurs
diagnos
cchf
laboratori
rtpcr
test
take
oral
ribavirin
decis
continu
therapi
symptom
began
resolv
third
day
discharg
hospit
histori
contact
insid
patient
room
without
mask
twice
conclus
although
main
way
transmiss
cchf
health
care
worker
close
contact
blood
bodi
fluid
transmiss
aerosol
air
droplet
may
possibl
f
l
skoura
k
dumaidi
papa
f
frantzid
thessaloniki
gr
object
present
studi
detect
common
herpesvirus
cerebrospin
fluid
csf
sampl
patient
central
nervou
system
cn
infect
northern
greec
order
greec
hospit
includ
studi
patient
enceph
patient
mening
patient
encephalomyel
patient
guillenbarr
syndrom
patient
variou
unspecifi
neurolog
diseas
polymeras
chain
reaction
multiplex
consensu
nest
pcr
well
serolog
perform
detect
herpesvirus
csf
result
herpesvirus
csf
detect
patient
ten
adult
one
child
herpesviru
genom
detect
pcr
patient
patient
enceph
etiolog
agent
hsv
identifi
intrathec
andibobi
product
patient
herpet
cn
infect
enceph
mening
one
patient
guillainbarr
syndrom
herp
simplex
viru
type
genom
detect
patient
enceph
patient
guillainbarr
herp
simplex
viru
type
patient
mening
varicellazost
viru
vzv
detect
patient
mening
patient
enceph
diagnosi
establish
hsv
intrathec
antibodi
detect
detect
herpesviru
genom
patient
csf
imposs
incid
herp
simplex
enceph
studi
patient
per
peopl
per
year
patient
mening
excel
outcom
howev
poor
outcom
led
death
observ
two
six
patient
enceph
mortal
poor
outcom
associ
low
glascow
coma
scale
admiss
hospit
conclus
common
herpesviru
detect
studi
caus
enceph
high
mortal
vzv
less
frequent
detect
caus
milder
diseas
good
outcom
object
present
case
miliari
tb
mimick
advanc
ovarian
cancer
thorac
spine
metastas
old
somalian
femal
complain
backach
constip
low
grade
fever
last
month
basic
laboratori
test
reveal
anemia
hb
mgdl
sever
thrombocytosi
plt
also
elev
uml
posit
tuberculin
test
mm
underw
ct
scan
reveal
pleural
effus
ascit
solid
lesion
right
ovari
osteolyt
sleros
lesion
lower
thorac
vertebra
transvagin
ultrasound
show
larg
cystic
mass
aris
right
ovari
paracentesi
ascit
perform
fluid
exud
posit
cytolog
atyp
cell
possibl
adenocarcinoma
neg
afb
gastroscopi
barium
enema
normal
find
suggest
advanc
ovarian
cancer
laparotomi
perform
macroscop
pictur
multipl
whitish
lesion
peritoneum
intestin
oment
cake
two
liter
ascet
fluid
remov
ada
test
done
came
back
posit
right
ovari
salpynx
remov
biopsi
show
granulomat
tissu
ct
guid
biopsi
vertebr
lesion
perform
pcr
myc
tuberculosi
materi
done
posit
patient
put
antitb
treatment
isoniazid
rifampicin
pyrazinamid
ethambutol
gradual
improv
conclus
tb
rare
develop
world
ovarian
periton
tb
often
misdiagnos
advanc
ovarian
cancer
lead
young
women
unnecessari
laparotomi
surgeri
ascit
periton
nodul
elev
even
presenc
osteolyt
lesion
vertebra
necessarili
indic
malign
tuberculosi
alway
suspect
especi
young
women
endem
countri
cultur
mycobacterium
time
consum
test
periton
fluid
often
neg
afb
pcr
ada
use
tool
differenti
diagnosi
object
clinic
sampl
sent
mycobacteria
laboratori
cultur
confirm
mycobacteri
infect
contamin
nonmycobacteri
organ
requir
digest
decontamin
allow
effect
diagnosi
mycobacteri
infect
optim
recoveri
mycobacteria
requir
tightli
regul
ph
basic
ph
quickli
elimin
nonmycobacteri
organ
patient
sampl
howev
prolong
exposur
high
ph
toxic
mycobacteri
organ
care
control
ph
throughout
sampl
prepar
essenti
assess
perform
alpha
tec
digest
decontamin
system
high
throughput
laboratori
johannesburg
south
africa
pulmonari
sampl
method
compar
current
implement
bd
kit
ph
decontamin
specimen
less
immedi
buffer
maintain
cultur
diagnosi
ph
level
optimum
surviv
mycobacteri
organ
ensur
alpha
tec
system
commerci
avail
system
effect
control
ph
help
reduc
mycobacteria
dieoff
specimen
prepar
process
sampl
split
process
use
bd
g
krimpeni
p
giannakako
georgouli
e
skout
athen
gr
object
access
incid
recogn
risk
factor
determin
rate
antimicrobi
resist
nosocomi
gramposit
strain
isol
patient
treat
icu
method
retrospect
studi
patient
hospit
seven
bed
icu
one
year
period
juli
juli
data
demograph
characterist
primari
diagnosi
comorbid
number
indwel
devic
current
antibiot
crosstabul
accord
presenc
type
gram
pathogen
isol
identif
antimicrobi
sensit
gramposit
pathogen
perform
microscan
dade
behr
accord
clsi
instruct
result
sixti
patient
document
nosocomi
infect
gram
isol
identifi
methicillinresist
staphylococcu
epidermidi
mrse
n
methicillinresist
staphylococcu
aureu
mrsa
n
commonli
isol
follow
e
faecali
n
e
faecium
n
signific
differ
group
accord
demograph
characterist
follow
independ
risk
factor
gram
nosocomi
infect
identifi
mrse
chronic
obstruct
pulmonari
diseas
comorbid
previou
isol
acinetobact
sp
pseudomona
sp
previouscurr
treatment
carbapenem
enterococcu
sp
previouscurr
treatment
third
gener
cephalosporin
number
indwel
devic
link
increas
risk
coagulas
neg
staphylococc
infect
staphylococci
strain
sensit
vancomycin
teicoplanin
linezolid
three
strain
enterococci
one
e
faecali
two
e
faecium
resist
vancomycin
teicoplanin
conclus
reduc
emerg
spread
antimicrobi
resist
gram
pathogen
icu
monitor
optimis
antimicrobi
use
consid
care
identif
associ
risk
factor
gram
posit
nosocomi
infect
would
aid
initi
antibiot
choic
patient
risk
object
rhodococcu
equi
infect
regard
opportunist
infect
immunocompromis
host
although
organ
easili
cultiv
specimen
may
misdiagnos
contamin
commmens
due
diphteroid
appear
aid
epidem
result
increas
awar
part
microbiolog
laboratori
identifi
case
r
equi
infect
preval
studi
r
equi
infect
yearold
institut
present
methodolog
clinic
signific
isol
r
equi
cultur
microbiolog
laboratori
sungai
buloh
hospit
malaysia
januari
octob
includ
laboratori
use
analyt
profil
index
api
system
identif
organ
case
file
patient
review
discuss
physician
done
determin
clinic
signific
isol
result
r
equi
deem
clinic
signific
isol
patient
twoyear
period
organ
cultur
blood
sputum
bronchoscopi
specimen
background
aim
studi
determin
predomin
pathogen
suscept
pattern
among
pediatr
neutropen
patient
proper
select
empir
antibiot
therapi
method
retrospect
chart
review
pediatr
patient
hematologiconcolog
disord
bacteremia
januari
decemb
demograph
data
underli
diseas
bacteri
isol
antibiot
suscept
analyz
result
one
thousand
eight
hundr
eighti
nine
bacteremia
episod
identifi
gram
neg
bacteria
gnb
frequent
isol
caus
episod
e
coli
p
aeruginosa
k
pneumonia
enterobact
spp
maltophilia
seventi
four
percent
gnb
suscept
pipracillintazobactam
ceftazidim
gentamicin
pipracillin
eightyseven
percent
test
sensit
imipinemmeropenem
gram
posit
bacteria
gpc
caus
episod
coagulas
neg
staphylococcu
frequent
follow
aureu
pneumonia
viridan
streptococcu
enterococcu
spp
vre
isol
conclus
result
concur
observ
studi
gnb
emerg
major
caus
bacteremia
children
cancer
support
includ
vancomycin
initi
empir
therapi
febril
neutropen
patient
potenti
need
better
util
conjug
pneumococc
vaccin
decreas
incid
invas
pneumococc
diseas
patient
popul
bratslavska
uzamecki
donina
lejniek
murovska
riga
lv
object
studi
design
determin
preval
parvoviru
infect
patient
colorect
cancer
investig
hematolog
immunolog
featur
relat
infect
subject
method
primari
diagnos
colorect
cancer
patient
sex
age
match
appar
healthi
person
enrol
studi
specif
igm
igg
antibodi
assess
enzymelink
immunosorb
assay
presenc
dna
serum
sampl
nest
polymeras
chain
reaction
viral
load
real
time
pcr
clinic
laboratori
data
includ
haemoglobin
valu
number
leukocyt
lymphocyt
monocyt
neutrophil
collect
examin
subpopul
determin
patient
cytofluorimetri
level
patient
serum
sampl
assess
use
quantit
elisa
result
dna
detect
patient
viral
load
copiesml
control
viral
load
copiesml
specif
igm
antibodi
reveal
patient
control
igg
antibodi
patient
control
person
frequenc
activ
infect
significantli
higher
patient
colorect
cancer
compar
control
person
p
patient
significantli
higher
frequenc
anaemia
significantli
lower
haemoglobin
valu
compar
control
person
p
p
respect
pcr
posit
patient
also
significantli
lower
number
cell
significantli
higher
level
compar
control
person
p
p
respect
result
studi
suggest
patient
colorect
cancer
may
significantli
increas
risk
reactiv
infect
impact
haematolog
immunolog
paramet
patient
screen
patient
pcr
recommend
infect
suspect
c
erol
e
guzel
tunccan
dizbay
g
sucak
zn
ozkurt
ankara
tr
object
bacteremia
consid
signific
caus
mortal
morbid
febril
neutropen
patient
epidemiolog
risk
factor
might
differ
among
institut
time
period
aim
studi
evalu
frequenc
epidemiolog
factor
predict
bacteremia
neutropen
patient
gazi
univers
hematolog
hematopoiet
stem
cell
transplant
hsct
unit
method
novemb
novemb
febril
neutropen
episod
patient
hematolog
malign
includ
studi
case
defin
patient
bloodstream
infect
control
patient
without
bloodstream
infect
evalu
case
control
risk
factor
complic
mortal
rate
microorgan
isol
blood
sampl
suscept
pattern
also
analys
preval
bacteremia
mortal
rate
durat
sever
neutropenia
neutrophil
count
underli
hematolog
malign
stem
cell
transplant
relaps
refractori
diseas
presenc
central
venou
cathet
presenc
mucos
signific
predict
factor
bacteremia
presenc
central
venou
cathet
relaps
refractori
diseas
independ
risk
factor
incid
hypotens
intens
care
necess
higher
case
candidemia
gramneg
bacteremia
significantli
associ
higher
mortal
rate
gramposit
microorgan
common
isol
predomin
coagulas
neg
staphylococci
methicillin
resist
rate
frequent
gramneg
pathogen
e
coli
extrem
high
quinolon
resist
rate
resist
rate
cephalosporin
conclus
monitor
epidemiolog
bacteremia
predict
signific
factor
associ
bacteremia
febril
neutropen
patient
consid
import
choic
initi
antibiot
therapi
g
b
kele
c
bereczki
k
bartyik
j
szege
hu
object
number
transplant
patient
increas
preval
malign
transplant
get
common
among
posttranspl
malign
import
lymphoma
signific
increas
preval
poor
prognosi
case
bcell
origin
ebvassoci
aim
show
ebvassoci
lymphoma
kidney
transplant
patient
case
descript
method
boy
underw
kidney
transplant
congenit
urolog
malform
patient
receiv
immunosuppress
treatment
urinari
chateter
necessari
due
bladder
dysfunct
howev
graft
function
appropri
urinari
tract
infect
diagnos
time
year
june
patient
admit
depart
paediatr
sudden
grand
mal
seizur
brain
mri
examin
reveal
bloodbrain
injuri
possibl
multifoc
granulomat
enceph
lymphoma
arisen
affect
white
matter
cortex
pcr
ebv
artu
ebv
lc
pcr
kit
qiagen
perform
csf
brain
biopsi
specimen
gave
posit
result
copiesml
copiesml
respect
cmv
pcr
artu
cmv
lc
pcr
kit
qiagen
neg
ebv
viral
load
determin
week
cytolog
examin
justifi
posttranspl
lymphoprolif
diseas
ptld
accord
find
parenter
acyclovir
rituximab
treatment
start
besid
everolimu
mycophenol
acid
immunosuppress
appli
therapi
viral
load
decreas
week
neg
ebv
pcr
result
obtain
control
brain
mri
exam
reveal
total
regress
previous
recognis
abnorm
recent
patient
treat
valagancyclovir
conclus
due
increas
number
immunosuppress
patient
occurr
posttranspl
lymphoprolif
diseas
becom
frequent
pay
attent
emerg
ebvassoci
case
achiev
correct
diagnosi
case
besid
serolog
molecular
method
crucial
role
detect
pathogen
monitor
effect
antivir
therapi
case
may
draw
attent
fact
screen
ebv
transplant
patient
consid
n
kmet
lukic
jereb
muzlov
ljubljana
si
object
procalcitonin
pct
concentr
increas
set
system
bacteri
infect
may
use
marker
sever
sepsi
studi
show
level
elev
also
neutropen
patient
sepsi
use
prognost
factor
febril
neutropenia
aim
retrospect
studi
find
whether
pct
level
prognost
factor
multiorgan
failur
mortal
neutropen
patient
sepsi
method
adult
patient
admit
intens
care
unit
diagnosi
sepsi
particip
retrospect
studi
base
absolut
neutrophil
count
patient
divid
two
group
neutropen
patient
nonneutropen
patient
neutropenia
defin
absolut
neutrophil
count
result
averag
pct
level
sepsi
patient
ngml
rang
ngml
neutropen
ngml
rang
ngml
nonneutropen
group
differ
signific
p
group
neutropen
patient
averag
pct
concentr
higher
multiorgan
failur
without
ngml
vs
ngml
differ
signific
p
among
neutropen
patient
die
averag
pct
concentr
ngml
rang
ngml
among
survivor
ngml
rang
ngml
howev
differ
signific
p
group
neutropen
patient
septic
shock
analys
among
found
signific
differ
pct
level
die
survivor
p
without
multiorgan
failur
p
group
compar
neutropen
patient
without
septic
shock
howev
found
significantli
higher
valu
pct
level
ngml
rang
ngml
vs
ngml
rang
ngml
p
mortal
rate
vs
p
rate
multiorgan
failur
vs
p
conclus
retrospect
studi
confirm
previou
find
pct
level
increas
also
neutropen
patient
sepsi
pct
concentr
neutropen
nonneutropen
patient
sepsi
similar
howev
studi
show
increas
pct
concentr
neutropen
patient
sepsi
use
prognost
factor
septic
shock
multiorgan
failur
mortal
aim
simplifi
manag
patient
unifi
polici
defin
febril
neutropenia
identifi
potenti
antimicrobi
agent
use
empir
monotherapi
aim
one
fn
polici
across
group
p
tya
collect
data
relat
gramneg
bacteraemia
aim
review
feasibl
suitabl
agent
monotherapi
patient
group
certain
patient
may
need
manag
differ
eg
post
allogen
stem
cell
transplant
sct
present
data
lesson
learn
achiev
import
goal
unif
polici
method
computeris
microbiolog
databas
identifi
gramneg
bacteraemia
patient
group
februari
may
organ
record
suscept
antimicrobi
agent
gentamicin
tobramycin
piperacillintazobactam
aztreonam
ceftazidim
meropenem
ciprofloxacin
record
absolut
neutrophil
count
anc
time
bacteraemia
diagnosi
treatment
receiv
isol
resist
piperacillin
tazobactam
determin
initi
antimicrobi
therapi
prescrib
subsequ
chang
made
includ
reason
chang
result
identifi
bacteraemia
adult
haematolog
patient
bacteraemia
paediatr
ho
patient
adult
patient
anc
anc
isol
resist
piperacillintazobactam
paediatr
group
bacteraemia
identifi
anc
anc
adult
patient
post
allogen
stem
cell
transplant
incid
resist
piperacillintazobactam
higher
compar
group
patient
shown
major
gramneg
bacteraemia
p
tya
ho
patient
occur
either
sever
neutropen
patient
patient
neutropen
major
patient
singl
agent
piperacillintazobactam
suitabl
agent
monotherapi
patient
undergon
allogen
sct
may
need
risk
stratifi
receiv
differ
antimicrobi
therapi
unifi
polici
feasibl
share
valuabl
lesson
learn
achiev
goal
object
know
epidemiolog
microbiolog
infecti
complic
patient
acut
myeloid
leukemia
aml
treatment
hospit
infantil
de
way
improv
manag
children
conduct
retrospect
observ
studi
includ
consecut
patient
aml
present
hospit
diagnosi
fever
neutropenia
fan
januari
decemb
collect
inform
regard
aml
treatment
phase
type
infect
sever
septic
shock
number
infect
patient
infecti
event
number
infecti
event
patient
infecti
agent
isol
site
isol
chemotherapi
phase
number
hospit
day
infecti
event
descript
statitist
done
result
fifti
children
suffer
infecti
event
frequent
aml
type
averag
fan
event
per
patient
n
analyz
infecti
event
n
event
fan
without
identifi
focu
among
infecti
complic
septic
shock
coliti
frequent
complic
n
nosocomi
pneumonia
infect
relat
cathet
diseas
n
patholog
second
import
sever
sepsi
mucos
grade
ii
third
frequent
complic
n
total
n
infecti
complic
happen
induct
n
occur
mainten
infect
clinic
microbiolog
document
n
case
coagulas
neg
staphylococcu
cn
repres
major
caus
septicemia
wherea
escherichia
coli
second
pathogen
frequent
isol
blood
gramneg
bacteria
account
isol
gramposit
account
fungal
infect
observ
result
indic
main
infecti
complic
aml
tiphlyti
nosocomi
pneumonia
septic
shock
commun
acquir
pneumonia
septic
shock
frequent
mainten
common
pathogen
e
coli
coagulas
neg
staphylococcu
p
aeruginosa
aureu
pneumonia
group
low
ill
burden
compar
igg
concentr
igm
memori
b
dendrit
cell
count
taci
mutat
group
fisher
statist
result
patient
evalu
cvid
igg
subclassdefici
iga
defici
recurr
lung
infect
common
manifest
patient
includ
group
rate
b
memori
igm
cell
dendrit
cell
count
cellsml
significantli
frequent
group
mutat
encod
taci
detect
group
sensit
specif
least
posit
test
detect
patient
high
ill
burden
respect
signific
correl
igg
mgdl
ill
burden
conclus
immunolog
genet
variabl
allow
better
character
cvid
igg
subclass
iga
defici
igg
concentr
alon
suffici
predict
patient
outcom
c
rizzi
h
eibel
w
kern
freiburg
de
object
asplenia
immunodefici
predispos
lifethreaten
infecti
complic
also
known
overwhelm
postsplenectomi
infect
opsi
sever
sepsi
septic
shock
clinic
sequela
inform
recent
studi
clinic
characterist
asplen
patient
infecti
complic
cohort
limit
one
like
reason
highli
increas
incid
infect
pneumoocci
encapsul
bacteria
relat
function
spleen
secondari
lymphoid
organ
allow
gener
plasma
cell
produc
antibodi
bacteria
bear
polysaccharid
capsul
method
sinc
begin
asplen
patient
treat
univers
medic
center
freiburg
includ
recent
splenectom
receiv
care
special
outpati
clinic
follow
prospect
patient
demograph
comorbid
reason
splenectomi
vaccin
statu
infecti
complic
document
use
structur
questionnair
pneumococc
antibodi
b
cell
phenotyp
measur
result
studi
period
patient
seen
outpati
clinic
mean
age
asplen
patient
rang
frequent
reason
splenectomi
abdomin
malign
follow
benign
tumor
iatrogen
surgic
complic
trauma
lymphoma
patient
previou
opsi
seen
three
patient
opsi
due
pneumonia
one
due
mening
complet
complianc
current
vaccin
recommend
patient
awar
overal
low
compar
individu
intact
spleen
asplen
patient
lower
margin
zone
b
cell
conclus
follow
cohort
asplen
patient
offer
uniqu
possibl
studi
clinic
immunolog
risk
factor
infecti
complic
prospect
communityacquir
infect
includ
cap
sepsi
std
result
total
msm
sti
screen
carri
test
rectal
ct
test
posit
rectal
ct
major
asymptomat
concurr
urethr
chlamydia
infect
howev
concurr
sti
hiv
posit
case
lymphogranuloma
venereum
conclus
data
show
high
rate
rectal
ct
cohort
msm
screen
major
asymptomat
identifi
routin
rectal
ct
screen
carri
popul
would
recommend
also
identifi
high
rate
rectal
ct
occur
concurr
sti
includ
hiv
neonat
sepsi
tertiari
care
hospit
eastern
nepal
laboratori
perspect
five
year
durat
n
shrestha
nk
bhatta
dharan
np
object
present
studi
undertaken
determin
preval
bacteri
etiolog
agent
associ
neonat
sepsi
pattern
antimicrobi
suscept
durat
last
five
year
bp
koirala
institut
health
scienc
bpkih
tertiari
care
hospit
eastern
nepal
materi
method
blood
cultur
sampl
obtain
suspect
case
neonat
sepsi
submit
microbiolog
depart
bpkih
cultur
sensit
durat
five
year
includ
isol
identif
antimicrobi
suscept
test
done
standard
microbiolog
method
result
total
blood
cultur
specimen
receiv
microbiolog
laboratori
year
includ
sampl
suspect
case
neonat
sepsi
fifteen
hundr
thirti
two
sampl
yield
growth
bacteria
slightli
higher
year
rate
posit
follow
year
rang
common
gramposit
organ
isol
staphylococcu
aureu
follow
con
enterococcu
spp
wherea
acinetobact
spp
klebsiella
pneumonia
enterobact
spp
remain
common
gramneg
organ
period
year
preval
aureu
increas
total
cultur
posit
similarli
enterococci
rais
coagulas
neg
staphylococci
declin
preval
bacteria
remain
less
studi
period
bacteria
exhibit
resist
commonli
use
antimicrobi
methicillin
resist
aureu
mrsa
vancomycin
intermedi
aureu
visa
vancomycin
resist
enterococci
vre
high
level
gentamicin
resist
enterococci
hlgr
esbl
produc
gram
neg
bacilli
found
emerg
special
later
part
studi
conclus
neonat
blood
stream
infect
common
set
variou
bacteria
associ
etiolog
agent
predomin
gram
posit
cocci
observ
resist
commonli
use
antimicrobi
emerg
problem
continu
monitor
ration
use
antimicrobi
strict
adher
infect
control
practic
may
prove
use
prevent
spread
antimicrobi
resist
aim
studi
assess
risk
factor
qr
male
futi
method
ambispect
studi
januari
octob
collect
clinic
data
male
mean
age
year
mean
charlson
score
commun
acquir
futi
due
e
coli
inclus
criteria
age
year
clinic
symptom
futi
armpit
temperatur
urinari
symptom
posit
urin
cultur
e
coli
suscept
pipemid
acid
ciprofloxacin
test
disk
diffus
techniqu
strain
consid
suscept
inhibit
zone
clsi
limit
resist
otherwis
statist
analysi
perform
chisquar
fisher
exact
test
variabl
associ
qr
univari
analysi
includ
binari
logist
regress
analysi
qr
depend
variabl
logist
model
age
charlson
score
analyz
median
dichotom
valu
statist
signific
defin
twotail
p
valu
result
among
e
coli
isol
resist
pipemid
acid
resist
ciprofloxacin
univari
analysi
compar
quinolon
suscept
strain
follow
variabl
associ
qr
older
age
vs
p
diabet
mellitu
dm
vs
p
high
charlson
score
vs
p
past
urinari
tract
infect
uti
vs
p
urinari
catheter
vs
p
urinari
tract
abnorm
vs
p
recent
antibiot
treatment
vs
p
urolog
manipul
vs
p
previou
hospit
vs
p
logist
model
factor
remain
associ
qr
dm
ci
p
past
uti
ci
p
recent
antibiot
treatment
ci
p
studi
show
futi
occur
male
dm
past
histori
urinari
infect
recent
antibiot
treatment
higher
risk
caus
qr
e
coli
strain
therefor
fluorquinolon
probabl
best
therapeut
empir
option
patient
p
cellerino
milanesi
r
beretta
fasolo
g
milan
object
anal
hpv
infect
hpv
relat
cancer
increas
among
hiv
infect
peopl
despit
introduct
haart
screen
treatment
strategi
still
undefin
retrospect
studi
investig
outcom
characterist
hiv
infect
patient
anal
cancer
diagnos
l
sacco
univers
hospit
period
method
clinic
immunovirolog
treatment
paramet
hiv
infect
anal
cancer
collect
clinic
record
hiv
infect
patient
admit
ii
surgic
unit
hospit
hpv
dna
test
high
low
risk
hpv
genotyp
perform
fix
histolog
sampl
result
hiv
infect
acquir
sexual
rout
male
femal
includ
studi
time
anal
cancer
diagnosi
patient
onhaart
patient
offhaart
accord
nation
guidelin
antiretrovir
treatment
hiv
infect
patient
patient
previou
diagnosi
aid
median
count
cellsmicrol
rang
median
viral
load
copiesml
rang
hpv
infect
combin
high
low
risk
genotyp
detect
histolog
sampl
patient
combin
therapi
radio
chemotherapi
perform
patient
patient
receiv
surgic
treatment
patient
radiotherapi
patient
chemotherapi
median
surviv
anal
cancer
diagnosi
month
rang
patient
aliv
month
follow
patient
diseas
free
month
surviv
rate
slightli
higher
patient
treat
combin
therapi
treat
singl
intervent
conclus
hiv
posit
patient
remain
high
risk
hpv
anal
relat
cancer
also
haart
era
surviv
rate
close
relat
treatment
regimen
hiv
immunovirolog
paramet
ant
stage
diseas
time
diagnosi
need
anal
cancer
screen
program
hiv
infect
peopl
earli
diagnosi
treatment
hpv
relat
anal
cancer
n
k
ohkusu
nakamura
k
koshihara
takei
takada
yamashina
matsumoto
tokyo
gifu
jp
object
helicobact
cinaedi
gramneg
spiral
rod
initi
isol
homosexu
men
proctocol
h
cinaedi
report
caus
agent
enter
cellul
bacteraemia
arthriti
mening
experienc
case
infect
endocard
ie
due
h
cinaedi
infect
report
previous
case
report
femal
endstag
renal
diseas
haemodialysi
aortic
valv
stenosi
abdomin
aortic
aneurysm
transfer
haemodialysi
clinic
lowgrad
fever
day
elev
creactiveprotein
crp
level
day
admiss
patient
complain
fatigu
wbc
l
crp
mgl
transthorac
echocardiogram
show
mm
veget
tricuspid
valv
vancomycin
start
empir
day
gramneg
spiral
rod
recov
blood
cultur
collect
day
admiss
day
antibiot
switch
ceftriaxon
daili
gentamicin
mg
everi
haemodialysi
empir
coverag
campylobact
fetu
gramneg
spiral
rod
known
caus
ie
organ
grew
blood
agar
microaerophil
condit
degre
celsiu
could
identifi
time
despit
administr
antibiot
fatigu
level
crp
improv
esr
elev
mmhr
size
veget
increas
mm
isol
analyz
polymeras
chain
reaction
pcr
use
rdna
univers
bacteri
primer
gyrb
genebas
h
cinaedi
specif
primer
conclud
h
cinaedi
base
result
antibiot
regimen
switch
day
intraven
common
clinic
symptom
lumbar
vertebra
frequent
involv
region
thoracolumbar
thorac
cervic
invol
seen
patient
respect
spinal
epidur
abscess
found
seven
case
one
patient
psoa
abscess
standart
tube
agglutin
test
posit
patient
total
cultur
posit
blood
abscess
specimen
three
patient
underw
surgic
intervent
diagnost
purpos
three
patient
requir
surgic
treatment
vertebr
stabil
nineteen
patient
receiv
combin
gentamycin
mgkgday
initi
day
plu
doxycyclin
mg
bid
rifampicin
mgday
two
patient
receiv
doxycyclin
plu
rifampicin
one
patient
receiv
doxycyclin
plu
streptomycin
durat
therapi
vari
accord
clinic
respons
presenc
epidur
psoa
abscess
shortest
durat
treatment
three
month
conclus
brucellosi
includ
differenti
diagnosi
back
pain
especi
countri
turkey
infect
endem
e
akhtar
r
fadaei
nobari
isfahan
ir
object
follow
declar
world
health
organ
human
case
infect
new
influenza
viru
iranian
ministri
health
moh
launch
system
monitor
report
presenc
new
viru
may
report
confirm
case
new
viru
identifi
isfahan
provinc
iran
method
laboratorybas
report
system
provinci
health
center
suppli
moh
case
definit
patient
inform
form
dissemin
health
care
institut
provinc
person
fulfil
case
definit
criteria
direct
one
three
design
health
facil
prepar
receiv
suspect
case
nasopharyng
sampl
sent
nation
influenza
refer
laboratori
tehran
school
public
health
viral
transport
medium
virocult
medic
wire
equip
uk
test
real
time
rtpcr
protocol
reagent
suppli
result
total
sampl
taken
suspect
case
juli
octob
sampl
posit
influenza
date
symptom
onset
first
confirm
case
pandem
influenza
juli
travel
mecca
saudi
arabia
alreadi
becom
symptomat
stay
case
femal
median
age
year
rang
year
major
case
year
old
hospit
patient
travel
histori
affect
area
travelassoci
case
return
travel
saudi
arabia
follow
malaysia
closecontact
patient
median
durat
develop
symptom
refer
health
center
day
rang
day
fever
common
symptom
present
case
follow
cough
myalgia
one
death
report
conclus
influenza
v
enter
isfahan
travel
mainli
come
saudi
arabia
major
confirm
case
consist
young
adult
report
countri
mainli
manifest
clinic
symptom
similar
report
area
mani
patient
influenza
like
symptom
may
visit
physician
possibl
case
diagnos
christova
gladnishka
e
taseva
v
ivanova
sofia
bg
object
lyme
borreliosi
endem
bulgaria
case
offici
report
everi
year
give
incid
method
use
elisa
recombin
b
burgdorferi
antigen
total
patient
diagnos
result
main
part
present
erythema
migran
second
common
clinic
manifest
neuroborreliosi
detect
patient
radiculoneur
cranial
neuriti
encephalopathi
meningoradiculoneur
myeliti
found
patient
resp
lyme
arthriti
much
less
common
found
patient
follow
heart
ocular
manifest
borreli
lymphocytoma
acrodermat
chronica
atrophican
borrelia
garinii
speci
frequent
associ
neuroborreliosi
contrari
bulgarian
ixod
ricinu
tick
collect
veget
examin
pcr
infect
differ
borrelia
speci
borrelia
afzelii
b
garinii
found
predomin
found
tick
follow
b
burgdorferi
sensu
stricto
b
garinii
b
valaisiana
b
lusitania
extent
discrep
could
due
higher
pathogen
potenti
b
garinii
variat
host
suscept
remain
determin
akinci
bu
kayaaslan
yilmaz
aliravci
yildiz
f
ulgen
ss
eren
gr
yilmaz
h
bodur
ankara
tr
object
pandem
influenza
viru
new
influenza
viru
caus
ill
peopl
viru
first
detect
mexico
april
spread
persontoperson
worldwid
turkey
number
case
increas
day
day
patient
die
octob
method
prospect
studi
pandem
influenza
case
hospit
clinic
octob
novemb
evalu
period
total
patient
sever
diseas
hospit
suspicion
pandem
influenza
patient
posit
nasopharyng
swab
specimen
viru
pcr
test
underli
diseas
present
patient
fifteen
patient
histori
contact
posit
peopl
admiss
durat
complaint
day
frequent
complaint
fever
myalgia
cough
headach
sore
throat
physic
examin
reveal
fever
oropharing
hyperemia
short
breath
crepitan
rale
lung
auscult
laboratori
test
leucopenia
thrombocytopenia
elev
liver
enzym
hyperglycemia
detect
patient
treat
oseltamivir
given
e
